

Return of Private Foundation

or Section 4947(a)(1) Trust Treated as Private Foundation

Do not enter social security numbers on this form as it may be made public. Go to www.irs.gov/Form990PF for instructions and the latest information.

2022

Open to Public Inspection

Form 990-PF

Department of the Treasury Internal Revenue Service

For calendar year 2022 or tax year beginning APR 1, 2022, and ending MAR 31, 2023

Name of foundation: THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST. A Employer identification number: 13-7184401. B Telephone number: 212-679-3600. C If exemption application is pending, check here... D 1. Foreign organizations, check here... D 2. Foreign organizations meeting the 85% test... E If private foundation status was terminated... F If the foundation is in a 60-month termination... H Check type of organization: Section 501(c)(3) exempt private foundation. I Fair market value of all assets at end of year: \$7,256,835,636. J Accounting method: Accrual.

Table with 5 columns: (a) Revenue and expenses per books, (b) Net investment income, (c) Adjusted net income, (d) Disbursements for charitable purposes. Rows include Revenue (1-12) and Operating and Administrative Expenses (13-26). Total revenue: 629,133,449. Total expenses: 534,910,918. Net investment income: 119,401,626.

Application for Automatic Extension of Time To File an Exempt Organization Return

Department of the Treasury
Internal Revenue Service

▶ **File a separate application for each return.**
▶ **Go to www.irs.gov/Form8868 for the latest information.**

Electronic filing (e-file). You can electronically file Form 8868 to request a 6-month automatic extension of time to file any of the forms listed below with the exception of Form 8870, Information Return for Transfers Associated With Certain Personal Benefit Contracts, for which an extension request must be sent to the IRS in paper format (see instructions). For more details on the electronic filing of this form, visit www.irs.gov/e-file-providers/e-file-for-charities-and-non-profits.

Automatic 6-Month Extension of Time. Only submit original (no copies needed).

All corporations required to file an income tax return other than Form 990-T (including 1120-C filers), partnerships, REMICs, and trusts must use Form 7004 to request an extension of time to file income tax returns.

Type or print	Name of exempt organization or other filer, see instructions. THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST	Taxpayer identification number (TIN) 13-7184401
File by the due date for filing your return. See instructions.	Number, street, and room or suite no. If a P.O. box, see instructions. 230 PARK AVENUE, 659	
	City, town or post office, state, and ZIP code. For a foreign address, see instructions. NEW YORK, NY 10169	

Enter the Return Code for the return that this application is for (file a separate application for each return) 0 4

Application Is For	Return Code	Application Is For	Return Code
Form 990 or Form 990-EZ	01	Form 1041-A	08
Form 4720 (individual)	03	Form 4720 (other than individual)	09
Form 990-PF	04	Form 5227	10
Form 990-T (sec. 401(a) or 408(a) trust)	05	Form 6069	11
Form 990-T (trust other than above)	06	Form 8870	12
Form 990-T (corporation)	07		

NICHOLAS J. SCHIAVO, CFO

• The books are in the care of ▶ **230 PARK AVENUE, SUITE 659 - NEW YORK, NY 10169**

Telephone No. ▶ **212-679-3600**

Fax No. ▶ _____

- If the organization does not have an office or place of business in the United States, check this box
- If this is for a Group Return, enter the organization's four digit Group Exemption Number (GEN) _____. If this is for the whole group, check this box . If it is for part of the group, check this box and attach a list with the names and TINs of all members the extension is for.

1 I request an automatic 6-month extension of time until **FEBRUARY 15, 2024**, to file the exempt organization return for the organization named above. The extension is for the organization's return for:

- ▶ calendar year _____ or
- ▶ tax year beginning **APR 1, 2022**, and ending **MAR 31, 2023**.

2 If the tax year entered in line 1 is for less than 12 months, check reason: Initial return Final return Change in accounting period

3a If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions.	3a	\$	18,683,219.
b If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit.	3b	\$	16,183,219.
c Balance due. Subtract line 3b from line 3a. Include your payment with this form, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions.	3c	\$	2,500,000.

Caution: If you are going to make an electronic funds withdrawal (direct debit) with this Form 8868, see Form 8453-TE and Form 8879-TE for payment instructions.

Part II Balance Sheets		Attached schedules and amounts in the description column should be for end-of-year amounts only.		
		Beginning of year	End of year	
		(a) Book Value	(b) Book Value	(c) Fair Market Value
Assets	1 Cash - non-interest-bearing	27,238,568.	85,800,732.	85,800,732.
	2 Savings and temporary cash investments	53,717,402.	143,734,047.	143,734,047.
	3 Accounts receivable 680,960.			
	Less: allowance for doubtful accounts	449,759.	680,960.	680,960.
	4 Pledges receivable			
	Less: allowance for doubtful accounts			
	5 Grants receivable			
	6 Receivables due from officers, directors, trustees, and other disqualified persons			
	7 Other notes and loans receivable			
	Less: allowance for doubtful accounts			
	8 Inventories for sale or use			
	9 Prepaid expenses and deferred charges	993,143.	1,129,528.	1,129,528.
	10a Investments - U.S. and state government obligations			
	b Investments - corporate stock STMT 9	591,948,988.	512,806,017.	512,806,017.
	c Investments - corporate bonds			
	11 Investments - land, buildings, and equipment: basis			
Less: accumulated depreciation				
12 Investments - mortgage loans				
13 Investments - other STMT 10	7,406,511,362.	6,449,780,993.	6,449,780,993.	
14 Land, buildings, and equipment: basis 9,935,728.				
Less: accumulated depreciation STMT 11 3,045,409.	7,299,371.	6,890,319.	6,890,319.	
15 Other assets (describe STATEMENT 12)	133,517,019.	56,013,040.	56,013,040.	
16 Total assets (to be completed by all filers - see the instructions. Also, see page 1, item I)	8,221,675,612.	7,256,835,636.	7,256,835,636.	
Liabilities	17 Accounts payable and accrued expenses	12,198,129.	11,336,884.	
	18 Grants payable	462,030,416.	482,673,051.	
	19 Deferred revenue			
	20 Loans from officers, directors, trustees, and other disqualified persons			
	21 Mortgages and other notes payable			
	22 Other liabilities (describe STATEMENT 13)	42,966,460.	41,684,887.	
23 Total liabilities (add lines 17 through 22)	517,195,005.	535,694,822.		
Net Assets or Fund Balances	Foundations that follow FASB ASC 958, check here <input checked="" type="checkbox"/> and complete lines 24, 25, 29, and 30.			
	24 Net assets without donor restrictions	7,704,480,607.	6,721,140,814.	
	25 Net assets with donor restrictions			
	Foundations that do not follow FASB ASC 958, check here <input type="checkbox"/> and complete lines 26 through 30.			
	26 Capital stock, trust principal, or current funds			
	27 Paid-in or capital surplus, or land, bldg., and equipment fund			
	28 Retained earnings, accumulated income, endowment, or other funds			
29 Total net assets or fund balances	7,704,480,607.	6,721,140,814.		
30 Total liabilities and net assets/fund balances	8,221,675,612.	7,256,835,636.		

Part III Analysis of Changes in Net Assets or Fund Balances

1 Total net assets or fund balances at beginning of year - Part II, column (a), line 29 (must agree with end-of-year figure reported on prior year's return)	1	7,704,480,607.
2 Enter amount from Part I, line 27a	2	94,222,531.
3 Other increases not included in line 2 (itemize) DEFERRED FEDERAL EXCISE TAX BENEFIT	3	15,189,247.
4 Add lines 1, 2, and 3	4	7,813,892,385.
5 Decreases not included in line 2 (itemize) UNREALIZED LOSS ON INVESTMENTS	5	1,092,751,571.
6 Total net assets or fund balances at end of year (line 4 minus line 5) - Part II, column (b), line 29	6	6,721,140,814.

Part IV Capital Gains and Losses for Tax on Investment Income

SEE ATTACHED STATEMENTS

(a) List and describe the kind(s) of property sold (for example, real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.)		(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a				
b				
c				
d				
e				
(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) ((e) plus (f) minus (g))	
a				
b				
c				
d				
e	900,001,356.	570,843,305.	27,587,383.	
Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69.				(l) Gains (Col. (h) gain minus col. (k), but not less than -0-) or Losses (from col. (h))
(i) FMV as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any		
a				
b				
c				
d				
e			27,587,383.	
2	Capital gain net income or (net capital loss)	{ If gain, also enter in Part I, line 7 If (loss), enter -0- in Part I, line 7 }		27,587,383.
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). See instructions. If (loss), enter -0- in Part I, line 8	{ }		N/A

Part V Excise Tax Based on Investment Income (Section 4940(a), 4940(b), or 4948 - see instructions)

1a	Exempt operating foundations described in section 4940(d)(2), check here <input type="checkbox"/> and enter "N/A" on line 1. Date of ruling or determination letter: _____ (attach copy of letter if necessary - see instructions)	1	1,659,683.
b	All other domestic foundations enter 1.39% (0.0139) of line 27b. Exempt foreign organizations, enter 4% (0.04) of Part I, line 12, col. (b)		
2	Tax under section 511 (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-)	2	0.
3	Add lines 1 and 2	3	1,659,683.
4	Subtitle A (income) tax (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-)	4	0.
5	Tax based on investment income. Subtract line 4 from line 3. If zero or less, enter -0-	5	1,659,683.
6	Credits/Payments:		
a	2022 estimated tax payments and 2021 overpayment credited to 2022	6a	16,183,219.
b	Exempt foreign organizations - tax withheld at source	6b	0.
c	Tax paid with application for extension of time to file (Form 8868)	6c	2,500,000.
d	Backup withholding erroneously withheld	6d	0.
7	Total credits and payments. Add lines 6a through 6d	7	18,683,219.
8	Enter any penalty for underpayment of estimated tax. Check here <input checked="" type="checkbox"/> if Form 2220 is attached	8	0.
9	Tax due. If the total of lines 5 and 8 is more than 7, enter amount owed	9	
10	Overpayment. If line 7 is more than the total of lines 5 and 8, enter the amount overpaid	10	17,023,536.
11	Enter the amount of line 10 to be: Credited to 2023 estimated tax 7,023,536. Refunded	11	10,000,000.

Part VI-A Statements Regarding Activities

	Yes	No
1a During the tax year, did the foundation attempt to influence any national, state, or local legislation or did it participate or intervene in any political campaign?		X
b Did it spend more than \$100 during the year (either directly or indirectly) for political purposes? See the instructions for the definition If the answer is "Yes" to 1a or 1b , attach a detailed description of the activities and copies of any materials published or distributed by the foundation in connection with the activities.		X
c Did the foundation file Form 1120-POL for this year?		X
d Enter the amount (if any) of tax on political expenditures (section 4955) imposed during the year: (1) On the foundation. \$ _____ 0. (2) On foundation managers. \$ _____ 0.		
e Enter the reimbursement (if any) paid by the foundation during the year for political expenditure tax imposed on foundation managers. \$ _____ 0.		
2 Has the foundation engaged in any activities that have not previously been reported to the IRS?		X
If "Yes," attach a detailed description of the activities.		
3 Has the foundation made any changes, not previously reported to the IRS, in its governing instrument, articles of incorporation, or bylaws, or other similar instruments? If "Yes," attach a conformed copy of the changes		X
4a Did the foundation have unrelated business gross income of \$1,000 or more during the year?	X	
b If "Yes," has it filed a tax return on Form 990-T for this year?	X	
5 Was there a liquidation, termination, dissolution, or substantial contraction during the year?		X
If "Yes," attach the statement required by <i>General Instruction T</i> .		
6 Are the requirements of section 508(e) (relating to sections 4941 through 4945) satisfied either: • By language in the governing instrument, or • By state legislation that effectively amends the governing instrument so that no mandatory directions that conflict with the state law remain in the governing instrument?	X	
7 Did the foundation have at least \$5,000 in assets at any time during the year? If "Yes," complete Part II, col. (c), and Part XIV	X	
8a Enter the states to which the foundation reports or with which it is registered. See instructions. _____ <u>NY</u>		
b If the answer is "Yes" to line 7, has the foundation furnished a copy of Form 990-PF to the Attorney General (or designate) of each state as required by <i>General Instruction G</i> ? If "No," attach explanation	X	
9 Is the foundation claiming status as a private operating foundation within the meaning of section 4942(j)(3) or 4942(j)(5) for calendar year 2022 or the tax year beginning in 2022? See the instructions for Part XIII. If "Yes," complete Part XIII		X
10 Did any persons become substantial contributors during the tax year? If "Yes," attach a schedule listing their names and addresses		X
11 At any time during the year, did the foundation, directly or indirectly, own a controlled entity within the meaning of section 512(b)(13)? If "Yes," attach schedule. See instructions <u>STATEMENT 15</u> <u>STATEMENT 16</u> <u>STMT 17</u>	X	
12 Did the foundation make a distribution to a donor advised fund over which the foundation or a disqualified person had advisory privileges? If "Yes," attach statement. See instructions		X
13 Did the foundation comply with the public inspection requirements for its annual returns and exemption application?	X	
Website address <u>HELMSLEYTRUST.ORG</u>		
14 The books are in care of <u>NICHOLAS J. SCHIAVO, CFO</u> Telephone no. <u>212-679-3600</u> Located at <u>230 PARK AVENUE, SUITE 659, NEW YORK, NY</u> ZIP+4 <u>10169</u>		
15 Section 4947(a)(1) nonexempt charitable trusts filing Form 990-PF in lieu of Form 1041 - check here <input type="checkbox"/> and enter the amount of tax-exempt interest received or accrued during the year 15 N/A		
16 At any time during calendar year 2022, did the foundation have an interest in or a signature or other authority over a bank, securities, or other financial account in a foreign country?	X	
See the instructions for exceptions and filing requirements for FinCEN Form 114. If "Yes," enter the name of the foreign country <u>SEE STATEMENT 14</u>		

Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required

File Form 4720 if any item is checked in the "Yes" column, unless an exception applies.

	Yes	No
1a During the year, did the foundation (either directly or indirectly):		
(1) Engage in the sale or exchange, or leasing of property with a disqualified person?	X	
(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person?		X
(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person?	X	
(4) Pay compensation to, or pay or reimburse the expenses of, a disqualified person?	X	
(5) Transfer any income or assets to a disqualified person (or make any of either available for the benefit or use of a disqualified person)?		X
(6) Agree to pay money or property to a government official? (Exception. Check "No" if the foundation agreed to make a grant to or to employ the official for a period after termination of government service, if terminating within 90 days.)		X
b If any answer is "Yes" to 1a(1)-(6), did any of the acts fail to qualify under the exceptions described in Regulations section 53.4941(d)-3 or in a current notice regarding disaster assistance? See instructions		X
c Organizations relying on a current notice regarding disaster assistance, check here <input type="checkbox"/>		
d Did the foundation engage in a prior year in any of the acts described in 1a, other than excepted acts, that were not corrected before the first day of the tax year beginning in 2022?		X
2 Taxes on failure to distribute income (section 4942) (does not apply for years the foundation was a private operating foundation defined in section 4942(j)(3) or 4942(j)(5)):		
a At the end of tax year 2022, did the foundation have any undistributed income (Part XII, lines 6d and 6e) for tax year(s) beginning before 2022?		X
If "Yes," list the years _____, _____, _____, _____		
b Are there any years listed in 2a for which the foundation is not applying the provisions of section 4942(a)(2) (relating to incorrect valuation of assets) to the year's undistributed income? (If applying section 4942(a)(2) to all years listed, answer "No" and attach statement - see instructions.)		N/A
c If the provisions of section 4942(a)(2) are being applied to any of the years listed in 2a, list the years here. _____, _____, _____, _____		
3a Did the foundation hold more than a 2% direct or indirect interest in any business enterprise at any time during the year?	X	
b If "Yes," did it have excess business holdings in 2022 as a result of (1) any purchase by the foundation or disqualified persons after May 26, 1969; (2) the lapse of the 5-year period (or longer period approved by the Commissioner under section 4943(c)(7)) to dispose of holdings acquired by gift or bequest; or (3) the lapse of the 10-, 15-, or 20-year first phase holding period? (Use Form 4720, Schedule C, to determine if the foundation had excess business holdings in 2022.)		X
4a Did the foundation invest during the year any amount in a manner that would jeopardize its charitable purposes?		X
b Did the foundation make any investment in a prior year (but after December 31, 1969) that could jeopardize its charitable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2022?		X

Form 990-PF (2022)

Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required (continued)

	Yes	No
5a During the year, did the foundation pay or incur any amount to:		
(1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))?		X
(2) Influence the outcome of any specific public election (see section 4955); or to carry on, directly or indirectly, any voter registration drive?		X
(3) Provide a grant to an individual for travel, study, or other similar purposes?		X
(4) Provide a grant to an organization other than a charitable, etc., organization described in section 4945(d)(4)(A)? See instructions	X	
(5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals?		X
b If any answer is "Yes" to 5a(1)-(5), did any of the transactions fail to qualify under the exceptions described in Regulations section 53.4945 or in a current notice regarding disaster assistance? See instructions		X
c Organizations relying on a current notice regarding disaster assistance, check here <input type="checkbox"/>		
d If the answer is "Yes" to question 5a(4), does the foundation claim exemption from the tax because it maintained expenditure responsibility for the grant? SEE STATEMENT 19	X	
If "Yes," attach the statement required by Regulations section 53.4945-5(d).		
6a Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?		X
b Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract? If "Yes" to 6b, file Form 8870.		X
7a At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction?		X
b If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? N/A		
8 Is the foundation subject to the section 4960 tax on payment(s) of more than \$1,000,000 in remuneration or excess parachute payment(s) during the year?	X	

Part VII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors

1 List all officers, directors, trustees, and foundation managers and their compensation.

(a) Name and address	(b) Title, and average hours per week devoted to position	(c) Compensation (If not paid, enter -0-)	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
SEE STATEMENT 18		3887249	578793.	0.

2 Compensation of five highest-paid employees (other than those included on line 1). If none, enter "NONE."

(a) Name and address of each employee paid more than \$50,000	(b) Title, and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
MEENAKSHI C. LAKSHMAN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIR. OF STRATEGY & RESEARCH 40.00	964,169.	156,520.	0.
JOSHUA W. FENTON - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	962,255.	156,520.	0.
AL Y. KIM - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	952,777.	156,520.	0.
CHRISTOPHER J. RAPCEWICZ - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY	DIR. OF RISK MNGMT. & OPERATIONS 40.00	960,510.	139,472.	0.
BRIAN B. CHUN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	INVESTMENT OFFICER 40.00	468,187.	78,701.	0.
Total number of other employees paid over \$50,000				88

Part VII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors (continued)

3 Five highest-paid independent contractors for professional services. If none, enter "NONE."

(a) Name and address of each person paid more than \$50,000	(b) Type of service	(c) Compensation
STARWOOD X 591 WEST PUTNAM AVENUE , GREENWICH, CT 06830	INVESTMENT MANAGEMENT	4,022,881.
HIG GROWTH II 600 5TH AVE., 24TH FL., NEW YORK, NY 10020	INVESTMENT MANAGEMENT	2,249,370.
HIG CAPITAL PARTNERS V, LP 600 5TH AVE., 24TH FL., NEW YORK, NY 10020	INVESTMENT MANAGEMENT	1,742,107.
HIGHCLERE INTERNATIONAL INVESTORS 2 MANCHESTER SQUARE, LONDON, UNITED KINGDOM	INVESTMENT MANAGEMENT	1,695,311.
IFP GLOBAL FRANCHISE - LEVEL 1, 10 PORTMAN SQUARE, LONDON, UNITED KINGDOM W1H 6AZ	INVESTMENT MANAGEMENT	1,080,516.
Total number of others receiving over \$50,000 for professional services		44

Part VIII-A Summary of Direct Charitable Activities

List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc.	Expenses
1 FOR THE PRODUCTION OF VIDEO AND OTHER DESIGN SUPPORT TO COMMUNICATE IMPACT IN FURTHERANCE OF THE FOUNDATION'S MISSION.	1,219,560.
2 FOR TECHNICAL SUPPORT TO GRANTEES TO MEET THEIR STRATEGIC AND COMMUNICATIONS NEEDS TO DRIVE FURTHER IMPACT OF THEIR CHARITABLE WORK.	174,112.
3 FOR CONVENING EXPERTS TO EXPLORE PROGRAM PRIORITIES, SHARE RESEARCH AND IDEAS, AND BRAINSTORM NEW AREAS OF IMPACT IN SUPPORT OF THE FOUNDATION'S MISSION.	419,722.
4	

Part VIII-B Summary of Program-Related Investments

Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2.	Amount
1 STARTUP HEALTH T1D PRI LP - CATALYZING SEED AND EARLY STAGE COMPANIES DEVELOPING INNOVATIVE T1D SOLUTIONS	2,500,000.
2 DIABETOMICS, INC. - POINT-OF-CARE RAPID TESTS FOR T1D SCREENING AND INTERVENTION	1,000,000.
All other program-related investments. See instructions.	
3	
SEE STATEMENT 20	1,243,630.
Total. Add lines 1 through 3	4,743,630.

Part IX Minimum Investment Return (All domestic foundations must complete this part. Foreign foundations, see instructions.)

1 Fair market value of assets not used (or held for use) directly in carrying out charitable, etc., purposes:			
a	Average monthly fair market value of securities	1a	7,158,769,720.
b	Average of monthly cash balances	1b	338,688,785.
c	Fair market value of all other assets (see instructions)	1c	450,277.
d	Total (add lines 1a, b, and c)	1d	7,497,908,782.
e	Reduction claimed for blockage or other factors reported on lines 1a and 1c (attach detailed explanation)	1e	0.
2	Acquisition indebtedness applicable to line 1 assets	2	0.
3	Subtract line 2 from line 1d	3	7,497,908,782.
4	Cash deemed held for charitable activities. Enter 1.5% (0.015) of line 3 (for greater amount, see instructions)	4	112,468,632.
5	Net value of noncharitable-use assets. Subtract line 4 from line 3	5	7,385,440,150.
6	Minimum investment return. Enter 5% (0.05) of line 5	6	369,272,008.

Part X Distributable Amount (see instructions) (Section 4942(j)(3) and (j)(5) private operating foundations and certain foreign organizations, check here and do not complete this part.)

1	Minimum investment return from Part IX, line 6	1	369,272,008.
2a	Tax on investment income for 2022 from Part V, line 5	2a	1,659,683.
b	Income tax for 2022. (This does not include the tax from Part V.)	2b	911,010.
c	Add lines 2a and 2b	2c	2,570,693.
3	Distributable amount before adjustments. Subtract line 2c from line 1	3	366,701,315.
4	Recoveries of amounts treated as qualifying distributions	4	441,259.
5	Add lines 3 and 4	5	367,142,574.
6	Deduction from distributable amount (see instructions)	6	0.
7	Distributable amount as adjusted. Subtract line 6 from line 5. Enter here and on Part XII, line 1	7	367,142,574.

Part XI Qualifying Distributions (see instructions)

1 Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:			
a	Expenses, contributions, gifts, etc. - total from Part I, column (d), line 26	1a	462,319,022.
b	Program-related investments - total from Part VIII-B	1b	4,743,630.
2	Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	2	298,195.
3 Amounts set aside for specific charitable projects that satisfy the:			
a	Suitability test (prior IRS approval required)	3a	
b	Cash distribution test (attach the required schedule)	3b	
4	Qualifying distributions. Add lines 1a through 3b. Enter here and on Part XII, line 4	4	467,360,847.

Form 990-PF (2022)

Part XII Undistributed Income (see instructions)

	(a) Corpus	(b) Years prior to 2021	(c) 2021	(d) 2022
1 Distributable amount for 2022 from Part X, line 7				367,142,574.
2 Undistributed income, if any, as of the end of 2022:				
a Enter amount for 2021 only			100,386,880.	
b Total for prior years:		0.		
3 Excess distributions carryover, if any, to 2022:				
a From 2017				
b From 2018				
c From 2019				
d From 2020				
e From 2021				
f Total of lines 3a through e	0.			
4 Qualifying distributions for 2022 from Part XI, line 4: \$ 467,360,847.				
a Applied to 2021, but not more than line 2a ...			100,386,880.	
b Applied to undistributed income of prior years (Election required - see instructions) ...		0.		
c Treated as distributions out of corpus (Election required - see instructions)	0.			
d Applied to 2022 distributable amount				366,973,967.
e Remaining amount distributed out of corpus	0.			
5 Excess distributions carryover applied to 2022 (If an amount appears in column (d), the same amount must be shown in column (a).)	0.			0.
6 Enter the net total of each column as indicated below:				
a Corpus. Add lines 3f, 4c, and 4e. Subtract line 5	0.			
b Prior years' undistributed income. Subtract line 4b from line 2b		0.		
c Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed		0.		
d Subtract line 6c from line 6b. Taxable amount - see instructions		0.		
e Undistributed income for 2021. Subtract line 4a from line 2a. Taxable amount - see instr. ...			0.	
f Undistributed income for 2022. Subtract lines 4d and 5 from line 1. This amount must be distributed in 2023				168,607.
7 Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(F) or 4942(g)(3) (Election may be required - see instructions)	0.			
8 Excess distributions carryover from 2017 not applied on line 5 or line 7	0.			
9 Excess distributions carryover to 2023. Subtract lines 7 and 8 from line 6a	0.			
10 Analysis of line 9:				
a Excess from 2018 ...				
b Excess from 2019 ...				
c Excess from 2020 ...				
d Excess from 2021 ...				
e Excess from 2022 ...				

Part XIII Private Operating Foundations (see instructions and Part VI-A, question 9) N/A

1 a If the foundation has received a ruling or determination letter that it is a private operating foundation, and the ruling is effective for 2022, enter the date of the ruling _____

b Check box to indicate whether the foundation is a private operating foundation described in section _____ 4942(j)(3) or 4942(j)(5)

	Tax year				(e) Total
	(a) 2022	(b) 2021	(c) 2020	(d) 2019	
2 a Enter the lesser of the adjusted net income from Part I or the minimum investment return from Part IX for each year listed _____					
b 85% (0.85) of line 2a _____					
c Qualifying distributions from Part XI, line 4, for each year listed _____					
d Amounts included in line 2c not used directly for active conduct of exempt activities _____					
e Qualifying distributions made directly for active conduct of exempt activities. Subtract line 2d from line 2c _____					
3 Complete 3a, b, or c for the alternative test relied upon:					
a "Assets" alternative test - enter:					
(1) Value of all assets _____					
(2) Value of assets qualifying under section 4942(j)(3)(B)(i) _____					
b "Endowment" alternative test - enter 2/3 of minimum investment return shown in Part IX, line 6, for each year listed _____					
c "Support" alternative test - enter:					
(1) Total support other than gross investment income (interest, dividends, rents, payments on securities loans (section 512(a)(5)), or royalties) _____					
(2) Support from general public and 5 or more exempt organizations as provided in section 4942(j)(3)(B)(iii) _____					
(3) Largest amount of support from an exempt organization _____					
(4) Gross investment income _____					

Part XIV Supplementary Information (Complete this part only if the foundation had \$5,000 or more in assets at any time during the year-see instructions.)

1 Information Regarding Foundation Managers:

a List any managers of the foundation who have contributed more than 2% of the total contributions received by the foundation before the close of any tax year (but only if they have contributed more than \$5,000). (See section 507(d)(2).)

NONE

b List any managers of the foundation who own 10% or more of the stock of a corporation (or an equally large portion of the ownership of a partnership or other entity) of which the foundation has a 10% or greater interest.

NONE

2 Information Regarding Contribution, Grant, Gift, Loan, Scholarship, etc., Programs:

Check here if the foundation only makes contributions to preselected charitable organizations and does not accept unsolicited requests for funds. If the foundation makes gifts, grants, etc., to individuals or organizations under other conditions, complete items 2a, b, c, and d.

a The name, address, and telephone number or email address of the person to whom applications should be addressed:

b The form in which applications should be submitted and information and materials they should include:

c Any submission deadlines:

d Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors:

Part XIV Supplementary Information (continued)

3 Grants and Contributions Paid During the Year or Approved for Future Payment				
Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
a Paid during the year				
4YOUANDME 2901 THIRD AVENUE SEATTLE, WA 98121	N/A	PC	LEVERAGING WEARABLES TO MEASURE STRESS AND FORECAST SYMPTOM TRANSITIONS IN CROHNS DISEASE	110,128.
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD AUSTIN, TX 78746	N/A	PF	INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA	1,129,775.
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD AUSTIN, TX 78746	N/A	PF	EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY	1,300,000.
ADVENTIST HEALTH SYSTEM/SUNBELT, INC. 601 EAST ROLLINS STREET ORLANDO, FL 32803	N/A	PC	DETERMINING WHETHER A NOVEL CLASS OF DRUGS MIGHT PREVENT HYPOGLYCEMIA IN T1D PATIENTS	731,837.
AITKIN COMMUNITY HOSPITAL, INC. 200 BUNKER HILL DRIVE AITKIN, MN 56431	N/A	PC	AITKIN COMMUNITY HOSPITAL/ RIVERWOOD HEALTHCARE CENTER ULTRASOUND PROJECT	233,092.
Total	SEE CONTINUATION SHEET(S)			3a 433,687,275.
b Approved for future payment				
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD AUSTIN, TX 78746	N/A	PF	EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY	2,053,426.
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD AUSTIN, TX 78746	N/A	PF	EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY	1,446,574.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	PRECLINICAL ACTIVITIES TO ADVANCE D-PEPTIDES AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES	556,499.
Total	SEE CONTINUATION SHEET(S)			3b 482,673,051.

Part XV-A Analysis of Income-Producing Activities

Enter gross amounts unless otherwise indicated.

Table with 5 main columns: (a) Business code, (b) Amount, (c) Exclusion code, (d) Amount, (e) Related or exempt function income. Rows include program service revenue, membership dues, interest on investments, dividends, rental income, and other revenue.

(See worksheet in line 13 instructions to verify calculations.)

Part XV-B Relationship of Activities to the Accomplishment of Exempt Purposes

Table with 2 columns: Line No., Explain below how each activity for which income is reported in column (e) of Part XV-A contributed importantly to the accomplishment of the foundation's exempt purposes (other than by providing funds for such purposes).

Part XVI Information Regarding Transfers to and Transactions and Relationships With Noncharitable Exempt Organizations

1 Did the organization directly or indirectly engage in any of the following with any other organization described in section 501(c) (other than section 501(c)(3) organizations) or in section 527, relating to political organizations?

a Transfers from the reporting foundation to a noncharitable exempt organization of:

(1) Cash **1a(1)**

(2) Other assets **1a(2)**

b Other transactions:

(1) Sales of assets to a noncharitable exempt organization **1b(1)**

(2) Purchases of assets from a noncharitable exempt organization **1b(2)**

(3) Rental of facilities, equipment, or other assets **1b(3)**

(4) Reimbursement arrangements **1b(4)**

(5) Loans or loan guarantees **1b(5)**

(6) Performance of services or membership or fundraising solicitations **1b(6)**

c Sharing of facilities, equipment, mailing lists, other assets, or paid employees **1c**

d If the answer to any of the above is "Yes," complete the following schedule. Column (b) should always show the fair market value of the goods, other assets, or services given by the reporting foundation. If the foundation received less than fair market value in any transaction or sharing arrangement, show in column (d) the value of the goods, other assets, or services received.

(a) Line no.	(b) Amount involved	(c) Name of noncharitable exempt organization	(d) Description of transfers, transactions, and sharing arrangements
A1	413,127.	ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS	SEE STATEMENT 21

2a Is the foundation directly or indirectly affiliated with, or related to, one or more tax-exempt organizations described in section 501(c) (other than section 501(c)(3)) or in section 527? Yes No

b If "Yes," complete the following schedule.

(a) Name of organization	(b) Type of organization	(c) Description of relationship
N/A		

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than taxpayer) is based on all information of which preparer has any knowledge.

Sign Here *Thomas Blaney* 10/08/2024 CFO
 Signature of officer or trustee Date Title

Paid Preparer Use Only	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	THOMAS BLANEY	THOMAS BLANEY	10/02/24		P00234022
	Firm's name	PKF O'CONNOR DAVIES ADVISORY, LLC		Firm's EIN	87-3231666
	Firm's address	245 PARK AVENUE, 12TH FLOOR NEW YORK, NY 10167		Phone no.	212-286-2600

May the IRS discuss this return with the preparer shown below? See instr. Yes No

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SALE OF PUBLICLY TRADED SECURITIES	P		
b EPIRIS FUND II B LP	P		11/23/22
c EPIRIS FUND II B LP	P		07/06/22
d EPIRIS FUND II B LP	P		09/30/22
e EPIRIS FUND II B LP	P		02/09/23
f EPIRIS FUND II B LP	P		05/03/22
g ACADIAN FRONTIER MARKETS	P		02/03/23
h ACADIAN FRONTIER MARKETS	P		02/10/23
i ACADIAN FRONTIER MARKETS	P		02/17/23
j FDAF DISLOCATED I LP	P		01/05/23
k FRAZIER LIFE SCI PUBLIC FD LP	P		01/18/23
l FRAZIER LIFE SCI PUBLIC FD LP	P		07/08/22
m FRAZIER LIFE SCI PUBLIC FD LP	P		04/29/22
n HIGHCLERE INTL SMID CAP FUND	P		04/30/22
o HIGHCLERE INTL SMID CAP FUND	P		03/31/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 111,466,353.			111,466,353.
b 108,024.			108,024.
c 9,097.			9,097.
d 4,609,105.			4,609,105.
e 35,515.			35,515.
f 141,155.			141,155.
g 436,838.			436,838.
h 11,604.			11,604.
i 259,155.			259,155.
j 1,197,999.			1,197,999.
k 188,575.			188,575.
l 764,109.			764,109.
m 686,779.			686,779.
n 54,225.			54,225.
o 46,174.			46,174.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			111,466,353.
b			108,024.
c			9,097.
d			4,609,105.
e			35,515.
f			141,155.
g			436,838.
h			11,604.
i			259,155.
j			1,197,999.
k			188,575.
l			764,109.
m			686,779.
n			54,225.
o			46,174.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIGHCLERE INTL SMID CAP FUND	P		02/28/23
b HIGHCLERE INTL SMID CAP FUND	P		01/31/23
c HIGHCLERE INTL SMID CAP FUND	P		12/31/22
d HIGHCLERE INTL SMID CAP FUND	P		10/31/22
e HIGHCLERE INTL SMID CAP FUND	P		05/06/22
f HIGHCLERE INTL SMID CAP FUND	P		05/31/22
g HIGHCLERE INTL SMID CAP FUND	P		06/30/22
h HIGHCLERE INTL SMID CAP FUND	P		07/31/22
i HIGHCLERE INTL SMID CAP FUND	P		08/31/22
j HIGHCLERE INTL SMID CAP FUND	P		09/30/22
k HIGHCLERE INTL SMID CAP FUND	P		11/30/22
l HIGHCLERE INTL SMALL CAP FUND	P		05/31/22
m HIGHCLERE INTL SMALL CAP FUND	P		03/31/23
n HIGHCLERE INTL SMALL CAP FUND	P		02/28/23
o HIGHCLERE INTL SMALL CAP FUND	P		01/31/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 45,869.			45,869.
b 46,852.			46,852.
c 43,276.			43,276.
d 38,637.			38,637.
e 15,000,000.			15,000,000.
f 45,305.			45,305.
g 41,627.			41,627.
h 43,149.			43,149.
i 40,710.			40,710.
j 37,024.			37,024.
k 42,487.			42,487.
l 104,030.			104,030.
m 98,668.			98,668.
n 97,462.			97,462.
o 100,508.			100,508.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			45,869.
b			46,852.
c			43,276.
d			38,637.
e			15,000,000.
f			45,305.
g			41,627.
h			43,149.
i			40,710.
j			37,024.
k			42,487.
l			104,030.
m			98,668.
n			97,462.
o			100,508.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIGHCLERE INTL SMALL CAP FUND	P		12/31/22
b HIGHCLERE INTL SMALL CAP FUND	P		11/30/22
c HIGHCLERE INTL SMALL CAP FUND	P		10/31/22
d HIGHCLERE INTL SMALL CAP FUND	P		09/30/22
e HIGHCLERE INTL SMALL CAP FUND	P		08/31/22
f HIGHCLERE INTL SMALL CAP FUND	P		07/31/22
g HIGHCLERE INTL SMALL CAP FUND	P		06/30/22
h HIGHCLERE INTL SMALL CAP FUND	P		05/06/22
i HIGHCLERE INTL SMALL CAP FUND	P		04/30/22
j ACADIAN FRONTIER MARKETS	P		05/13/22
k ACADIAN FRONTIER MARKETS	P		05/20/22
l ACADIAN FRONTIER MARKETS	P		05/27/22
m ACADIAN FRONTIER MARKETS	P		07/01/19
n ACADIAN FRONTIER MARKETS	P		06/03/22
o ACADIAN FRONTIER MARKETS	P		06/10/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 94,864.			94,864.
b 93,455.			93,455.
c 88,541.			88,541.
d 85,564.			85,564.
e 95,844.			95,844.
f 100,604.			100,604.
g 95,275.			95,275.
h 15,000,000.			15,000,000.
i 115,161.			115,161.
j 4,208,062.			4,208,062.
k 2,990,472.			2,990,472.
l 1,101,600.			1,101,600.
m		443,545.	-443,545.
n 243,622.			243,622.
o 2,126,548.			2,126,548.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			94,864.
b			93,455.
c			88,541.
d			85,564.
e			95,844.
f			100,604.
g			95,275.
h			15,000,000.
i			115,161.
j			4,208,062.
k			2,990,472.
l			1,101,600.
m			-443,545.
n			243,622.
o			2,126,548.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACADIAN FRONTIER MARKETS	P		06/17/22
b ACADIAN FRONTIER MARKETS	P		07/08/22
c ACADIAN FRONTIER MARKETS	P		07/15/22
d ACADIAN FRONTIER MARKETS	P		07/22/22
e ACADIAN FRONTIER MARKETS	P		07/29/22
f ACADIAN FRONTIER MARKETS	P		08/05/22
g ACADIAN FRONTIER MARKETS	P		08/12/22
h ACADIAN FRONTIER MARKETS	P		09/02/22
i ACADIAN FRONTIER MARKETS	P		09/09/22
j ACADIAN FRONTIER MARKETS	P		09/23/22
k ACADIAN FRONTIER MARKETS	P		06/24/22
l ACADIAN FRONTIER MARKETS	P		09/30/22
m ACADIAN FRONTIER MARKETS	P		10/11/22
n ACADIAN FRONTIER MARKETS	P		10/28/22
o ACADIAN FRONTIER MARKETS	P		11/25/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 6,592,050.			6,592,050.
b 687,808.			687,808.
c 4,980,132.			4,980,132.
d 2,228,858.			2,228,858.
e 1,085,738.			1,085,738.
f 452,886.			452,886.
g 7,131,197.			7,131,197.
h 1,714,214.			1,714,214.
i 2,210,663.			2,210,663.
j 4,804,526.			4,804,526.
k 856,588.			856,588.
l 447,336.			447,336.
m 5,111,460.			5,111,460.
n 2,955,250.			2,955,250.
o 157,852.			157,852.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			6,592,050.
b			687,808.
c			4,980,132.
d			2,228,858.
e			1,085,738.
f			452,886.
g			7,131,197.
h			1,714,214.
i			2,210,663.
j			4,804,526.
k			856,588.
l			447,336.
m			5,111,460.
n			2,955,250.
o			157,852.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACADIAN FRONTIER MARKETS	P		11/14/22
b ACADIAN FRONTIER MARKETS	P		11/18/22
c ACADIAN FRONTIER MARKETS	P		12/02/22
d ACADIAN FRONTIER MARKETS	P		12/09/22
e ACADIAN FRONTIER MARKETS	P		12/16/22
f ACADIAN FRONTIER MARKETS	P		12/23/22
g ACADIAN FRONTIER MARKETS	P		12/30/22
h ACADIAN FRONTIER MARKETS	P		01/11/23
i ACADIAN FRONTIER MARKETS	P		01/13/23
j ACADIAN FRONTIER MARKETS	P		01/20/23
k ACADIAN FRONTIER MARKETS	P		04/14/22
l ACADIAN FRONTIER MARKETS	P		04/22/22
m ACADIAN FRONTIER MARKETS	P		04/29/22
n BRILLIANT US FEEDER 2 FUND LTD	P		02/24/23
o BRILLIANT US FEEDER 2 FUND LTD	P		12/29/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 6,349,893.			6,349,893.
b 1,516,813.			1,516,813.
c 635,988.			635,988.
d 7,055,410.			7,055,410.
e 3,843,387.			3,843,387.
f 2,089,676.			2,089,676.
g 178,059.			178,059.
h 519,344.			519,344.
i 3,896,492.			3,896,492.
j 738,170.			738,170.
k 8,199,943.			8,199,943.
l 402,678.			402,678.
m 498,861.			498,861.
n 17,347,230.		20,574,178.	-3,226,948.
o 14,440,458.		20,574,178.	-6,133,720.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			6,349,893.
b			1,516,813.
c			635,988.
d			7,055,410.
e			3,843,387.
f			2,089,676.
g			178,059.
h			519,344.
i			3,896,492.
j			738,170.
k			8,199,943.
l			402,678.
m			498,861.
n			-3,226,948.
o			-6,133,720.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a BRILLIANT US FEEDER 2 FUND LTD	P		11/28/22
b BRILLIANT US FEEDER 2 FUND LTD	P		10/31/22
c BRILLIANT US FEEDER 2 FUND LTD	P		01/25/23
d CHATHAM CO INVEST	P		11/30/22
e CHATHAM CO INVEST	P		12/31/22
f CHATHAM CO INVEST	P		01/31/23
g CHATHAM CO INVEST	P		02/28/23
h CHATHAM CO INVEST	P		03/31/23
i CHATHAM CO INVEST	P		11/30/22
j CHATHAM CO INVEST	P		10/31/22
k CHATHAM CO INVEST	P		09/30/22
l CHATHAM CO INVEST	P		08/31/22
m CHATHAM CO INVEST	P		07/31/22
n CHATHAM CO INVEST	P		03/31/23
o CHATHAM CO INVEST	P		06/30/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 12,196,681.		17,377,384.	-5,180,703.
b 14,669,169.		20,900,082.	-6,230,913.
c 15,637,450.		20,574,178.	-4,936,728.
d 5,000,000.		2,408,186.	2,591,814.
e 10,000,000.		4,459,515.	5,540,485.
f 10,000,000.		4,020,733.	5,979,267.
g 10,000,000.		3,738,131.	6,261,869.
h 11,230,000.		3,551,785.	7,678,215.
i 5,000,000.		2,408,186.	2,591,814.
j 5,000,000.		2,341,731.	2,658,269.
k 5,000,000.		2,269,238.	2,730,762.
l 5,000,000.		2,307,510.	2,692,490.
m 5,000,000.		2,450,963.	2,549,037.
n 229,186.		72,486.	156,700.
o 5,000,000.		2,504,097.	2,495,903.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			-5,180,703.
b			-6,230,913.
c			-4,936,728.
d			2,591,814.
e			5,540,485.
f			5,979,267.
g			6,261,869.
h			7,678,215.
i			2,591,814.
j			2,658,269.
k			2,730,762.
l			2,692,490.
m			2,549,037.
n			156,700.
o			2,495,903.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a CHATHAM CO INVEST	P		04/30/22
b CHATHAM CO INVEST	P		05/31/22
c BLACKROCK US DEBT INDEX FUND B	P		11/02/22
d BLACKROCK US DEBT INDEX FUND B	P		02/08/23
e BLACKROCK US DEBT INDEX FUND B	P		08/01/22
f BLACKROCK US DEBT INDEX FUND B	P		05/06/22
g CHATHAM ASSET PARTNERS HIGH	P		09/30/22
h CHATHAM ASSET PARTNERS HIGH	P		06/30/22
i CHATHAM ASSET HIGH YIELD	P		06/30/22
j CHATHAM ASSET HIGH YIELD	P		09/30/22
k GOLDENTREE OFFSHORE FUND SIDE	P		02/28/22
l GOLDENTREE OFFSHORE FUND SIDE	P		02/28/22
m CAMBER CAPITAL OFFSHORE FUND	P		12/31/22
n LA CAPITAL GLOBAL EQUITY FUND	P		03/31/23
o LA CAPITAL GLOBAL EQUITY FUND	P		01/31/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 5,000,000.		2,703,801.	2,296,199.
b 5,000,000.		2,650,592.	2,349,408.
c 20,305.		24,209.	-3,904.
d 19,815.		22,379.	-2,564.
e 20,379.		22,216.	-1,837.
f 23,774.		26,724.	-2,950.
g 5,000,000.		2,778,325.	2,221,675.
h 5,000,000.		2,822,397.	2,177,603.
i 5,000,000.		2,846,607.	2,153,393.
j 5,000,000.		2,751,016.	2,248,984.
k		130,055.	-130,055.
l 130,113.			130,113.
m 30,000,000.		20,331,454.	9,668,546.
n 13,216.			13,216.
o 13,161.			13,161.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			2,296,199.
b			2,349,408.
c			-3,904.
d			-2,564.
e			-1,837.
f			-2,950.
g			2,221,675.
h			2,177,603.
i			2,153,393.
j			2,248,984.
k			-130,055.
l			130,113.
m			9,668,546.
n			13,216.
o			13,161.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a LA CAPITAL GLOBAL EQUITY FUND	P		02/28/23
b LA CAPITAL GLOBAL EQUITY FUND	P		12/31/22
c LA CAPITAL GLOBAL EQUITY FUND	P		11/30/22
d LA CAPITAL GLOBAL EQUITY FUND	P		10/31/22
e LA CAPITAL GLOBAL EQUITY FUND	P		09/30/22
f LA CAPITAL GLOBAL EQUITY FUND	P		08/31/22
g LA CAPITAL GLOBAL EQUITY FUND	P		07/31/22
h LA CAPITAL GLOBAL EQUITY FUND	P		06/30/22
i LA CAPITAL GLOBAL EQUITY FUND	P		06/06/22
j LA CAPITAL GLOBAL EQUITY FUND	P		05/31/22
k LA CAPITAL GLOBAL EQUITY FUND	P		05/05/22
l LA CAPITAL GLOBAL EQUITY FUND	P		04/30/22
m THE MARATHON-LONDON GLOBAL	P		12/30/22
n THE MARATHON-LONDON GLOBAL	P		11/30/22
o THE MARATHON-LONDON GLOBAL	P		10/31/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 12,853.			12,853.
b 12,571.			12,571.
c 12,859.			12,859.
d 9,282.			9,282.
e 11,403.			11,403.
f 12,474.			12,474.
g 12,885.			12,885.
h 12,196.			12,196.
i 10,000,000.			10,000,000.
j 14,845.			14,845.
k 15,000,000.			15,000,000.
l 17,372.			17,372.
m 63,988.		56,233.	7,755.
n 65,373.		56,093.	9,280.
o 59,405.		56,967.	2,438.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			12,853.
b			12,571.
c			12,859.
d			9,282.
e			11,403.
f			12,474.
g			12,885.
h			12,196.
i			10,000,000.
j			14,845.
k			15,000,000.
l			17,372.
m			7,755.
n			9,280.
o			2,438.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a THE MARATHON-LONDON GLOBAL	P		08/31/22
b THE MARATHON-LONDON GLOBAL	P		09/30/22
c THE MARATHON-LONDON GLOBAL	P		01/31/23
d THE MARATHON-LONDON GLOBAL	P		06/30/22
e THE MARATHON-LONDON GLOBAL	P		05/31/22
f THE MARATHON-LONDON GLOBAL	P		04/29/22
g THE MARATHON-LONDON GLOBAL	P		03/31/23
h THE MARATHON-LONDON GLOBAL	P		02/28/23
i THE MARATHON-LONDON GLOBAL	P		07/29/22
j LACM WORLD SMALL CAP EQUITY	P		07/29/22
k LACM WORLD SMALL CAP EQUITY	P		06/30/22
l LACM WORLD SMALL CAP EQUITY	P		06/06/22
m LACM WORLD SMALL CAP EQUITY	P		05/31/22
n LACM WORLD SMALL CAP EQUITY	P		05/05/22
o LACM WORLD SMALL CAP EQUITY	P		04/29/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 62,269.		56,620.	5,649.
b 57,013.		57,399.	-386.
c 67,850.		55,281.	12,569.
d 61,049.		56,872.	4,177.
e 65,908.		56,254.	9,654.
f 64,932.		56,414.	8,518.
g 68,480.		54,913.	13,567.
h 66,345.		55,861.	10,484.
i 64,859.		56,310.	8,549.
j 12,768.			12,768.
k 11,713.			11,713.
l 10,000,000.			10,000,000.
m 14,822.			14,822.
n 15,000,000.		27,524,860.	-12,524,860.
o 17,216.		642,513.	-625,297.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			5,649.
b			-386.
c			12,569.
d			4,177.
e			9,654.
f			8,518.
g			13,567.
h			10,484.
i			8,549.
j			12,768.
k			11,713.
l			10,000,000.
m			14,822.
n			-12,524,860.
o			-625,297.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a LACM WORLD SMALL CAP EQUITY	P		08/31/22
b LACM WORLD SMALL CAP EQUITY	P		10/31/22
c LACM WORLD SMALL CAP EQUITY	P		09/30/22
d LACM WORLD SMALL CAP EQUITY	P		11/30/22
e LACM WORLD SMALL CAP EQUITY	P		12/30/22
f LACM WORLD SMALL CAP EQUITY	P		03/31/23
g LACM WORLD SMALL CAP EQUITY	P		01/31/23
h LACM WORLD SMALL CAP EQUITY	P		02/28/23
i RIDGEWOOD ENERGY OIL & GAS FD	P		09/29/22
j RIDGEWOOD ENERGY OIL & GAS FD	P		06/27/22
k HARBOUR ENERGY FUND LP	P		12/27/22
l SEQUOIA CAP CHINA GROWTH IV LP	P		12/16/22
m SEQUOIA CAP CHINA GROWTH IV LP	P		04/22/22
n MHR INSTITUTIONAL PTNRS IV LP	P		12/28/22
o MHR INSTITUTIONAL PTNRS IV LP	P		02/22/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 12,307.			12,307.
b 11,452.			11,452.
c 11,177.			11,177.
d 12,938.			12,938.
e 12,559.			12,559.
f 13,300.			13,300.
g 13,764.			13,764.
h 13,609.			13,609.
i 51,043.			51,043.
j 86,923.			86,923.
k 437,156.			437,156.
l 1,605,960.			1,605,960.
m 1,589,903.			1,589,903.
n 1,029.			1,029.
o 727,731.			727,731.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			12,307.
b			11,452.
c			11,177.
d			12,938.
e			12,559.
f			13,300.
g			13,764.
h			13,609.
i			51,043.
j			86,923.
k			437,156.
l			1,605,960.
m			1,589,903.
n			1,029.
o			727,731.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a MHR INSTITUTIONAL PTNRS IV LP	P		09/30/22
b MHR INSTITUTIONAL PTNRS IV LP	P		05/24/22
c FDAF DISLOCATED II LP	P		07/08/22
d COLLER INTL PARTNERS VII LP	P		03/30/23
e COLLER INTL PARTNERS VII LP	P		02/01/23
f HIG BRAZIL & LATIN AME PTNRS	P		07/28/22
g HIG BRAZIL & LATIN AME PTNRS	P		09/28/22
h HIG BRAZIL & LATIN AME PTNRS	P		07/28/22
i HIG BRAZIL & LATIN AME PTNRS	P		09/28/22
j IDG CHINA CAPITAL FUND III LP	P		08/18/22
k IDG CHINA CAPITAL FUND III LP	P		12/28/22
l ORBIMED PRIVATE INVEST VI LP	P		08/23/22
m ORBIMED PRIVATE INVEST VI LP	P		01/12/23
n SEQUOIA CAP GBL GROWTH FD II	P		12/14/22
o SEQUOIA CAP GBL GROWTH FD II	P		05/27/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 34,416.			34,416.
b 162,699.			162,699.
c 3,314,638.			3,314,638.
d 1,616,063.			1,616,063.
e 586,823.			586,823.
f 62,808.			62,808.
g 60,180.			60,180.
h 62,808.			62,808.
i 60,180.			60,180.
j 563,968.			563,968.
k		54,049.	-54,049.
l 1,078,047.			1,078,047.
m 102,313.			102,313.
n 1,304,133.			1,304,133.
o 1,410,518.			1,410,518.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			34,416.
b			162,699.
c			3,314,638.
d			1,616,063.
e			586,823.
f			62,808.
g			60,180.
h			62,808.
i			60,180.
j			563,968.
k			-54,049.
l			1,078,047.
m			102,313.
n			1,304,133.
o			1,410,518.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ANGELENO INVESTORS III	P		09/08/22
b GSO CAPITAL SOLUTION	P		02/17/23
c ENERGY FUND XV-A LP	P		01/06/23
d ENERGY FUND XV-A LP	P		08/26/22
e ENERGY FUND XV-A LP	P		11/01/22
f HIG BIOVENTURES II	P		01/09/23
g IDG-ACCEL CHINA GROWTH FUND	P		06/30/22
h IDG-ACCEL CHINA GROWTH FUND	P		02/14/23
i IDG-ACCEL CHINA CAPITAL FUND	P		09/29/22
j H.I.G. GROWTH BUYOUTS & EQUITY	P		06/21/22
k H.I.G. GROWTH BUYOUTS & EQUITY	P		02/28/23
l H.I.G. GROWTH BUYOUTS & EQUITY	P		05/27/22
m ACCEL XI	P		03/31/23
n COLLER INTERNATIONAL PARTNERS	P		05/27/22
o COLLER INTERNATIONAL PARTNERS	P		06/29/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 969,295.			969,295.
b 383,012.			383,012.
c 3,128.			3,128.
d 173,634.			173,634.
e 85,839.			85,839.
f 1,845,838.			1,845,838.
g 358,328.			358,328.
h 892,819.			892,819.
i 1,200,880.			1,200,880.
j 962,530.			962,530.
k 2,739,853.			2,739,853.
l 5,389,421.			5,389,421.
m 215,852.			215,852.
n 472,500.			472,500.
o 343,000.			343,000.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			969,295.
b			383,012.
c			3,128.
d			173,634.
e			85,839.
f			1,845,838.
g			358,328.
h			892,819.
i			1,200,880.
j			962,530.
k			2,739,853.
l			5,389,421.
m			215,852.
n			472,500.
o			343,000.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a COLLER INTERNATIONAL PARTNERS	P		03/28/23
b COLLER INTERNATIONAL PARTNERS	P		11/30/22
c COLLER INTERNATIONAL PARTNERS	P		01/20/23
d COLLER INTERNATIONAL PARTNERS	P		09/30/22
e SEQUOIA CAPITAL GLOBAL GROWTH	P		05/27/22
f SEQUOIA CAPITAL U.S. VENTURE	P		08/31/22
g SEQUOIA CAP CHINA VENTURE FD	P		11/03/22
h SEQUOIA CAPITAL ISRAEL VENTURE	P		10/07/22
i GSO CAPITAL SOLUTIONS FUND II	P		11/14/22
j GENERAL ATLANTIC SERVICE	P		05/05/22
k GENERAL ATLANTIC SERVICE	P		06/28/22
l GENERAL ATLANTIC SERVICE	P		08/10/22
m GENERAL ATLANTIC SERVICE	P		09/01/22
n GENERAL ATLANTIC SERVICE	P		09/28/22
o GENERAL ATLANTIC SERVICE	P		11/15/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 189,000.			189,000.
b 490,000.			490,000.
c 354,200.			354,200.
d 261,845.			261,845.
e 969,235.			969,235.
f 86,130.			86,130.
g 1,793,535.			1,793,535.
h 100,508.			100,508.
i 68,808.			68,808.
j 5,937,285.			5,937,285.
k 273,890.			273,890.
l 117,654.			117,654.
m 488,732.			488,732.
n 639,230.			639,230.
o 2,041,621.			2,041,621.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			189,000.
b			490,000.
c			354,200.
d			261,845.
e			969,235.
f			86,130.
g			1,793,535.
h			100,508.
i			68,808.
j			5,937,285.
k			273,890.
l			117,654.
m			488,732.
n			639,230.
o			2,041,621.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GENERAL ATLANTIC SERVICE	P		12/15/22
b GENERAL ATLANTIC SERVICE	P		09/09/22
c GENERAL ATLANTIC SERVICE	P		09/22/22
d GENERAL ATLANTIC SERVICE	P		11/22/22
e GENERAL ATLANTIC SERVICE	P		12/01/22
f GENERAL ATLANTIC SERVICE	P		12/23/22
g GENERAL ATLANTIC SERVICE	P		12/28/22
h GENERAL ATLANTIC SERVICE	P		02/13/23
i GENERAL ATLANTIC SERVICE	P		04/13/22
j GENERAL ATLANTIC SERVICE	P		05/13/22
k HIG CAPITAL PARTNERS V L P	P		04/27/22
l HIG CAPITAL PARTNERS V L P	P		09/19/22
m HIG CAPITAL PARTNERS V L P	P		10/31/22
n HIG CAPITAL PARTNERS V L P	P		12/09/22
o HIG CAPITAL PARTNERS V L P	P		01/26/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 493,219.			493,219.
b		66,239.	-66,239.
c 657,223.			657,223.
d 26,556.			26,556.
e 1,088,910.			1,088,910.
f 314,363.			314,363.
g		520,499.	-520,499.
h 1,252,737.			1,252,737.
i 811,993.			811,993.
j 442,504.			442,504.
k 313,965.			313,965.
l 316,366.			316,366.
m 1,134,270.			1,134,270.
n 1,456,647.			1,456,647.
o 3,483,920.			3,483,920.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			493,219.
b			-66,239.
c			657,223.
d			26,556.
e			1,088,910.
f			314,363.
g			-520,499.
h			1,252,737.
i			811,993.
j			442,504.
k			313,965.
l			316,366.
m			1,134,270.
n			1,456,647.
o			3,483,920.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a EIG ENERGY FUND XVI LP	P		05/31/22
b CRESTVIEW PARTNERS III LP	P		10/31/22
c CRESTVIEW PARTNERS III LP	P		01/13/23
d HIG MIDDLE MKT LBO FD II LP	P		05/16/22
e ACCEL XII LP	P		09/12/22
f ACCEL GROWTH FUND III LP	P		01/24/23
g ACCEL GROWTH FUND III LP	P		03/31/23
h SEQUOIA CAP CHINA GROWTH FD	P		12/14/22
i BAYVIEW OPPORTUNITY OFFSHORE	P		12/15/22
j BAYVIEW OPPORTUNITY OFFSHORE	P		09/13/22
k BAYVIEW OPPORTUNITY OFFSHORE	P		05/13/22
l BAYVIEW OPPORTUNITY OFFSHORE	P		04/13/22
m BAYVIEW OPPORTUNITY OFFSHORE	P		05/13/22
n BAYVIEW OPPORTUNITY OFFSHORE	P		06/15/22
o BAYVIEW OPPORTUNITY OFFSHORE	P		11/15/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 3,250,586.			3,250,586.
b 329,312.			329,312.
c 1,766,140.			1,766,140.
d 327,477.			327,477.
e 549,404.			549,404.
f 2,295,401.			2,295,401.
g 338,994.			338,994.
h 1,525,192.			1,525,192.
i 5,346,389.			5,346,389.
j 15,122,989.			15,122,989.
k 32,962,679.			32,962,679.
l 1,735,120.			1,735,120.
m 1,000,000.			1,000,000.
n 5,021,099.			5,021,099.
o 535,409.			535,409.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			3,250,586.
b			329,312.
c			1,766,140.
d			327,477.
e			549,404.
f			2,295,401.
g			338,994.
h			1,525,192.
i			5,346,389.
j			15,122,989.
k			32,962,679.
l			1,735,120.
m			1,000,000.
n			5,021,099.
o			535,409.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GAVEA INVESTMENT FUND V B LP	P		09/27/22
b GAVEA INVESTMENT FUND V B LP	P		04/19/22
c GAVEA INVESTMENT FUND V B LP	P		06/24/22
d GAVEA INVESTMENT FUND V B LP	P		08/25/22
e GAVEA INVESTMENT FUND V B LP	P		12/27/22
f FRAZIER LIFE SCIENCES X LP	P		04/28/22
g FRAZIER LIFE SCIENCES X LP	P		07/08/22
h ORBIMED ASIA PARTNERS IV LP	P		08/05/22
i SEQUOIA CAP US GR FUND IX LP	P		09/07/22
j PEG SECONDARY PE INVESTORS III	P		12/23/22
k PEG SECONDARY PE INVESTORS III	P		04/25/22
l FDAF DISLOCATED III LP	P		04/14/22
m FDAF DISLOCATED III LP	P		12/08/22
n FDAF DISLOCATED III LP	P		07/08/22
o GSO CAPITAL SOLUTIONS FD III	P		09/01/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 945,261.			945,261.
b 1,234,873.			1,234,873.
c 209,845.			209,845.
d 404,145.			404,145.
e 361,684.			361,684.
f 272,754.			272,754.
g 156,427.			156,427.
h 1,400,360.			1,400,360.
i 51,823.			51,823.
j 69,059.			69,059.
k 103,515.			103,515.
l 3,350,383.			3,350,383.
m 510,163.			510,163.
n 3,812,352.			3,812,352.
o 8,074.			8,074.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			945,261.
b			1,234,873.
c			209,845.
d			404,145.
e			361,684.
f			272,754.
g			156,427.
h			1,400,360.
i			51,823.
j			69,059.
k			103,515.
l			3,350,383.
m			510,163.
n			3,812,352.
o			8,074.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GSO CAPITAL SOLUTIONS FD III	P		04/07/22
b GSO CAPITAL SOLUTIONS FD III	P		06/07/22
c GSO CAPITAL SOLUTIONS FD III	P		03/13/23
d GSO CAPITAL SOLUTIONS FD III	P		10/19/22
e GSO CAPITAL SOLUTIONS FD III	P		12/06/22
f IDG CHINA VENTURE CAPITAL V LP	P		05/31/22
g EIG ENERGY FD XVII LP	P		12/16/22
h EIG ENERGY FD XVII LP	P		12/16/22
i EIG ENERGY FD XVII LP	P		05/27/22
j FRAZIER LIFE SCIENCES IX LP	P		01/25/23
k FRAZIER LIFE SCIENCES IX LP	P		08/31/22
l S CAPITAL LP	P		12/27/22
m ORBIMED PRIVATE INVEST VII LP	P		07/08/22
n GAVEA INVEST FD V PLUS B LP	P		12/23/22
o SEQUOIA CAP CN VENT FD VII LP	P		12/14/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 138,797.			138,797.
b 574.			574.
c 4,767.			4,767.
d 125,153.			125,153.
e 2,897.			2,897.
f		29,910.	-29,910.
g 13,967.			13,967.
h		13,967.	-13,967.
i 651,863.			651,863.
j 89,357.			89,357.
k		324,425.	-324,425.
l 1,151,735.			1,151,735.
m 4,443,455.			4,443,455.
n 79,169.			79,169.
o 527,957.			527,957.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			138,797.
b			574.
c			4,767.
d			125,153.
e			2,897.
f			-29,910.
g			13,967.
h			-13,967.
i			651,863.
j			89,357.
k			-324,425.
l			1,151,735.
m			4,443,455.
n			79,169.
o			527,957.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP CHINA GR FD V LP	P		12/14/22
b GA MANAGED ACCOUNT PROGRAM	P		08/03/22
c GA MANAGED ACCOUNT PROGRAM	P		06/14/22
d GA MANAGED ACCOUNT PROGRAM	P		06/08/22
e GA MANAGED ACCOUNT PROGRAM	P		03/16/23
f GA MANAGED ACCOUNT PROGRAM	P		12/30/22
g GA MANAGED ACCOUNT PROGRAM	P		12/22/22
h GA MANAGED ACCOUNT PROGRAM	P		11/22/22
i GA MANAGED ACCOUNT PROGRAM	P		11/01/22
j GA MANAGED ACCOUNT PROGRAM	P		09/26/22
k GA MANAGED ACCOUNT PROGRAM	P		08/10/22
l GA MANAGED ACCOUNT PROGRAM	P		03/09/23
m CRESTVIEW PARTNERS IV LP	P		01/06/23
n CRESTVIEW PARTNERS IV LP	P		06/30/22
o FRAZIER LIFE SCIENCES XI LP	P		01/26/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 261,116.			261,116.
b 33,497.			33,497.
c 175,604.			175,604.
d 177,058.			177,058.
e 51,142.			51,142.
f 301,585.			301,585.
g 63,221.			63,221.
h 11,664.			11,664.
i 40,618.			40,618.
j 122,530.			122,530.
k 4,251.			4,251.
l 317,252.			317,252.
m 139,853.			139,853.
n 506,346.			506,346.
o 127,727.			127,727.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			261,116.
b			33,497.
c			175,604.
d			177,058.
e			51,142.
f			301,585.
g			63,221.
h			11,664.
i			40,618.
j			122,530.
k			4,251.
l			317,252.
m			139,853.
n			506,346.
o			127,727.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a FRAZIER LIFE SCI PUBLIC	P		01/18/23
b IDG CHINA VENTURE CAP FD IV LP	P		12/28/22
c PEG SECONDARY PE INVESTORS LLC	P		01/18/22
d PEG SECONDARY PE INVESTORS LLC	P		01/18/22
e HARBOUR ENERGY FUND LP	P		07/08/22
f HARBOUR ENERGY FUND LP	P		07/08/22
g SEQUOIA CAP CHINA GROWTH IV LP	P		06/02/22
h SEQUOIA CAP CHINA GROWTH IV LP	P		06/01/22
i SEQUOIA CAP CHINA GROWTH IV LP	P		05/31/22
j SEQUOIA CAP CHINA GROWTH IV LP	P		06/01/22
k VENTURE LENDING & LEASING VIII	P		09/15/22
l SEQUOIA CAP US GROWTH FD VII	P		03/28/23
m SEQUOIA CAP US GROWTH FD VII	P		03/07/23
n SEQUOIA CAP US GROWTH FD VII	P		02/14/23
o SEQUOIA CAP US GROWTH FD VII	P		02/02/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 370,586.			370,586.
b		108,071.	-108,071.
c		1,638,552.	-1,638,552.
d 1,638,552.			1,638,552.
e 162,213,018.			162,213,018.
f		109,064,493.	-109,064,493.
g 665,612.			665,612.
h 635,410.			635,410.
i 635,410.			635,410.
j		635,410.	-635,410.
k 100,731.			100,731.
l 59,414.			59,414.
m 168,955.			168,955.
n 168,229.			168,229.
o 160,406.			160,406.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			370,586.
b			-108,071.
c			-1,638,552.
d			1,638,552.
e			162,213,018.
f			-109,064,493.
g			665,612.
h			635,410.
i			635,410.
j			-635,410.
k			100,731.
l			59,414.
m			168,955.
n			168,229.
o			160,406.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP US GROWTH FD VII	P		12/12/22
b SEQUOIA CAP US GROWTH FD VII	P		02/28/23
c SEQUOIA CAP US GROWTH FD VII	P		11/30/22
d SEQUOIA CAP US GROWTH FD VII	P		05/06/22
e SEQUOIA CAP US GROWTH FD VII	P		08/05/22
f SEQUOIA CAP US GROWTH FD VII	P		08/15/22
g SEQUOIA CAP US GROWTH FD VII	P		09/09/22
h SEQUOIA CAP US GROWTH FD VII	P		11/10/22
i SEQUOIA CAP US GROWTH FD VII	P		12/09/22
j SEQUOIA CAP US GROWTH FD VII	P		11/10/22
k SEQUOIA CAP US GROWTH FD VII	P		03/31/23
l SEQUOIA CAP GBL GROWTH FD II	P		05/06/22
m SEQUOIA CAP GBL GROWTH FD II	P		03/07/23
n SEQUOIA CAP GBL GROWTH FD II	P		02/28/23
o SEQUOIA CAP GBL GROWTH FD II	P		08/05/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 383,070.			383,070.
b 157,945.			157,945.
c 133,782.			133,782.
d 21,360.			21,360.
e 33,421.			33,421.
f 199,587.			199,587.
g 482,725.			482,725.
h 121,882.			121,882.
i 83,138.			83,138.
j 1.			1.
k 66,073.			66,073.
l 253,159.			253,159.
m 478,985.			478,985.
n 447,146.			447,146.
o 408,252.			408,252.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			383,070.
b			157,945.
c			133,782.
d			21,360.
e			33,421.
f			199,587.
g			482,725.
h			121,882.
i			83,138.
j			1.
k			66,073.
l			253,159.
m			478,985.
n			447,146.
o			408,252.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP GBL GROWTH FD II	P		06/02/22
b SEQUOIA CAP GBL GROWTH FD II	P		05/31/22
c SEQUOIA CAP GBL GROWTH FD II	P		06/01/22
d SEQUOIA CAP GBL GROWTH FD II	P		06/01/22
e ACCEL LEADERS FUND LP	P		04/13/22
f ACCEL GROWTH FD IV LP	P		02/07/23
g ACCEL GROWTH FD IV LP	P		01/23/23
h SEQUOIA CAPITAL U.S. GROWTH	P		05/06/22
i SEQUOIA CAPITAL U.S. GROWTH	P		05/25/22
j AH PARALLEL FUND III LP	P		05/25/22
k ANDREESSEN HOROWITZ FD III LP	P		05/25/22
l SEQUOIA CAPITAL GLOBAL GROWTH	P		08/05/22
m SEQUOIA CAPITAL GLOBAL GROWTH	P		08/05/22
n SEQUOIA CAPITAL GLOBAL GROWTH	P		02/28/23
o SEQUOIA CAPITAL GLOBAL GROWTH	P		05/25/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 413,953.			413,953.
b 391,481.			391,481.
c 391,481.			391,481.
d		391,481.	-391,481.
e 542,803.			542,803.
f 635,287.			635,287.
g 411,921.			411,921.
h 565,022.			565,022.
i 909,173.			909,173.
j 606,504.			606,504.
k 1,027,581.			1,027,581.
l 206,335.			206,335.
m 950,313.			950,313.
n 88,965.			88,965.
o 884,407.			884,407.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			413,953.
b			391,481.
c			391,481.
d			-391,481.
e			542,803.
f			635,287.
g			411,921.
h			565,022.
i			909,173.
j			606,504.
k			1,027,581.
l			206,335.
m			950,313.
n			88,965.
o			884,407.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL GLOBAL GROWTH	P		05/25/22
b SEQUOIA CAPITAL GLOBAL GROWTH	P		05/25/22
c SEQUOIA CAPITAL GLOBAL GROWTH	P		05/06/22
d SEQUOIA CAPITAL GLOBAL GROWTH	P		05/06/22
e SEQUOIA CAPITAL U.S. VENTURE	P		03/07/23
f SEQUOIA CAPITAL U.S. VENTURE	P		12/02/22
g SEQUOIA CAPITAL U.S. VENTURE	P		02/28/23
h SEQUOIA CAPITAL U.S. VENTURE	P		08/24/22
i SEQUOIA CAPITAL U.S. VENTURE	P		02/18/23
j SEQUOIA CAPITAL U.S. VENTURE	P		02/15/23
k SEQUOIA CAPITAL U.S. VENTURE	P		11/16/22
l VENTURE LENDING & LEASING VII	P		09/15/22
m PEG SECONDARY PE INVESTORS II	P		01/18/22
n PEG SECONDARY PE INVESTORS II	P		01/18/22
o THE SILCHESTER INTERNATIONAL	P		04/29/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,048,917.			1,048,917.
b 123,364.			123,364.
c 172,514.			172,514.
d 1,134,279.			1,134,279.
e 433,171.			433,171.
f 901,021.			901,021.
g 1,015,853.			1,015,853.
h 1,001,349.			1,001,349.
i 406,774.			406,774.
j 1,056,367.			1,056,367.
k 966,912.			966,912.
l 322,991.			322,991.
m 1,943,541.			1,943,541.
n		1,943,541.	-1,943,541.
o 70,505.		66,829.	3,676.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,048,917.
b			123,364.
c			172,514.
d			1,134,279.
e			433,171.
f			901,021.
g			1,015,853.
h			1,001,349.
i			406,774.
j			1,056,367.
k			966,912.
l			322,991.
m			1,943,541.
n			-1,943,541.
o			3,676.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a THE SILCHESTER INTERNATIONAL	P		05/31/22
b THE SILCHESTER INTERNATIONAL	P		03/31/23
c THE SILCHESTER INTERNATIONAL	P		02/28/23
d THE SILCHESTER INTERNATIONAL	P		01/31/23
e THE SILCHESTER INTERNATIONAL	P		12/30/22
f THE SILCHESTER INTERNATIONAL	P		11/30/22
g THE SILCHESTER INTERNATIONAL	P		10/31/22
h THE SILCHESTER INTERNATIONAL	P		06/06/22
i THE SILCHESTER INTERNATIONAL	P		06/30/22
j THE SILCHESTER INTERNATIONAL	P		07/29/22
k THE SILCHESTER INTERNATIONAL	P		08/31/22
l THE SILCHESTER INTERNATIONAL	P		09/30/22
m ACCEL XII LP	P		01/23/23
n SEQUOIA CAP US GROWTH FD VI LP	P		02/18/23
o SEQUOIA CAP US GROWTH FD VI LP	P		02/15/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 70,921.		66,691.	4,230.
b 69,694.		60,972.	8,722.
c 69,099.		61,144.	7,955.
d 69,625.		61,053.	8,572.
e 65,942.		62,003.	3,939.
f 64,682.		62,381.	2,301.
g 59,435.		64,062.	-4,627.
h 10,000,000.		9,317,252.	682,748.
i 63,211.		62,979.	232.
j 64,486.		62,574.	1,912.
k 61,994.		63,283.	-1,289.
l 57,858.		64,671.	-6,813.
m 496,351.			496,351.
n 335,547.			335,547.
o 349,095.			349,095.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			4,230.
b			8,722.
c			7,955.
d			8,572.
e			3,939.
f			2,301.
g			-4,627.
h			682,748.
i			232.
j			1,912.
k			-1,289.
l			-6,813.
m			496,351.
n			335,547.
o			349,095.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP US GROWTH FD VI LP	P		09/09/22
b SEQUOIA CAP US GROWTH FD VI LP	P		12/02/22
c SEQUOIA CAP US GROWTH FD VI LP	P		12/06/22
d SEQUOIA CAP US GROWTH FD VI LP	P		03/07/23
e SEQUOIA CAP US GROWTH FD VI LP	P		11/16/22
f SEQUOIA CAP US GROWTH FD VI LP	P		12/12/22
g SEQUOIA CAP US GROWTH FD VI LP	P		02/28/23
h ANDREESSEN HOROWITZ FD IV LP	P		09/06/22
i SEQUOIA CAP US GR FD VIII LP	P		11/10/22
j SEQUOIA CAP US GR FD VIII LP	P		11/30/22
k SEQUOIA CAP US GR FD VIII LP	P		02/02/23
l SEQUOIA CAP US GR FD VIII LP	P		03/28/23
m SEQUOIA CAP US GR FD VIII LP	P		03/31/23
n SEQUOIA CAP US GR FD VIII LP	P		08/15/22
o SEQUOIA CAPITAL GLOBAL GROWTH	P		09/09/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 262,830.			262,830.
b 296,259.			296,259.
c 11,205.			11,205.
d 152,484.			152,484.
e 317,935.			317,935.
f 8,446.			8,446.
g 284,920.			284,920.
h 443,562.			443,562.
i 20,548.			20,548.
j 23,961.			23,961.
k 31,600.			31,600.
l 53,320.			53,320.
m 63,483.			63,483.
n 42,840.			42,840.
o 1,470,885.			1,470,885.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			262,830.
b			296,259.
c			11,205.
d			152,484.
e			317,935.
f			8,446.
g			284,920.
h			443,562.
i			20,548.
j			23,961.
k			31,600.
l			53,320.
m			63,483.
n			42,840.
o			1,470,885.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL GLOBAL GROWTH	P		12/12/22
b MHR LONGEVITY FUND LP	P		05/02/22
c MHR LONGEVITY FUND LP	P		02/18/22
d MHR LONGEVITY FUND LP	P		08/08/22
e SEQUOIA CAPITAL FUND	P		11/30/22
f SEQUOIA CAPITAL FUND	P		07/31/22
g SEQUOIA CAPITAL FUND	P		08/26/22
h SEQUOIA CAPITAL FUND	P		09/20/22
i SEQUOIA CAPITAL FUND	P		10/21/22
j SEQUOIA CAPITAL FUND	P		03/31/23
k SEQUOIA CAPITAL FUND	P		10/21/22
l SEQUOIA CAPITAL FUND	P		11/04/22
m SEQUOIA CAPITAL FUND	P		11/30/22
n SEQUOIA CAPITAL FUND	P		11/30/22
o SEQUOIA CAPITAL FUND	P		08/26/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,154,086.			1,154,086.
b 2,969,326.		2,514,426.	454,900.
c 2,499,792.		2,068,122.	431,670.
d 6,449,504.		5,392,143.	1,057,361.
e 21,038.		25,133.	-4,095.
f 159,018.		194,997.	-35,979.
g 47,705.		58,499.	-10,794.
h 333,938.		409,493.	-75,555.
i 21,038.		25,213.	-4,175.
j 21,038.		24,035.	-2,997.
k 524,759.		628,894.	-104,135.
l 524,759.		626,904.	-102,145.
m 178,050.		212,708.	-34,658.
n 79,509.		94,986.	-15,477.
o 21,038.		25,798.	-4,760.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,154,086.
b			454,900.
c			431,670.
d			1,057,361.
e			-4,095.
f			-35,979.
g			-10,794.
h			-75,555.
i			-4,175.
j			-2,997.
k			-104,135.
l			-102,145.
m			-34,658.
n			-15,477.
o			-4,760.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL FUND	P		12/31/22
b SEQUOIA CAPITAL FUND	P		01/31/23
c IRON POINT RE PARTNERS IV LP	P		03/29/23
d IRON POINT RE PARTNERS IV LP	P		11/30/22
e IRON POINT RE PARTNERS IV LP	P		07/29/22
f IRON POINT RE PARTNERS IV LP	P		05/31/22
g ACADIAN FRONTIER	P		11/30/22
h ACADIAN FRONTIER	P		02/28/23
i ACADIAN FRONTIER	P		10/31/22
j ACADIAN FRONTIER	P		01/31/23
k ACADIAN FRONTIER	P		02/28/23
l ACADIAN FRONTIER	P		03/31/23
m ACADIAN FRONTIER	P		02/28/23
n ACADIAN FRONTIER	P		03/31/23
o ACADIAN FRONTIER	P		10/31/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 21,038.		24,796.	-3,758.
b 21,038.		24,796.	-3,758.
c 253,320.			253,320.
d 738,305.			738,305.
e 490,226.			490,226.
f 1,533,567.			1,533,567.
g		519,621.	-519,621.
h		604,199.	-604,199.
i		656,749.	-656,749.
j		63,133.	-63,133.
k		57,826.	-57,826.
l		29,950.	-29,950.
m		41,642.	-41,642.
n		466.	-466.
o 519,621.			519,621.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			-3,758.
b			-3,758.
c			253,320.
d			738,305.
e			490,226.
f			1,533,567.
g			-519,621.
h			-604,199.
i			-656,749.
j			-63,133.
k			-57,826.
l			-29,950.
m			-41,642.
n			-466.
o			519,621.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACADIAN FRONTIER	P		09/30/22
b ACADIAN FRONTIER	P		10/31/22
c ACADIAN FRONTIER	P		11/30/22
d ACADIAN FRONTIER	P		12/31/22
e ACADIAN FRONTIER	P		01/31/23
f ACADIAN FRONTIER	P		03/31/23
g ACADIAN FRONTIER	P		09/30/22
h ACADIAN FRONTIER	P		11/30/22
i ACADIAN FRONTIER	P		12/31/22
j ACADIAN FRONTIER	P		09/30/22
k ACADIAN FRONTIER	P		10/31/22
l ACADIAN FRONTIER	P		11/30/22
m ACADIAN FRONTIER	P		12/31/22
n ACADIAN FRONTIER	P		01/31/23
o ARBORETUM IV	P		04/28/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 8,264,216.			8,264,216.
b 1,745,328.			1,745,328.
c 1,948,974.			1,948,974.
d		4,168,430.	-4,168,430.
e 733,825.			733,825.
f 24,294.			24,294.
g 944,347.			944,347.
h 243,597.			243,597.
i 261,840.			261,840.
j 7,431.			7,431.
k 31,709.			31,709.
l 91,239.			91,239.
m		118,517.	-118,517.
n 30,469.			30,469.
o 4,818,402.			4,818,402.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			8,264,216.
b			1,745,328.
c			1,948,974.
d			-4,168,430.
e			733,825.
f			24,294.
g			944,347.
h			243,597.
i			261,840.
j			7,431.
k			31,709.
l			91,239.
m			-118,517.
n			30,469.
o			4,818,402.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ARBORETUM IV	P		02/13/23
b GENERL ATLANTIC 2013	P		06/28/22
c GENERL ATLANTIC 2013	P		09/01/22
d GENERL ATLANTIC 2013	P		02/13/23
e CRESTVIEW III	P		10/31/22
f CRESTVIEW III	P		01/13/23
g FORTISSIMO V	P		09/29/22
h FORTISSIMO V	P		01/04/23
i GENERL ATLANTIC 2018	P		09/09/22
j GENERL ATLANTIC 2018	P		09/22/22
k GENERL ATLANTIC 2018	P		09/26/22
l GENERL ATLANTIC 2018	P		02/27/23
m CRESTVIEW IV	P		06/30/22
n CRESTVIEW IV	P		01/06/23
o GOLDEN GATE CAPITAL OPPORTUNITY FUND	P		

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 147,954.			147,954.
b 96,864.			96,864.
c 136,841.			136,841.
d 187,531.			187,531.
e 456,641.			456,641.
f 184,847.			184,847.
g 696,000.			696,000.
h 480,000.			480,000.
i		85,399.	-85,399.
j 18,218.			18,218.
k 34,150.			34,150.
l 138,544.			138,544.
m 2,074,447.			2,074,447.
n 626,024.			626,024.
o		13,138,789.	-13,138,789.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			147,954.
b			96,864.
c			136,841.
d			187,531.
e			456,641.
f			184,847.
g			696,000.
h			480,000.
i			-85,399.
j			18,218.
k			34,150.
l			138,544.
m			2,074,447.
n			626,024.
o			-13,138,789.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a NEWPORT CARRY LP	P		
b FDAF DISLOCATED I	P		
c GSO I	P		
d HARBOUR ENERGY FUND LP	P		
e ACADIAN FRONTIER	P		
f K-1 ADJUSTMENTS, NET OF UBI AND RELATED AMOUNTS ABOVE	P		
g			
h			
i			
j			
k			
l			
m			
n			
o			

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 118,414.			118,414.
b		423,557.	-423,557.
c		1,184,353.	-1,184,353.
d		213,604,729.	-213,604,729.
e			-5,261,285.
f			-296,309,383.
g			
h			
i			
j			
k			
l			
m			
n			
o			

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			118,414.
b			-423,557.
c			-1,184,353.
d			-213,604,729.
e			-5,261,285.
f			-296,309,383.
g			
h			
i			
j			
k			
l			
m			
n			
o			

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	27,587,383.
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	N/A

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM 4000 AMBASSADOR DRIVE ANCHORAGE, AK 99508	N/A	PC	YAKUTAT UTILITY PROJECT	1,373,068.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY	163,648.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM	948,511.
ALLINA ASSOCIATED FOUNDATION 3915 GOLDEN VALLEY ROAD MINNEAPOLIS, MN 55422	N/A	PC	ALLINA HEALTH ULTRASOUND PROJECT	758,911.
ALVIN AILEY DANCE FOUNDATION, INC. THE JOAN WEILL CENTER FOR DANCE NEW YORK, NY 10019	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH 84 SHMARYAHU LEVIN ST JERUSALEM, ISRAEL	N/A	PC	ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH	717,219.
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE	610,817.
Total from continuation sheets				430,182,443.

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN CAMPING ASSOCIATION INC 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2022-2024	48,955.
AMERICAN COLLEGE OF DIABETOLOGY INC PO BOX 87633 FAYETTEVILLE, NC 28304	N/A	PC	IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS	810,203.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	ADAS FOCUS ON FELLOWS, DIABETES IS PRIMARY, AND PROFESSIONAL MEMBERSHIP INTEREST GROUPS PROJECTS (2020-2022)	300,000.
AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE 4930 DEL RAY AVE BETHESDA, MD 20814	N/A	PC	STRATEGIES FOR INDIVIDUALIZING MANAGEMENT OF INFLAMMATORY BOWEL DISEASE FOR ADVANCED PRACTICE PROVIDERS	155,930.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	AMERICAN BOARD OF TELEHEALTH PROGRAM EXPANSION	200,000.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE MONTANA AND POST-ACUTE STROKE CARE QUALITY STANDARDS FIELD TESTING	1,321,419.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA	403,132.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE IOWA	1,680,053.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	993,762.
AMERICAN PHARMACISTS ASSOCIATION FOUNDATION 2215 CONSTITUTION AVE NW WASHINGTON, DC 20037	N/A	PC	PROJECT IMPACT CGM: EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES	1,976,075.
AMERICAN TELEMEDICINE ASSOCIATION 901 N.GLEBE RD ARLINGTON, VA 22203	N/A	PC	ATA SPONSORING MEMBERSHIP	25,500.
AMERICARES FOUNDATION, INC. 88 HAMILTON AVE STAMFORD, CT 06840	N/A	PC	MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS	752,688.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	2,500,000.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	474,464.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	474,464.
APPLETON AREA HEALTH 30 SOUTH BEHL ST. APPLETON, MN 56208	N/A	GOV	APPLETON AREA HEALTH ULTRASOUND INITIATIVE	281,865.
AQUAYA INSTITUTE P.O. BOX 1603 SAN ANSELMO, CA 94979	N/A	PC	WATER QUALITY ASSURANCE FUND EXPANSION IN GHANA	1,492,399.
ARAD MUNICIPALITY 6 HAPALMACH STREET ARAD, ISRAEL	N/A	GOV	ARAD OCCUPATIONAL REHABILITATION CENTER	560,000.
ASIAN HEALTH CARE FOUNDATION 6-3-661, SOMAJIGUDA HYDERABAD, INDIA	N/A	PC	IMPROVING ACCESS TO DIAGNOSTICS FOR CROHN'S DISEASE PATIENTS LIVING BELOW THE POVERTY LINE IN SOUTHERN INDIA	210,551.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE	413,127.
ASSOCIATION SANTE DIABTE 17 AVENUE MALHERBE GRENOBLE, FRANCE	N/A	PC	IMPROVE THE MANAGEMENT OF DIABETES AND THE SUPPORT TO PEOPLE AFFECTED BY THE DISEASE IN BURKINA FASO, MALI AND THE UNION OF COMOROS	272,362.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES	587,840.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES	587,840.
AVERA HEALTH 3900 W AVERA DR SIOUX FALLS, SD 57108	N/A	PC	AVERA HEALTH ULTRASOUND PROJECT	682,498.
AVERA MCKENNAN FOR THE AVERA MCKENNAN HOSPITAL AND UNI. HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,500,000.
AVERA MCKENNAN FOR THE AVERA MCKENNAN HOSPITAL AND UNI. HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	500,000.
BANNER HEALTH DBA BANNER CHURCHILL COMMUNITY HOSPITAL 801 EAST WILLIAMS AVE. FALLON, NV 89406	N/A	PC	BANNER CHURCHILL COMMUNITY HOSPITAL ULTRASOUND INITIATIVE	139,574.
BAPTIST MEDICAL CENTRE BAPTIST MEDICAL CENTRE ROAD NALERIGU, GHANA	N/A	PC	EMERGENCY CENTRE AND DOCTOR HOUSING DEVELOPMENT	315,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BEHAVIORAL DIABETES INSTITUTE 5230 CARROLL CANYON RD. SAN DIEGO, CA 92121	N/A	PC	CONSTRUCTION OF UPDATED T1-DIABETES DISTRESS SCALE (T1-DDS)	346,980.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING	1,671,429.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CROHN'S DISEASE.	1,066,797.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE.	519,550.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3	149,167.
BHSB SYSTEM 100 MICHIGAN ST NE GRAND RAPIDS, MI 49503	N/A	PC	STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS	3,670,399.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59102	N/A	PC	MONTANA PSYCHIATRY RESIDENCY PROGRAM SUSTAINING SUPPORT	1,000,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING HEALTH CARE DELIVERY AND SERVICES IN RURAL AND FRONTIER AMERICA	625,293.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	3,500,000.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	2,500,000.
BNAI ZION MEDICAL CENTER 47 GOLOMB ST. HAIFA, ISRAEL	N/A	GOV	ACQUISITION OF A DA VINCI XI SURGICAL SYSTEM WITH SINGLE CONSOLE + FIREFLY ROBOTIC SURGICAL SYSTEM.	2,665,020.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM	597,995.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN NEVADA	624,068.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	LONGITUDINAL STUDY OF MYOELECTRIC GUTPRINT OF HEALTHY CONTROLS AND CROHN'S DISEASE PATIENTS DURING FLARES AND IN REMISSION	150,162.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D	1,942,299.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE	1,009,155.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXERCISE EDUCATION AT NEW ONSET OF T1D	256,007.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON INTENSIVE INSULIN THERAPY (IIT)	330,000.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	PROFESSIONAL VERSION OF DIABETESWISE: AVENUE TO INCREASE DIABETES DEVICE UPTAKE IN PEOPLE WITH INSULIN-REQUIRING DIABETES	1,005,939.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EFFECTS OF AN INTERMITTENT REDUCED CALORIE DIET ON CROHNS DISEASE	551,070.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXERCISE EDUCATION AT NEW ONSET OF T1D	339,811.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON INTENSIVE INSULIN THERAPY (IIT)	1,741,076.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE	690,953.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	GENERAL OPERATING SUPPORT FOR STANFORD UNIVERSITY GRADUATE SCHOOL OF BUSINESS CLASS OF 1986 35TH REUNION	25,000.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON INTENSIVE INSULIN THERAPY (IIT)	1,296,812.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	PROFESSIONAL VERSION OF DIABETESWISE: AVENUE TO INCREASE DIABETES DEVICE UPTAKE IN PEOPLE WITH INSULIN-REQUIRING DIABETES	817,475.
BOSTON SYMPHONY ORCHESTRA, INC. 301 MASSACHUSETTS AVENUE BOSTON, MA 02115	N/A	PC	GENERAL OPERATING SUPPORT:	10,000.
BOULDER CITY HOSPITAL INC 901 ADAMS BLVD BOULDER CITY, NV 89005	N/A	PC	BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT	37,497.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION 505 EIGHTH AVENUE, 5TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING	547,655.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA	2,812,542.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	ZAMBIA ASSESSMENT	142,110.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	ETHIOPIA ASSESSMENT	142,110.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUTOANTIBODIES AS A DISEASE DETERMINANT IN CROHNS DISEASE	698,657.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	5,661,004.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	1,308,107.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUTOANTIBODIES AS A DISEASE DETERMINANT IN CROHNS DISEASE	1,189,617.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GENERAL OPERATING SUPPORT FOR 2022 WOMEN'S HEALTH LUNCHEON	15,000.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	1,329,719.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PASSIVE WIRELESS MONITORING OF CROHNS DISEASE PATIENTS TO TRACK DISEASE ACTIVITY AND PREDICT FLARES	360,771.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE: TRANSLATING TODAY'S SCIENCE INTO TOMORROW'S TREATMENTS IN CROHNS DISEASE	955,956.
CANDID 32 OLD SLIP, 24TH FLOOR NEW YORK, NY 10005	N/A	PC	GENERAL OPERATING SUPPORT AND GUIDESTAR PARTNERSHIP	17,551.
CARE-FOR-RARE FOUNDATION DR. VON HAUNERSCHES KINDERSPITAL KLINIKUM DER UNIVERSITAT MUNCHEN MUNICH, GERMANY	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES	54,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CASS LAKE INDIAN HOSPITAL 425 7TH ST. NW CASS LAKE, MN 56633	N/A	GOV	CASS LAKE INDIAN HOSPITAL ULTRASOUND PROJECT	191,462.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	KOM-YILMA III BURKINA FASO	749,145.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	INTEGRATED COMMUNITY WATER, SANITATION AND HYGIENE IMPROVEMENT (ICOWASH 2.0)	1,556,214.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	MAYI MWANA PROJECT: HELPING ZAMBIAN MOTHERS AND NEWBORNS SURVIVE AND THRIVE	1,100,098.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	REST4D - RURAL EMERGENCY HEALTH SERVICE AND TRANSPORT FOR SYSTEM DEVELOPMENT	1,344,542.
CCM HEALTH 824 NORTH 11TH STREET MONTEVIDEO, MN 56265	N/A	GOV	CCM HEALTH ULTRASOUND PROJECT	696,689.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	LONG-TERM RESPONSES TO SARS-COV-2 VACCINATION IN A DIVERSE INFLAMMATORY BOWEL DISEASE POPULATION: A MULTI-OMIC STUDY	522,999.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	216,002.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION	459,453.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNAMEQ TO BETTER UNDERSTAND THE CAUSES OF, AND HETEROGENEITY IN, CROHN'S DISEASE	231,849.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNAMEQ TO BETTER UNDERSTAND THE CAUSES OF, AND HETEROGENEITY IN, CROHN'S DISEASE	268,151.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	204,837.
CENTER FOR EXCELLENCE IN HEALTH CARE JOURNALISM 10 NEFF HALL COLUMBIA, MO 65211	N/A	SOII	TRAINING AND DEVELOPMENT OF HEALTH CARE JOURNALISTS AND RESOURCES FOR HEALTH REPORTING	219,995.
CENTER FOR HEALTH CARE STRATEGIES INC 200 AMERICAN METRO BLVD TRENTON, NJ 08619	N/A	PC	TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN	653,574.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CENTER FOR HEALTH CARE STRATEGIES INC 200 AMERICAN METRO BLVD TRENTON, NJ 08619	N/A	PC	OPPORTUNITIES FOR PEDIATRIC AUTOANTIBODY SCREENING IN MEDICAID	80,412.
CENTRACARE HEALTH SYSTEM 1406 6TH AVE N ST CLOUD, MN 56303	N/A	PC	CENTRACARE HEALTH SYSTEM ULTRASOUND PROJECT	1,746,643.
CENTRAL MONTANA MEDICAL FACILITIES, INC. 408 WENDELL AVE. LEWISTOWN, MT 59457	N/A	PC	CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER	3,469,965.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	89,352.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	98,364.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE	159,416.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA	556,046.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	PHARMACOLOGICAL MODULATION TO RESTORE COUNTERREGULATORY GLUCAGON SECRETION IN TYPE 1 DIABETES	546,306.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ICARUS IBD: INTERNATIONAL STUDY OF COVID-19 ANTIBODY RESPONSE UNDER SUSTAINED IMMUNE SUPPRESSION IN INFLAMMATORY BOWEL DISEASE	82,500.
CHASE COUNTY COMMUNITY HOSPITAL 600 WEST 12TH STREET IMPERIAL, NE 69033	N/A	GOV	EEMERGENCY AT CHASE COUNTY COMMUNITY HOSPITAL	12,656.
CHASE COUNTY COMMUNITY HOSPITAL 600 WEST 12TH STREET IMPERIAL, NE 69033	N/A	GOV	EEMERGENCY AT CHASE COUNTY COMMUNITY HOSPITAL	29,056.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	ULTRASOUND PROJECTS AT BAUDETTE, BRECKENRIDGE, LITTLE FALLS, AND PARK RAPIDS, MINNESOTA	1,079,546.
CHILDREN OF THE LIGHT INTERNATIONAL MINISTRIES, INC. 1171 E 95TH STREET BROOKLYN, NY 11236	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ROLE OF PPAR-ALPHA IN PROMOTING BRUSH BORDER MATURITY OF INTESTINAL ENTEROCYTES	399,330.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS	235,507.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	BIOMARKERS OF INTESTINAL FIBROSIS IN SMALL BOWEL CROHNS DISEASE	282,554.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D	349,553.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	A CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM	272,676.
CHILDREN'S HUNGER FUND 13931 BALBOA BLVD SYLMAR, CA 91342	N/A	PC	MERCY NETWORK FOOD SUPPORT IN ETHIOPIA AND ZAMBIA	151,800.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY, MO 64108	N/A	PC	TYPE 1 DIABETES RAPID LEARNING LAB	2,966,873.
CITIZENS HOUSING AND PLANNING COUNCIL OF NEW YORK, INC. 42 BROADWAY STE 2010 NEW YORK, NY 10004	N/A	PC	EDUCATION FOR NYC POLICYMAKERS ON HOUSING INITIATIVES TO IMPROVE HEALTH	200,000.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	CATALYST: GROWING INTENSIVE PARK ENGAGEMENT IN VULNERABLE COMMUNITIES	491,131.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN RELIEF & RECOVERY FUND	680,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	YOSEFTAL HOSPITAL ADDITION	3,847,500.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	BIOMARKER-BASED MULTIDISCIPLINARY TEAM (BIO-MDT) APPROACH TO PERSONALIZED MICROBIAL-TARGETED TREATMENT OF POUCHITIS AND CROHN'S DISEASE	599,718.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	4,100,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	1,032,229.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION	243,216.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	406,254.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES	444,314.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT	137,856.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION	242,153.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	YOSEFTAL HOSPITAL ADDITION	2,058,214.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	COVID-19 VACCINE RESPONSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE	177,281.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE	1,597,167.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE	60,578.
COMMUNITY CENTERS INC 2 ST ROCH AVENUE GREENWICH, CT 06830	N/A	PC	GENERAL OPERATING SUPPORT.	45,000.
COMMUNITY MEMORIAL HOSPITAL DISTRICT 2731 HEALTHCARE DRIVE SYRACUSE, NE 68446	N/A	GOV	ECARE EMERGENCY AT SYRACUSE AREA HEALTH	13,320.
CONSORCI INSTITUT D'INVESTIGACIONES BIOMDICAS AUGUST PI I SUNYER ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE- PATHOPHYSIOLOGY AND IMAGING	177,122.
CONSORCI INSTITUT D'INVESTIGACIONES BIOMDICAS AUGUST PI I SUNYER ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE- PATHOPHYSIOLOGY AND IMAGING	261,948.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
COOK COUNTY HOSPITAL DISTRICT 515 5TH AVENUE WEST GRAND MARAIS, MN 55604	N/A	GOV	NORTH SHORE HEALTH ULTRASOUND PROJECT	207,235.
COUNCIL ON FOUNDATIONS, INC. 1255 23RD ST NW WASHINGTON, DC 20037	N/A	PC	GENERAL OPERATING SUPPORT	34,000.
COUNTY OF MURRAY 2042 JUNIPER AVE SLAYTON, MN 56172	N/A	GOV	ULTRASOUND REVITALIZATION PROJECT	216,230.
CRITICAL PATH INSTITUTE 1730 E. RIVER RD. TUCSON, AZ 85718	N/A	PC	T1D CONSORTIUM 2.0	266,741.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE	570,830.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	TRAINING AWARDS PROGRAM - CLASS OF 2021	1,067,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	IBD VENTURES ACADEMIC INCUBATOR	1,185,400.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE	570,831.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE	253,783.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE	255,521.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	275,688.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 & 2022 OPERATING SUPPORT FOR CROHN'S AND COLITIS UK: KNOWLEDGE AND EVIDENCE PERSONNEL	75,900.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	SUPPORT FOR THE CROHNS AND COLITIS UK RESEARCH AWARDS	329,900.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	SUPPORT FOR CROHN'S AND COLITIS UK'S MULTI-CHANNEL HELPLINE SERVICE	263,570.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 & 2022 OPERATING SUPPORT FOR CROHN'S AND COLITIS UK: KNOWLEDGE AND EVIDENCE PERSONNEL	75,900.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF A PEDIATRIC-SPECIFIC CROHNS DISEASE ELECTRONIC MEDICAL RECORD TO DRIVE CARE CONSISTENCY AND ENHANCE TRANSITIONS IN CARE	141,158.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF A PEDIATRIC-SPECIFIC CROHNS DISEASE ELECTRONIC MEDICAL RECORD TO DRIVE CARE CONSISTENCY AND ENHANCE TRANSITIONS IN CARE	68,358.
CUYUNA REGIONAL MEDICAL CENTER 320 EAST MAIN STREET CROSBY, MN 56401	N/A	PC	CUYUNA REGIONAL MEDICAL CENTER ULTRASOUND PROJECT	92,550.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR DARTMOUTH HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	269,933.
DAWSON AREA HOSPITAL DISTRICT 1282 WALNUT STREET DAWSON, MN 56232	N/A	GOV	JOHNSON MEMORIAL HEALTH SERVICES ULTRASOUND PROJECT	70,018.
DE LA SALLE SOLIDARIET INTERNAZIONALE ONLUS VIA AUREALIA, 476 ROME, ITALY	N/A	PC	ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY	191,462.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DIABETES NSW 26 ARUNDEL ST SYDNEY, AUSTRALIA	N/A	PC	IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES	3,000,000.
DREAMED DIABETES LTD. 14 KAPLAN ST PETAH TIKVA, ISRAEL	N/A	NC	INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES	1,500,000.
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	121,593.
EB RESEARCH PARTNERSHIP, INC. 244 MADISON AVENUE, SUITE 104 NEW YORK, NY 10016	N/A	PC	EB RESEARCH PARTNERSHIP ACCELERATOR	1,000,000.
ELY-BLOOMENSON COMMUNITY HOSPITAL 328 W. CONAN ST. ELY, MN 55731	N/A	PC	ELY-BLOONEMSON COMMUNITY HOSPITAL ULTRASOUND REVITALIZATION PROJECT	285,654.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	ALASKA WASH PROJECT	7,020,410.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	MASTER PLANNING PROJECT AT MOUNT GRANT GENERAL HOSPITAL	57,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ESSENTIA HEALTH 502 E 2ND ST DULUTH, MN 55805	N/A	PC	ESSENTIA HEALTH ULTRASOUND PROJECT	1,473,638.
FLORESTA USA INCORPORATED 4747 MORENA BLVD. STE 100 SAN DIEGO, CA 92117	N/A	PC	SCALING AT THE WATERSHED LEVEL TO EQUIP RURAL FAMILIES	516,231.
FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST) 200 BEDFORD STREET MANCHESTER, NH 03101	N/A	PC	FIRST SENIOR MENTOR PROGRAM	200,000.
FORT ATKINSON FOUNDATION 201 S 7TH ST FORT CALHOUN,, NE 68023	N/A	PC	FORT ATKINSON STATE HISTORICAL PARK FORT RESTORATION AND INTERPRETIVE CENTER REMODEL	37,639.
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND CAMPUS BIOTECH GENEVA, SWITZERLAND	N/A	PC	ACCESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT	1,119,378.
FRIENDS OF THE ISRAEL DEFENSE FORCES 60 EAST 42 STREET NEW YORK, NY 10165	N/A	PC	IMPACT! SCHOLARSHIP PROGRAM	165,600.
FUND FOR PUBLIC HEALTH IN NEW YORK, INC. 22 CORTLANDT STREET, SUITE 802 NEW YORK, NY 10007	N/A	PC	NYC VACCINE EQUITY PARTNER ENGAGEMENT PROJECT	700,467.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FUND FOR PUBLIC HOUSING, INC. 90 CHURCH STREET NEW YORK, NY 10007	N/A	PC	DEVELOPING AND ACTIVATING GREENSPACE USING THE CONNECTED COMMUNITIES' PARTICIPATORY PROCESS AT FOUR NYCHA DEVELOPMENTS	1,570,000.
GEISINGER CLINIC 100 NORTH ACADEMY AVE DANVILLE, PA 17822-3057	N/A	PC	STUDY OF PRE-IMPLEMENTATION OUTCOMES REQUIRED TO IMPLEMENT PREVENTIVE SCREENING AT WELL-CHILD VISITS	701,056.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	156,725.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	480,848.
GEOSCIENCE AUSTRALIA 101 JERRABOMBERRA AVE SYMONSTON, AUSTRALIA	N/A	GOV	DIGITAL EARTH AFRICA - SUSTAINABLE UPTAKE AND IMPACT	6,604,232.
GIRLS WITH GUTS 6024 RIDGE AVENUE PHILADELPHIA, PA 19128	N/A	PC	2021 & 2022 OPERATING SUPPORT TO PROVIDE POST-OPERATIVE AND INFUSION KITS FOR WOMEN WITH INFLAMMATORY BOWEL DISEASE	11,100.
GIRLS WITH GUTS 6024 RIDGE AVENUE PHILADELPHIA, PA 19128	N/A	PC	2021 & 2022 OPERATING SUPPORT TO PROVIDE POST-OPERATIVE AND INFUSION KITS FOR WOMEN WITH INFLAMMATORY BOWEL DISEASE	11,100.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GLACIAL RIDGE HOSPITAL DISTRICT 10 4TH AVE SE GLENWOOD, MN 56334	N/A	PC	GLACIAL RIDGE HEALTH SYSTEM ULTRASOUND PROJECT	459,547.
GLENCOE REGIONAL HEALTH SERVICES 1805 HENNEPIN AVENUE NORTH GLENCOE, MN 55336	N/A	PC	ULTRASOUND REVITALIZATION PROJECT	186,843.
GLOBAL SOLIDARITY FUND 425 LEXINGTON AVE. NEW YORK, NY 10017	N/A	PC	JOB CREATION IN ETHIOPIA	1,508,200.
GOLDEN RAINBOW OF NEVADA, INC. 714 E. SAHARA AVE LAS VEGAS, NV 89104	N/A	PC	CAPITAL SUPPORT FOR GOLDEN RAINBOW OF NEVADA, INC. HOUSING	1,050,000.
GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO 27 KING'S COLLEGE CIRCLE TORONTO, CANADA	N/A	PC	DEVELOPMENT OF A GLUCOSE RESPONSIVE GLUCAGON (GRG) MICRONEEDLE PATCH FOR THE PREVENTION OF HYPOGLYCEMIA	289,960.
GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO 27 KING'S COLLEGE CIRCLE TORONTO, CANADA	N/A	PC	DEVELOPMENT OF A GLUCOSE RESPONSIVE GLUCAGON (GRG) MICRONEEDLE PATCH FOR THE PREVENTION OF HYPOGLYCEMIA	185,460.
GRAND ITASCA CLINIC AND HOSPITAL 1601 GOLF COURSE RD GRAND RAPIDS, MN 55744	N/A	PC	GRAND ITASCA CLINIC AND HOSPITAL ULTRASOUND PROJECT	335,587.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GRANTMAKERS IN HEALTH 1100 CONNECTICUT AVENUE NW WASHINGTON, DC 20036	N/A	PC	GENERAL OPERATING SUPPORT	23,760.
GRANTMAKERS IN HEALTH 1100 CONNECTICUT AVENUE NW WASHINGTON, DC 20036	N/A	PC	GRANTMAKERS IN HEALTH EFFECTIVE PHILANTHROPY FUND	119,803.
HADASSAH MEDICAL ORGANIZATION EIN KEREM ADDRESS: KALMAN YA'AKOV MAN STREET JERUSALEM, ISRAEL	N/A	PC	CREATING AND EQUIPPING A NEW COMPREHENSIVE DIAGNOSTIC AND INTERVENTIONAL IMAGING CENTER	3,864,000.
HANNOVERSCHE KINDERHEILANSTALT JANUSZ-KORCZAK-ALLEE 12 HANNOVER, GERMANY	N/A	PC	FRIDA IN NORTHERN GERMANY: PRE-SYMPTOMATIC TYPE 1 DIABETES TESTING IN CHILDREN	267,694.
HEALTH ADVOCACY SUMMIT, INC. 1962 DOCKSIDE DRIVE GREENWOOD, IN 46143	N/A	PC	CROHNS AND COLITIS YOUNG ADULTS NETWORK LEARNING COMMUNITY, ROUNDTABLE ON ADOLESCENTS AND YOUNG ADULTS WITH IBD	59,940.
HEALTH RESEARCH ALLIANCE, INC. 65 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK, NC 27709	N/A	PC	GENERAL OPERATING SUPPORT	22,150.
HEALTHPARTNERS INSTITUTE 8170 33RD AVENUE SOUTH BLOOMINGTON, MN 55425-4516	N/A	PC	DIRECT INTEGRATION OF CGM DATA INTO THE EMR	751,067.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HEALTHPARTNERS INSTITUTE 8170 33RD AVENUE SOUTH BLOOMINGTON, MN 55425-4516	N/A	PC	PILOT STUDY OF DIRECT INTEGRATION OF CONTINUOUS GLUCOSE MONITORING DATA INTO THE ELECTRONIC HEALTH RECORD TO IMPROVE DIABETES CARE	332,200.
HEALTHPARTNERS RC 100 HEALTHY WAY OLIVIA, MN 56277	N/A	PC	OLIVIA HOSPITAL & CLINIC ULTRASOUND PROJECT	216,022.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS DISEASE	671,024.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD BIOSAMPLE RFP	2,000,000.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	EUROPEAN PRE-T1D REGISTRY	142,350.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	2,101,247.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	1,257,107.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	644,244.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	1,973,807.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,415,657.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	232,068.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	697,881.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	691,810.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	513,083.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HENDRICKS COMMUNITY HOSPITAL ASSOCIATION AND RETIREMENT HOME 503 EAST LINCOLN STREET HENDRICKS, MN 56136	N/A	PC	ULTRASOUND REVITALIZATION PROJECT	19,850.
HENNEPIN COUNTY 1313 PENN AVENUE NORTH MINNEAPOLIS, MN 55411	N/A	GOV	NORTHPOINT HEALTH AND WELLNESS CENTER ULTRASOUND PROJECT	44,431.
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KAISER HEALTH NEWS RURAL HEALTH DESK	1,057,620.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D	109,023.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS	57,744.
HILLEL YAFFE MEDICAL CENTER HA-SHALOM ST. HADERA, ISRAEL	N/A	GOV	EYE INSTITUTE AND AMBULATORY SURGERY CENTER	2,756,300.
HOLY ROSARY HEALTHCARE FOUNDATION 2600 WILSON STREET MILES CITY, MT 59301	N/A	PC	HOLY ROSARY HEALTHCARE COMPREHENSIVE CANCER CENTER	4,000,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	415,688.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE MELODY TRIAL: MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHN'S DISEASE	409,388.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE FOR NYCS MOST VULNERABLE MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.	547,667.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	415,688.
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	UNITED HATZALAH PRE-HOSPITAL EMS SIMULATION TRAINING EQUIPMENT	499,890.
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	UNITED HATZALAH HUMANITARIAN MISSION FOR UKRAINE	739,000.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	ECARE PHARMACY AT HORN MEMORIAL HOSPITAL	9,677.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
IDEO.ORG 444 SPEAR STREET SAN FRANCISCO, CA 94105	N/A	PC	HUMAN-CENTERED DESIGN STUDY OF TYPE 1 DIABETES IN MEDICALLY UNDERSERVED COMMUNITIES IN THE U.S.	227,950.
IDEO.ORG 444 SPEAR STREET SAN FRANCISCO, CA 94105	N/A	PC	HUMAN-CENTERED DESIGN STUDY OF TYPE 1 DIABETES IN MEDICALLY UNDERSERVED COMMUNITIES IN THE U.S.	200,000.
INCLINE VILLAGE COMMUNITY HOSPITAL FOUNDATION 880 ALDER AVE INCLINE VILLAGE, NV 89451	N/A	PC	MAMMOGRAPHY FOR INCLINE VILLAGE COMMUNITY HOSPITAL	1,938,683.
INCLINE VILLAGE COMMUNITY HOSPITAL FOUNDATION 880 ALDER AVE INCLINE VILLAGE, NV 89451	N/A	PC	ULTRASOUND EQUIPMENT FOR INCLINE VILLAGE COMMUNITY HOSPITAL	87,080.
INNODIA HERESTRAAT 49 LEUVEN, BELGIUM	N/A	NC	INNODIA NONPROFIT LAUNCH FOR THE CARE AND PREVENTION OF T1D.	755,460.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	81,892.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	95,241.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSTITUT NATIONALE DE LA SANTE ET DE LA RECHERCHE MEDICALE 86, RUE REGNAULT PARIS, FRANCE	N/A	GOV	FROM BENIGN ISLET AUTOIMMUNITY TO TYPE 1 DIABETES: MECHANISTIC CD8+ T-CELL BIOMARKERS OF PROGRESSION	164,338.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET GAINESVILLE, FL 32608	N/A	PC	INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY	320,933.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.	718,578.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.	779,377.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES: INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY	172,967.
INTERNATIONAL FALLS MEMORIAL HOSPITAL ASSOCIATION 1400 HIGHWAY 71 INTERNATIONAL FALLS, MN 56649	N/A	PC	RAINY LAKE MEDICAL CENTER ULTRASOUND PROJECT	173,810.
IOWA DEPARTMENT OF PUBLIC HEALTH 321 EAST 12TH DES MOINES, IA 50319	N/A	GOV	IOWA FIRST RESPONDER AED INITIATIVE	186,944.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ISRAEL ANTIQUITIES AUTHORITY 27 SULTAN SULEIMAN STREET JERUSALEM, ISRAEL	N/A	GOV	THE JAY AND JEANIE SCHOTTENSTEIN NATIONAL CAMPUS FOR THE ARCHAEOLOGY OF ISRAEL	400,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	183,039.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	CGM MONITORING OF MATERNAL DYSGLYCEMIA	100,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING	256,190.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	625,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	CGM MONITORING OF MATERNAL DYSGLYCEMIA	481,111.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	400,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF AUSTRALIA 80-84 CHANDOS STREET, ST LEONARDS, 2065, NSW, AUSTRALIA SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA	2,595,980.
JDRF AUSTRALIA 80-84 CHANDOS STREET, ST LEONARDS, 2065, NSW, AUSTRALIA SYDNEY, AUSTRALIA	N/A	PC	ENDIA EARLY TO MID CAREER SCIENCE ACCELERATOR AWARDS 2021	232,577.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JDRF TRAINING PROGRAMS	750,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HCP T1D EDUCATION PROGRAM (STATE OF AFFAIRS AND PEAK)	99,699.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JDRF GLOBAL DIABETES ACCESS INITIATIVE	999,800.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	AUTOIMMUNITY SCREENING FOR KIDS PROGRAM TRANSITION TOWARDS A SUSTAINABLE SCREENING FOR T1D AND CELIAC DISEASE IN COLORADO	511,143.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A 3-B-HYDROXYBUTYRATE BINDING PROTEIN BASED CONTINUOUS KETONE MONITORING MICROSENSOR	200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE	133,334.
JDRF T1D FUND, LLC 50 MILK STREET, 16TH FLOOR BOSTON, MA 02109	N/A	PC	T1D FUND INITIATIVE TO DRIVE PHARMA INVESTMENT IN T1D	500,000.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING	4,165,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	ENGINEERED CYTOKINE/ANTIBODY FUSION PROTEIN TO TREAT CROHNS DISEASE	750,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS	562,008.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING	701,873.
JUVENILE DIABETES RESEARCH FOUNDATION CANADA 235 YORKLAND BLVD., SUITE 600 TORONTO, CANADA	N/A	PC	JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE	36,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	246,663.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	INNODIA EXPANSION	807,155.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY	656,542.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	530,354.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	816,358.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS	270,269.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL	288,101.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KITTSON MEMORIAL HOSPITAL ASSOCIATION 1010 SOUTH BIRCH AVENUE HALLOCK, MN 56728	N/A	PC	KITTSON HEALTHCARE ULTRASOUND PROJECT	65,393.
KITTSON MEMORIAL HOSPITAL ASSOCIATION 1010 SOUTH BIRCH AVENUE HALLOCK, MN 56728	N/A	PC	EEMERGENCY AT KITTSON HEALTHCARE	11,729.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	1,304,315.
KMR ADVANCEMENT OF MEDICAL CENTERS LTD. 8 HA'ALIYAH ST. HAIFA, ISRAEL	N/A	PC	PROPOSAL FOR BUILDING OF PRINCIPAL INFRASTRUCTURE FOR ALL 20 FLOORS OF THE HELMSLEY HEALTH DISCOVERY TOWER	2,000,000.
KYLER CARES FOUNDATION 1101 DECATUR STREET, APARTMENT 302 NEW ORLEANS, LA 70116	N/A	PC	GENERAL OPERATING SUPPORT	150,000.
LAKE REGION HEALTHCARE CORPORATION 712 SOUTH CASCADE ST FERGUS FALLS, MN 56537	N/A	PC	LAKE REGION HEALTHCARE CORPORATION ULTRASOUND PROJECT	538,148.
LAKE VIEW MEMORIAL HOSPITAL FOUNDATION OF NORTHEAST MINNESOTA 325 11TH AVE TWO HARBORS, MN 55616	N/A	PC	LAKE VIEW HOSPITAL ULTRASOUND PROJECT	253,075.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
LAKES REGIONAL HEALTHCARE HIGHWAY 71 SOUTH SPIRIT LAKE, IA 51360	N/A	GOV	ECARE PHARMACY AT LAKES REGIONAL HEALTHCARE	10,856.
LAKEWOOD HEALTH SYSTEM 49725 COUNTY 83 STAPLES, MN 56479	N/A	PC	LAKEWOOD HEALTH SYSTEM ULTRASOUND PROJECT	574,338.
LIFECARE MEDICAL CENTER 715 DELMORE DRIVE ROSEAU, MN 56751	N/A	PC	LABOR AND DELIVERY POC ULTRASOUND PROJECT	67,971.
LINCOLN COUNTY HOSPITAL DISTRICT 700 NORTH SPRING STREET CALIENTE, NV 89008	N/A	GOV	GROVER C. DILS MEDICAL CENTER ULTRASOUND PROJECT	36,064.
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, TX 77477	N/A	PC	INTEGRATED WATER ACCESS, SANITATION AND HYGIENE PROGRAM IN CHIPATA DISTRICT, ZAMBIA	1,369,113.
LONDON NORTH WEST UNIVERSITY HEALTHCARE NHS TRUST NORTHWICK PARK HOSPITAL, WATFORD ROAD, HARROW, MIDDLESEX, HA1 3UJ HARROW, UNITED KINGDOM	N/A	GOV	PERIANAL CROHNS DISEASE CONSORTIUM	69,442.
LUCAS COUNTY HEALTH CENTER 1200 NORTH 7TH STREET CHARITON, IA 50049	N/A	PC	AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER	45,334.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MADELIA HEALTH 121 DREW AVE SE MADELIA, MN 56062	N/A	PC	MADELIA HEALTH ULTRASOUND PROJECT	193,530.
MADISON COUNTY MEMORIAL HOSPITAL 300 W. HUTCHINGS STREET WINTERSSET, IA 50273	N/A	GOV	IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM	37,965.
MARY C. WHEELER SCHOOL, INC. 216 HOPE STREET PROVIDENCE, RI 02906	N/A	PC	GENERAL OPERATING SUPPORT TO SUPPORT THE PROGRAMS, STUDENTS, AND TEACHERS OF THE WHEELER SCHOOL.	10,000.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	TETHERED CAPSULE ENDOMICROSCOPY FOR DETAILED VISUALIZATION OF THE CROHN'S BOWEL WALL	546,985.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	WIRELESS INFRARED IMAGING CAPSULE FOR PINPOINTING INFLAMMATION IN CROHNS DISEASE	843,986.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	CROHN'S DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION AND BETTER TREATMENT	350,278.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS	300,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	MAYO CLINIC HEALTH SYSTEM POINT-OF-CARE ULTRASOUND EQUIPMENT	941,738.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOPMENT AND EVALUATION OF A NOVEL ALGORITHM FOR AID CONTROL FOR PREGNANT WOMEN WITH T1D	1,081,500.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	MAYO CLINIC HEALTH SYSTEM ULTRASOUND PROJECT	635,535.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM	103,827.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	MILITARY SCIENCES MEDICAL TRAINING 2022-2024	182,000.
MEDECINS SANS FRONTIERS USA, INC. 40 RECTOR STREET NEW YORK, NY 10006	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
MEDICINES FOR HUMANITY, INC. 800 HINGHAM STREET ROCKLAND, MA 02370	N/A	PC	MAI MBELEKI II EXPANSION	677,164.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MEDSTAR HEALTH INC 3007 TILDEN STREET NW WASHINGTON, DC 20008	N/A	SOIII FI	2022 SUPPORT FOR THE 'MASTERING CLINICAL CHALLENGES IN IBD' SYMPOSIUM	35,000.
MEEKER MEMORIAL HOSPITAL 612 S SIBLEY AVE LITCHFIELD, MN 55355	N/A	GOV	ULTRASOUND EQUIPMENT REVITALIZATION	66,612.
MEEKER MEMORIAL HOSPITAL 612 S SIBLEY AVE LITCHFIELD, MN 55355	N/A	GOV	EPHARMACY AT MEEKER MEMORIAL HOSPITAL	12,269.
MICHIGAN STATE UNIVERSITY HANNAH ADMINISTRATION BUILDING EAST LANSING, MI 48824-2601	N/A	PC	A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH TYPE 1 DIABETES	382,594.
MILLE LACS HEALTH SYSTEM 200 ELM STREET NORTH ONAMIA, MN 56359	N/A	PC	TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM	56,434.
MINNESOTA ACADEMY OF FAMILY PHYSICIANS FOUNDATION 1400 VANBUREN STE STE 215 MINNEAPOLIS, MN 55413	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	2,362,600.
MINNESOTA RURAL HEALTH ASSOCIATION 27011 460TH AVE HENNING, MN 56551	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA	220,100.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MINNESOTA STATE COLLEGES AND UNIVERSITIES 30 E. 7TH STREET ST. PAUL, MN 55101	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA	595,848.
MONROE COUNTY HOSPITAL 6580 165TH STREET ALBIA, IA 52531	N/A	GOV	EPHARMACY AT MONROE COUNTY HOSPITAL & CLINICS	17,577.
MONTANA PEDIATRICS 259 W. FRONT STREET MISSOULA, MT 59802	N/A	PC	CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D	104,900.
MONTANA PEDIATRICS 259 W. FRONT STREET MISSOULA, MT 59802	N/A	PC	CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D	284,500.
MONUMENT HEALTH STURGIS HOSPITAL 2140 JUNCTION AVE. STURGIS, SD 57785	N/A	PC	EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL	41,418.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BERING LAND BRIDGE VISITOR CENTER	2,449,328.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER	3,150,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	2023-2025 PARTNERSHIP	2,409,000.
NEBRASKA DEPART.OF HEALTH & HUMAN SERVICES, DIVISION OF PUBLIC HEALTH 301 CENTENNIAL MALL SOUTH LINCOLN, NE 68508	N/A	GOV	NEBRASKA FIRST RESPONDER AED PROJECT	545,083.
NEVADA COMMUNITY FOUNDATION, INC. 1980 FESTIVAL PLAZA DRIVE LAS VEGAS, NV 89135	N/A	PC	RURAL NEVADA ULTRASOUND CARE INITIATIVE	1,035,951.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA FIRST RESPONDER AED PROJECT	6,627,661.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,333,324.
NEVADA HEALTH CENTERS, INC. 3325 RESEARCH WAY CARSON CITY, NV 89706	N/A	PC	QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM	602,796.
NEVADA PRIMARY CARE ASSOCIATION 755 N ROOP ST CARSON CITY, NV 89701	N/A	PC	POINT-OF-CARE ULTRASOUND EQUIPMENT FOR NEVADA CLINICS	36,654.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEVADA RURAL HOSPITAL PARTNERS FOUNDATION, INC. 4600 KIETZKE LANE RENO, NV 89502	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS	33,000.
NEW DESTINY HOUSING CORPORATION 12 W. 37TH STREET, 7TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AFTERCARE INTERVENTION TO IMPROVE HOUSING AND HEALTH STABILITY FOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS	296,096.
NEW VENTURE FUND 1201 CONNECTICUT AVE NW, SUITE 300 WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)	1,435,500.
NEW YORK CITY BALLET, INC. DAVID H. KOCH THEATER NEW YORK, NY 10023	N/A	PC	GENERAL OPERATING SUPPORT FOR NEW COMBINATIONS FUND	15,000.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC	800,000.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS	101,043.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	EVALUATION OF PILOT INTERVENTIONS FOR THE COLLABORATIVE FOR HOMELESS HEALTHCARE	205,596.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	IDENTIFYING ENVIRONMENTAL CONTRIBUTORS TO CROHN'S DISEASE	1,046,686.
NORTH DAKOTA DEPARTMENT OF HEALTH 600 E BOULEVARD AVENUE BISMARCK, ND 58505-0200	N/A	GOV	NORTH DAKOTA LAW ENFORCEMENT AED PROJECT	146,189.
NORTHERN ITASCA HOSPITAL DISTRICT 258 PINE TREE DRIVE BIGFORK, MN 56628	N/A	GOV	BIGFORK VALLEY HOSPITAL ULTRASOUND PROJECT	102,400.
NORTHERN WESTCHESTER HOSPITAL ASSOCIATION 400 EAST MAIN STREET MOUNT KISCO, NY 10549	N/A	PC	MATERNAL CHILD HEALTH UNIT FACILITIES RENOVATION	200,000.
NURU INTERNATIONAL 2020 PENNSYLVANIA AVE NW WASHINGTON, CA 20006	N/A	PC	EXPANDING AND SUSTAINING AGRIBUSINESS IMPACT IN ETHIOPIA	300,000.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 1)	780,628.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT	784,875.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ORTONVILLE AREA HEALTH SERVICES 450 EASTVOLD AVENUE ORTONVILLE, MN 56278	N/A	GOV	ORTONVILLE AREA HEALTH SERVICES ULTRASOUND PROJECT	102,614.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	499,175.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	500,825.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	999,473.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE	2,004,478.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	GENERAL OPERATING SUPPORT FOR THE COALITION FOR ACCESS TO NCD MEDICINES & PRODUCTS	17,750.
PAWNEE COUNTY MEMORIAL HOSPITAL 600 I STREET PAWNEE CITY, NE 68420	N/A	GOV	ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL	17,845.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PENNINGTON COUNTY HEALTH AND HUMAN SERVICES 321 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	GOV	PENNINGTON COUNTY CRISIS STABILIZATION UNIT	2,000,000.
PERHAM HOSPITAL DISTRICT 1000 CONEY STREET WEST PERHAM, MN 56573	N/A	GOV	PERHAM HEALTH VASCULAR ULTRASOUND SERVICE EXPANSION PROJECT	38,000.
PERKINS COUNTY HOSPITAL DISTRICT 900 LINCOLN AVE GRANT, NE 69140	N/A	GOV	TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES	106,817.
PHILIP HEALTH SERVICES, INC. 503 W. PINE STREET PHILIP, SD 57567	N/A	PC	IMPLEMENTATION OF AVERA EEMERGENCY AT PHILIP HEALTH SERVICES	12,317.
PHILLIPS COUNTY HOSPITAL ASSOCIATION 311 S. 8TH AVENUE EAST MALTA, MT 59538	N/A	PC	TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY	234,588.
PIONEER MEDICAL CENTER 301 WEST 7TH AVE BIG TIMBER, MT 59011	N/A	PC	TELE-PHARMACY AT PIONEER MEDICAL CENTER	339,522.
PIPESTONE COUNTY MEDICAL CENTER 916 4TH AVE. SW PIPESTONE, MN 56164	N/A	GOV	PCMC ULTRASOUND REVITALIZATION PROJECT.	141,701.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02138- 5366	N/A	PC	PRE-SYMPTOMATIC AUTOANTIBODY AND VIRAL PROFILE OF US MILITARY PERSONNEL WITH ADULT-ONSET TYPE 1 DIABETES	274,787.
PROJECT HOSPITALITY, INC. 100 PARK AVENUE STATEN ISLAND, NY 10302	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
PROJECT NYAME NSA, LTD. 33 WILLETS LANE MANHASSET, NY 11030	N/A	PC	PROJECT NYAME NSA ZAMBIA EXPANSION	241,600.
PROJECT NYAME NSA, LTD. 33 WILLETS LANE MANHASSET, NY 11030	N/A	PC	FARM EXPANSION FOR SUSTAINABILITY	1,215,500.
PROVIDENCE MEDICAL CENTER 1200 PROVIDENCE ROAD WAYNE, NE 68787	N/A	PC	EPHARMACY AT PROVIDENCE MEDICAL CENTER	8,457.
PUBLIC HEALTH SOLUTIONS 40 WORTH STREET, 5TH FLOOR NEW YORK, NY 10013	N/A	PC	NEW YORK CITY FUND FOR YOUTH AND FAMILY HOMELESSNESS	812,335.
PUBLIC HEALTH SOLUTIONS 40 WORTH STREET, 5TH FLOOR NEW YORK, NY 10013	N/A	PC	NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE	900,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION	302,170.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S	951,750.
RED LAKE INDIAN HEALTH SERVICES 24760 HOSPITAL DRIVE RED LAKE, MN 56671	N/A	GOV	RED LAKE IHS HOSPITAL ULTRASOUND PROJECT	179,899.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHN'S DISEASE	187,370.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	USING NATURAL LANGUAGE PROCESSING OF CLINICAL DOCUMENTATION TO IMPROVE PERSONALIZATION OF CARE IN CROHN'S DISEASE	385,780.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	PHASE 2: ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES	250,000.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	REDEFINING THE FUTURE OF EMERGENCY MEDICINE	5,026,234.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	DEVELOPING OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES	285,177.
REGION HOVEDSTADEN KONGENS VNGE 2 HILLEROD, DENMARK	N/A	GOV	CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?	104,349.
RENOWN HEALTH FOUNDATION 245 E. LIBERTY ST RENO, NV 89501	N/A	PC	SIMULATION AND INNOVATION CENTER AT RENOWN HEALTH	3,099,867.
RESEARCH TRIANGLE INSTITUTE 3040 EAST CORNWALLIS ROAD RESEARCH TRIANGLE PARK, NC 27709-2194	N/A	PC	USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY	1,172,646.
RIDGEVIEW MEDICAL CENTER 500 SOUTH MAPLE STREET WACONIA, MN 55387	N/A	PC	RIDGEVIEW SIBLEY AND LE SUEUR MEDICAL CENTERS ULTRASOUND PROJECT	28,382.
RIVER'S EDGE HOSPITAL AND CLINIC 1900 N. SUNRISE DRIVE ST. PETER, MN 56082	N/A	GOV	TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL	135,695.
ROUNDAABOUT THEATRE COMPANY, INC. 231 W 39TH STREET, 1200 NEW YORK, NY 10018	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING-MCGILL UNI JAMES ADMINISTRATION BUILDING MONTREAL, CANADA	N/A	PC	THE HUMAN CELL ATLAS: ETHICS AND DATA GOVERNANCE	189,596.
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY	1,595,750.
SAINT LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD SAINT LOUIS, MO 63103	N/A	PC	IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES	765,477.
SANFORD RESEARCH 2301 E 60TH STREET N SIOUX FALL, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	1,013,239.
SANFORD RESEARCH 2301 E 60TH STREET N SIOUX FALL, SD 57104-0569	N/A	PC	SANFORD PLEDGE: PHASES 1 AND 2	212,565.
SANFORD 801 BROADWAY N FARGO, ND 58102-3641	N/A	PC	SANFORD HEALTH ULTRASOUND PROJECT	2,894,734.
SAPIR ACADEMIC COLLEGE D.N. HOF ASHKELON REGIONAL COUNCIL SHAAR HANEDEV, ISRAEL	N/A	PC	PLANNING FOR SAPIR ACADEMIC COLLEGE LAW SCHOOL BUILDING	447,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SEATTLE CHILDREN'S HOSPITAL PO BOX 5731, M/S: S-200 SEATTLE, WA 98145-5005	N/A	PC	DEVELOPMENT OF ANTIGEN-SPECIFIC ETREG THERAPY IN T1D - STAGE 3 STUDIES	1,224,949.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT	1,143,133.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK: THE PIONIR TRIAL (PREVENTING IBD ONSET IN INDIVIDUALS AT RISK)	148,825.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	SUPPORT OF IMAGING AND PATIENT TREATMENT EQUIPMENT FOR THE HELMSLEY CANCER CENTER AND THE HELMSLEY NEUROLOGICAL INSTITUTE	2,342,997.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	UPGRADED PET-CT SCANNER UTILIZING NEW TECHNOLOGICAL DEVELOPMENTS FOR MORE ACCURATE, QUICKER AND SAFER DIAGNOSIS AND MONITORING.	2,700,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	RCT OF TASTY & HEALTHY DIETARY APPROACH FOR REMISSION IN CROHNS DISEASE	527,468.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK: THE PIONIR TRIAL (PREVENTING IBD ONSET IN INDIVIDUALS AT RISK)	355,916.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	THE HELMSLEY CANCER CENTER AT SHAARE ZEDEK MEDICAL CENTER JERUSALEM	5,226,272.
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK, 1ST FLOOR NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	230,000.
SHENANDOAH MEDICAL CENTER 300 PERSHING AVE SHENANDOAH, IA 51601	N/A	PC	SHENANDOAH MEDICAL CENTER / AVERA EEMERGENCY IMPLEMENTATION PROJECT	15,320.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	700,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	CAPACITY BUILDING TOWARD A SUSTAINABLE SIMULATION IN MOTION MONTANA	108,298.
SIOUX VALLEY MEMORIAL HOSPITAL ASSOCIATION 300 SIOUX VALLEY DRIVE CHEROKEE, IA 51012	N/A	PC	ECARE EMERGENCY AT CHEROKEE REGIONAL MEDICAL CENTER	13,877.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	HEALTHY FUTURE FOR ALL (HF4A) IMPROVING WATER, SANITATION, HYGIENE AND NUTRITION	1,207,754.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SOCIAL SCIENCE RESEARCH COUNCIL ONE PIERREPONT PLAZA, 15TH FLOOR BROOKLYN, NY 11201	N/A	PC	DATA2GO.NYC REVAMP AND DATA CLINIC	1,024,408.
SOCIETY FOR THE PRESERVATION OF NEW ENGLAND ANTIQUITIES 141 CAMBRIDGE STREET BOSTON, MA 02114	N/A	PC	GENERAL OPERATING SUPPORT	40,000.
SOS CHILDREN'S VILLAGES-USA, INC. 1620 I STREET, NW, SUITE 220 WASHINGTON, DC 20006	N/A	PC	EDUCARE 4.0: DEBRE TABOR AND GONDAR CITY, ETHIOPIA	1,386,577.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER	151,487.
SOUTHSIDE COMMUNITY HEALTH SERVICES, INC. 4243 4TH AVE SOUTH MINNEAPOLIS, MN 55409	N/A	PC	SOUTHSIDE COMMUNITY HEALTH SERVICES ULTRASOUND PROJECT	53,240.
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	REPLACEMENT OF ESSENTIAL HEALTH CARE EQUIPMENT	1,005,020.
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH 9 PRINCES ST MELBOURNE, AUSTRALIA	N/A	PC	WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?	343,506.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STEVENS COMMUNITY MEDICAL CENTER INC 400 EAST 1ST STREET MORRIS, MN 56267	N/A	PC	ULTRASOUND REVITALIZATION PROJECT	130,205.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227 AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO T1D CARE	750,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE III	1,287,681.
STICHTING PHARMACCESS INTERNATIONAL AHTC, TOWER C4, PAASHEUVELWEG 25 AMSTERDAM, NETHERLANDS	N/A	PC	MED4ALL EXPANSION	1,712,785.
STIFTELSEN FOR UTBILDNING (IOIBD) DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD	132,000.
SWIFT COUNTY-BENSON HOSPITAL 1815 WISCONSIN AVENUE BENSON, MN 56215	N/A	GOV	SWIFT COUNTY BENSON HOSPITAL ULTRASOUND PROJECT	252,828.
SYNERGOS INSTITUTE, INC. 3 EAST 54TH STREET NEW YORK, NY 10022	N/A	PC	IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS	1,063,518.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	1,285,307.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	325,000.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	325,000.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	1,285,307.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	A DATA DRIVEN APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH TYPE 1 DIABETES	261,908.
TEAR AUSTRALIA 1/4 SOLWOOD LANE BLACKBURN, AUSTRALIA	N/A	PC	FACILITATE SECURE ENVIRONMENTS FOR AMPLIFIED NUTRITION	224,000.
TECHNISCHE UNIVERSITAET MUENCHEN ARCISSTRABE 21 MUNCHEN, GERMANY	N/A	GOV	METAGENOMIC PILOT PROJECT	245,905.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TECHNISCHE UNIVERSITAT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	FR1DA IN SACHSEN	52,102.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS	385,330.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	GENETICS INSTITUTE AND GENOMICS CENTER	1,576,052.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH	1,685,000.
THE ASPEN INSTITUTE INC. 2300 N STREET WASHINGTON, DC 20037	N/A	PC	BUILDING VISIONARY AND EFFECTIVE TEAMS TO ACCELERATE PROGRESS AGAINST TYPE 1 DIABETES (T1D) AND OTHER NON-COMMUNICABLE DISEASES (NCDS)	996,251.
THE BARUCH PADEH MEDICAL CENTER, PORIYA THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	THE HELMSLEY REHABILITATION CENTER OF THE NORTH	4,453,113.
THE BARUCH PADEH MEDICAL CENTER, PORIYA THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	ROBOTIC ASSISTED SURGERY - PURCHASE OF A SURGICAL ROBOT	2,500,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS	956,452.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	A HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE	463,755.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	A HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE	463,751.
THE CENTER FOR EFFECTIVE PHILANTHROPY, INC. 675 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	GENERAL OPERATING SUPPORT	41,500.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY	430,508.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	MOTHER-TO-INFANT TRANSFER OF BACTERIOME, VIROME, FUNGOME AND METABOLOME IN HEALTH AND CROHN'S DISEASE (MOMMY-CD)	492,017.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY	251,789.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	GENETIC PROTECTION BY HLA-DQ6 IN T1D	197,874.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND INDEX AND A HISTOPATHOLOGY INDEX FOR STRICTURING SMALL BOWEL CROHNS DISEASE	348,000.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM	155,544.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	1,335,936.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA	41,415.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	954,604.
THE COMMUNICATIONS NETWORK 1717 NORTH NAPER BLVD NAPERVILLE, IL 60563	N/A	PC	GENERAL OPERATING SUPPORT	31,000.
THE DIATRIBE FOUNDATION 804 HAIGHT STREET SAN FRANCISCO, CA 94117	N/A	PC	DIATRIBE LEARN MENTAL HEALTH SERIES	99,715.
THE END FUND, INC. 2 PARK AVENUE, 18TH FLOOR NEW YORK, NY 10016	N/A	PC	NEGLECTED TROPICAL DISEASE: REACHING THE LAST MILE	22,500,000.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CROHNS DISEASE: A KNOWLEDGE TRANSLATION STRATEGY	89,047.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	QUANTITATIVE PROTEOMIC PROFILING OF FIBROSTENOTIC CROHNS DISEASE PATIENTS	419,010.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	122,854.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CROHNS DISEASE: A KNOWLEDGE TRANSLATION STRATEGY	89,047.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE	186,777.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	119,554.
THE HARDING FORD VISION, INC. 157-22 TUSKEGEE AIRMEN WAY JAMAICA, NY 11433	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
THE HOLE IN THE WALL GANG FUND, INC. 555 LONG WHARF DRIVE NEW HAVEN, CT 06511	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES	589,623.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE	997,937.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE JEWISH AGENCY FOR ISRAEL 48 KING GEORGE STREET JERUSALEM, ISRAEL	N/A	PC	FLIGHTS FOR NEW IMMIGRANTS FROM RUSSIA	3,000,000.
THE JEWISH AGENCY FOR ISRAEL 48 KING GEORGE STREET JERUSALEM, ISRAEL	N/A	PC	THE JEWISH AGENCY SECURITY FUND (THE FUND)	645,910.
THE LEGATUM INSTITUTE FOUNDATION 11 CHARLES STREET LONDON, UNITED KINGDOM	N/A	NC	PHASE TWO OF US PROSPERITY INDEX: EXPANDING COUNTY-LEVEL INDEX TO INCLUDE WYOMING AND DEEPENING IMPACT	50,000.
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD. (CC) YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN-ISRAELIS PURSUING NURSING DEGREES	220,000.
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	FASTERCURES LEADERSLINK PROGRAM EXPANSION	250,000.
THE ONE LOVE FOUNDATION IN HONOR OF YEARDLEY LOVE, INC. 44 PONDFIELD ROAD, SUITE 12 BRONXVILLE, NY 10708	N/A	PC	BUILDING FOR THE FUTURE	1,023,100.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS	211,526.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D	335,309.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	THE DRUGGABLE GPCROME IN CROHNS DISEASE	1,309,981.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN	1,015,503.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF PATIENT REGISTRY	433,333.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	ENGINEERING ISLET ANTIGEN-SPECIFIC TREGS FOR T1D	537,711.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	480,988.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	1,111,050.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	CULTURALLY SENSITIVE GROUP CLINIC MODEL FOR DIABETES CARE FOR LATINO PATIENTS: FEASIBILITY AND DISSEMINATION TO DIABETES CENTERS IN THE US	607,893.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY	1,047,134.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	TRIAL OF EARLY INITIATION OF CGM-GUIDED INSULIN THERAPY IN T1D	155,376.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	COMPLEMENT SYSTEM IN THE INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY	99,618.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	1,169,515.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL	300,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02	266,200.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	DIABETIC KETOACIDOSIS TRENDS AND RESOURCE UTILIZATION AT DIAGNOSIS OF TYPE 1 DIABETES IN THE UNITED STATES	330,758.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	SINGLE PERSISTENT ISLET AUTOANTIBODY (SPIA) PHENOTYPE: PERSONALIZED RISK ASSESSMENT	264,341.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	ASK THE EXPERTS	543,207.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	580,677.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	EVALUATING THE FEASIBILITY OF AUTOMATED INSULIN DELIVERY IN PRIMARY CARE AND THROUGH TELEHEALTH	705,874.
THE REGENTS OF THE UNIVERSITY OF NEW MEXICO SPONSORED PROJECTS - PREAWARD ALBUQUERQUE, NM 87131-0001	N/A	GOV	THE ECHO INSTITUTE: ADDRESSING GLOBAL HEALTHCARE DISPARITIES THROUGH REPLICATION OF THE ECHO MODEL	1,188,238.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT MEDICAL CENTER	1,179,326.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT RESILIENCE COMPLEX, RESILIENCE CENTER AND PARENTHOOD HOUSE	184,286.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	PURCHASING THE REQUISITE EQUIPMENT FOR ESTABLISHING THE SHEBA PANDEMIC PREPAREDNESS RESEARCH INSTITUTE (SPRI)	2,739,000.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	798,066.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	THE HELMSLEY CENTER FOR INNOVATIVE SURGICAL TRAINING	3,614,073.
THE SONIA NABETA FOUNDATION, INC. P.O. BOX 2222 NEW YORK, NY 10008-2222	N/A	PC	PROJECT BODA-BODA	412,944.
THE SONIA NABETA FOUNDATION, INC. P.O. BOX 2222 NEW YORK, NY 10008-2222	N/A	PC	PROJECT BODA-BODA	76,580.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX (HAREDI) MEN PURSUING B.S. DEGREES IN NURSING	306,724.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	210,638.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SUPPORT FOR T1D TRANSITION PROGRAMS	250,000.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	WEBSITE FOR THE NYC*T1D NETWORK	10,000.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SPATIALLY RESOLVED GENOMIC PROFILING AT SUB-CELLULAR RESOLUTION AND HIGH THROUGHPUT OF CROHNS DISEASE TISSUE BIOPSIES	210,228.
THE UNITED NATIONS INSTITUTE FOR TRAINING AND RESEARCH UNITED NATIONS INSTITUTE FOR TRAINING AND RESEARCH GENEVA, SWITZERLAND	N/A	PC	ACCELERATING ACCESS TO TREATMENT AND CARE FOR PEOPLE LIVING WITH NON-COMMUNICABLE DISEASES IN LOW AND MIDDLE-INCOME COUNTRIES.	1,000,000.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA EXPANDED SUPPORT	256,408.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA SCIENCE CONTINUATION	612,868.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND	484,264.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	IMMUNO-PHARMACOGENOMICS TO UNDERSTAND AND PREDICT RESPONSE TO BIOLOGICS IN CROHN'S DISEASE	305,353.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	A CELL ATLAS OF ILEAL COLONIC CROHN'S DISEASE	487,806.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)	618,790.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	444,247.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	382,456.
THE UNIVERSITY OF MANCHESTER OXFORD RD MANCHESTER, UNITED KINGDOM	N/A	PC	A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION	1,177,927.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BOULEVARD DALLAS, TX 75390-9020	N/A	GOV	IMMUNE CHECKPOINT ENGINEERED BETA CELL AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF TYPE I DIABETES	275,000.
THE UNIVERSITY OF WESTERN AUSTRALIA 35 STIRLING HIGHWAY CRAWLEY, AUSTRALIA	N/A	PC	CGM ASSESSMENTS OF ENDIA CHILDREN	72,816.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	2,000,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	DECODING THE CLINICAL IMPACT OF HOST AND MICROBIAL INTESTINAL PROTEOMIC LANDSCAPE IN CROHNS DISEASE	701,115.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	THE QUANTUM MATERIALS DEVICES FABRICATION LAB	660,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	DECODING PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IMPACTING CLINICAL AND PROGNOSTIC FEATURES IN CROHNS DISEASE	1,320,206.
TIDEPOOL PROJECT 555 BRYANT STREET, #429 PALO ALTO, CA 94301	N/A	PC	TIDEPOOL DATA PLATFORM EXPANSION	500,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TIDEPOOL PROJECT 555 BRYANT STREET, #429 PALO ALTO, CA 94301	N/A	PC	TIDEPOOL DATA PLATFORM EXPANSION	500,000.
TIDEPOOL PROJECT 555 BRYANT STREET, #429 PALO ALTO, CA 94301	N/A	PC	TIDEPOOL DATA PLATFORM EXPANSION	1,000,000.
TIDEPOOL PROJECT 555 BRYANT STREET, #429 PALO ALTO, CA 94301	N/A	PC	EXPANDING THE AVAILABILITY OF THE LOOP AID SYSTEM	421,085.
TOWNSEND HEALTH SYSTEMS, INC. 110 NORTH OAK TOWNSEND, MT 59644	N/A	PC	TELE-PHARMACY AT BILLINGS CLINIC BROADWATER	35,128.
TRICKLE UP PROGRAM, INC. 104 WEST 27TH STREET, 12TH FLOOR NEW YORK, NY 10001	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
TRI-COUNTY HOSPITAL, INC. 415 JEFFERSON ST. N. WADENA, MN 56482	N/A	PC	TRI-COUNTY HEALTH CARE ULTRASOUND PROJECT	400,329.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, MI 47401-3654	N/A	GOV	TARGETING METABOLIC DRIVERS OF B CELL DIFFERENTIATION IN TYPE 1 DIABETES	114,365.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, MI 47401-3654	N/A	GOV	MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES	696,962.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS	407,000.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE	285,463.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE	285,463.
UNITED HOSPITAL DISTRICT, INC. 515 SOUTH MOORE STREET BLUE EARTH, MN 56013	N/A	PC	UNITED HOSPITAL DISTRICT INC. ULTRASOUND PROJECT	240,907.
UNITED NATIONS DEVELOPMENT PROGRAMME 1 UNITED NATIONS PLAZA NEW YORK, NY 10017	N/A	PC	INCREASING ACCESS TO HEALTHCARE FOR PEOPLE LIVING WITH DIABETES AND OTHER NCDS	377,955.
UNITED STATES AFRICAN DEVELOPMENT FOUNDATION 1400 I STREET NW WASHINGTON, DC 20005	N/A	GOV	LIVELIHOOD IMPROVEMENT PROGRAM	1,779,762.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D	147,087.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING	295,566.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY AND IMMUNOTHERAPY BIRMINGHAM, UNITED KINGDOM	N/A	PC	DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES: AN EXPERIMENTAL MEDICINE STUDY	322,498.
UNIVERSITY OF BRISTOL SENATE HOUSE BRISTOL, UNITED KINGDOM	N/A	PC	TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY	407,937.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - A NOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE	711,485.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)	496,568.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES	157,744.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	ADVANCING B-CELL SPECIFIC THERAPY BY IDENTIFYING B-CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS	190,161.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES	30,509.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	837,493.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	THE NETWORK FOR PANCREATIC ORGAN DONORS WITH DIABETES (NPOD): A COLLABORATIVE TYPE 1 DIABETES RESEARCH PROJECT	1,199,692.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENTAL AND EARLY LIFE PANCREAS / IMMUNITY (HANDEL)-P/I CONTINUATION	1,043,638.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY	672,494.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION	194,408.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	999,877.
UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC. 2385 IRVING HILL ROAD LAWRENCE, KS 66045	N/A	PC	PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D	1,740,145.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	482,825.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	311,133.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES	295,977.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	A HOLISTIC DIET INTERVENTION FOR PEOPLE WITH CROHN'S DISEASE	471,158.
UNIVERSITY OF NEBRASKA FOUNDATION 1010 LINCOLN MALL LINCOLN, NE 68501	N/A	PC	SIMULATION IN MOTION NEBRASKA SUSTAINABILITY AND BUSINESS MODEL DEVELOPMENT	582,072.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR	1,019,519.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES	585,750.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS	966,865.
UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE & HEALTH SCIENCES GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	114,070.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	397,048.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	ANALOGUE VS HUMAN INSULIN FOR YOUTH WITH TYPE 1 DIABETES IN LOW-RESOURCE SETTINGS: A RANDOMIZED CONTROLLED TRIAL (ANHUT1D TRIAL).	1,338,570.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	239,587.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF SOUTHERN CALIFORNIA 3720 SOUTH FLOWER STREET LOS ANGELES, CA 90089-0701	N/A	PC	CGM REAL WORLD	120,000.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	63,693.
UNIVERSITY OF UTAH 201 S. PRESIDENTS CIRCLE SALT LAKE CITY, UT 84112	N/A	PC	ANTI-PHAGE ANTIBODIES IN STRATIFYING CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE	203,988.
UNIVERSITY OF WASHINGTON OFFICE OF SPONSORED PROGRAMS SEATTLE, WA 98195-9472	N/A	GOV	PATHOGENIC ACTION OF AUTOANTIBODIES ON ISLET FUNCTION AND VIABILITY IN TYPE 1 DIABETES	220,000.
UNIVERSITY OF ZURICH DEPARTMENT OF IMMUNOLOGY CH-8091, SWITZERLAND	N/A	GOV	GENERATE BISPECIFIC INTERLEUKIN-2 IMMUNOTHERAPY TO TREAT T1D MELLITUS	126,830.
UPPSALA UNIVERSITET BOX 256 UPPSALA, SWEDEN	N/A	GOV	ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION	76,573.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEVELOPMENT OF AN ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GUT CELL ATLAS	244,200.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	SCREENING HUMAN ISLETS TO IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA	108,069.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR A CROHN'S DISEASE GUT CELL ATLAS	146,933.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	275,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEVELOPMENT OF AN ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GUT CELL ATLAS	244,200.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	140,766.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR A CROHN'S DISEASE GUT CELL ATLAS	656,092.
VANDERBILT UNIVERSITY SPONSORED PROGRAMS ADMINISTRATION NASHVILLE, TN 37203-2417	N/A	PC	NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING	275,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	700,486.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	122,000.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	591,068.
VETERANS MEMORIAL HOSPITAL 40 1ST STREET, SE WAUKON, IA 52172	N/A	GOV	ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL	74,191.
VILLAGES OF HOPE: AFRICA SOCIETY 2450 MILLTOWER COURT MISSISSAUGA, CANADA	N/A	PC	VILLAGES OF HOPE COMMUNITY DEVELOPMENT - FOOD PRODUCTION FACILITIES, WATER SUPPLY UPGRADE, AND EDUCATION FACILITIES.	502,010.
WARREN COMMUNITY HOSPITAL INC. 300 WEST GOOD SAMARITAN DRIVE WARREN, MN 56762	N/A	PC	NORTH VALLEY HEALTH CENTER ULTRASOUND PROJECT	146,513.
WARREN MEMORIAL HOSPITAL 905 2ND ST. FRIEND, NE 68359	N/A	GOV	TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM	118,006.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130	N/A	PC	CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE	187,844.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130	N/A	PC	RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING	330,000.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130	N/A	PC	COVID-19 VACCINE RESPONSES IN PATIENTS WITH AUTOIMMUNE DISEASE (COVARIPAD)	656,480.
WASHOE BARTON MEDICAL CLINIC 1107 US HIGHWAY 395 N GARDNERVILLE, NV 89410	N/A	PC	CARSON VALLEY MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT	1,465,248.
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER	1,439,503.
WATERAID AMERICA, INC. 233 BROADWAY NEW YORK, NY 10279	N/A	PC	RESOLUTION TO REVOLUTION: CREATING A NEW REALITY FOR WASH IN HEALTHCARE FACILITIES IN ZAMBIA (R2R)	2,166,773.
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE	863,618.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WELIA HEALTH 301 HIGHWAY 65 S MORA, MN 55051	N/A	PC	WELIA HEALTH ULTRASOUND EQUIPMENT PROJECT	191,358.
WHITE EARTH HEALTH CENTER 40520 COUNTY HIGHWAY 34 OGEMA, MN 56569	N/A	GOV	NAYTAHWAUSH CLINIC ULTRASOUND PROJECT	192,403.
WHITE EARTH HEALTH CENTER 40520 COUNTY HIGHWAY 34 OGEMA, MN 56569	N/A	GOV	WHITE EARTH INDIAN HEALTH CENTER ULTRASOUND PROJECT	188,669.
WILDLIFE CONSERVATION SOCIETY 2300 SOUTHERN BOULEVARD BRONX, NY 10460	N/A	PC	GENERAL OPERATING SUPPORT FOR THE ELEPHANT CONSERVATION PROGRAM	10,000.
WINONA HEALTH SERVICES 855 MANKATO AVE WINONA, MN 55987	N/A	PC	ULTRASOUND REVITALIZATION PROJECT AT WINONA HEALTH	216,473.
WNET FOR THE WLIW-21 PUBLIC BROADCASTING 825 EIGHTH AVENUE NEW YORK, NY 10019-7435	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA 27, SWITZERLAND	N/A	PC	STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT	4,420,294.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WYOMING DEPARTMENT OF HEALTH 6101 YELLOWSTONE RD. SUITE 400 CHEYENNE, WY 82009	N/A	GOV	WYOMING FIRST RESPONDER AED PROJECT	167,693.
WYOMING STATE PARKS AND CULTURAL RESOURCES 2301 CENTRAL AVENUE CHEYENNE, WY 82002	N/A	GOV	SHINING MOUNTAINS INTERPRETIVE CENTER AT FORT PHIL KEARNY STATE HISTORIC SITE	30,000.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	443,827.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	EXPANSION AND RENOVATION OF THE CANCER INSTITUTE AT SHAMIR MEDICAL CENTER	6,082,143.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2022	200,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY	168,556.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY	173,613.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM	542,299.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD AND IMPROVE HEALTH OUTCOMES	267,835.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD AND IMPROVE HEALTH OUTCOMES	259,951.
ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH 84 SHMARYAHU LEVIN ST JERUSALEM, ISRAEL	N/A	PC	ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH	694,034.
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE	50,570.
Total from continuation sheets				478,616,552.

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN CAMPING ASSOCIATION INC 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2022-2024	51,040.
AMERICAN COLLEGE OF DIABETOLOGY INC PO BOX 87633 FAYETTEVILLE, NC 28304	N/A	PC	IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS	1,093,900.
AMERICAN COLLEGE OF DIABETOLOGY INC PO BOX 87633 FAYETTEVILLE, NC 28304	N/A	PC	IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS	1,087,885.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024)	337,310.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	399,368.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024)	278,350.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	399,368.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	805,382.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	805,382.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	805,382.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE MONTANA AND POST-ACUTE STROKE CARE QUALITY STANDARDS FIELD TESTING	1,024,257.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA	1,102,824.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE IOWA	2,105,298.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	996,262.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	1,011,199.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE IOWA	2,521,277.
AMERICAN PHARMACISTS ASSOCIATION FOUNDATION 2215 CONSTITUTION AVE NW WASHINGTON, DC 20037	N/A	PC	PROJECT IMPACT CGM: EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES	1,502,893.
AMERICARES FOUNDATION, INC. 88 HAMILTON AVE STAMFORD, CT 06840	N/A	PC	MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS	749,599.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	2,500,000.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	2,500,000.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	474,464.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	948,928.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	367,129.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	421,681.
ARAD MUNICIPALITY 6 HAPALMACH STREET ARAD, ISRAEL	N/A	GOV	ARAD OCCUPATIONAL REHABILITATION CENTER	290,000.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE	831,327.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE	855,546.
ASSOCIATION SANTE DIABTE 17 AVENUE MALHERBE GRENOBLE, FRANCE	N/A	PC	IMPROVE THE MANAGEMENT OF DIABETES AND THE SUPPORT TO PEOPLE AFFECTED BY THE DISEASE IN BURKINA FASO, MALI AND THE UNION OF COMOROS	205,984.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES	450,697.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES	907,233.
AVERA MCKENNAN FOR THE AVERA MCKENNAN HOSPITAL AND UNI. HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,000,000.
AVERA MCKENNAN FOR THE AVERA MCKENNAN HOSPITAL AND UNI. HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,500,000.
BALLAD RESEARCH INSTITUTE 10865 ROAD TO THE CURE SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS	325,801.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE	500,180.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE	532,841.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE	524,854.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE	547,540.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D	661,927.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D	567,763.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CROHN'S DISEASE.	938,641.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING	5,785,714.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CROHN'S DISEASE.	765,436.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING	9,542,857.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE	797,851.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE	797,851.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	1,200,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	940,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	1,060,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3	149,166.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	1,200,000.
BHSB SYSTEM 100 MICHIGAN ST NE GRAND RAPIDS, MI 49503	N/A	PC	STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS	3,104,271.
BHSB SYSTEM 100 MICHIGAN ST NE GRAND RAPIDS, MI 49503	N/A	PC	STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS	2,081,202.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	1,740,266.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	1,740,267.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	3,480,533.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	3,480,533.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	4,470,844.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	4,470,844.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	3,470,843.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN NEVADA	197,208.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM	101,000.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN NEVADA	197,208.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM	101,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE	836,979.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D	1,483,787.
BOULDER CITY HOSPITAL INC 901 ADAMS BLVD BOULDER CITY, NV 89005	N/A	PC	BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT	34,997.
BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION 505 EIGHTH AVENUE, 5TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING	567,155.
BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION 505 EIGHTH AVENUE, 5TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING	585,924.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA	2,648,126.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	1,785,375.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUTOANTIBODIES AS A DISEASE DETERMINANT IN CROHNS DISEASE	499,459.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	9,013,397.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE	292,476.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE	462,323.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE	767,757.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE	657,605.
CARE-FOR-RARE FOUNDATION DR. VON HAUNERSCHES KINDERSPITAL KLINIKUM DER UNIVERSITAT MUNCHEN MUNICH, GERMANY	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES	655,603.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CARE-FOR-RARE FOUNDATION DR. VON HAUNERSCHES KINDERSPITAL KLINIKUM DER UNIVERSITAT MUNCHEN MUNICH, GERMANY	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES	667,252.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: CEDARS-SINAI	115,500.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	200,041.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	LONG-TERM RESPONSES TO SARS-COV-2 VACCINATION IN A DIVERSE INFLAMMATORY BOWEL DISEASE POPULATION: A MULTI-OMIC STUDY	364,763.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	202,791.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION	701,215.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: CEDARS-SINAI	115,500.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	219,514.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	211,815.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION	488,364.
CENTER FOR HEALTH CARE STRATEGIES INC 200 AMERICAN METRO BLVD TRENTON, NJ 08619	N/A	PC	TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN	1,002,514.
CENTER FOR HEALTH CARE STRATEGIES INC 200 AMERICAN METRO BLVD TRENTON, NJ 08619	N/A	PC	TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN	626,707.
CENTRAL MONTANA MEDICAL FACILITIES, INC. 408 WENDELL AVE. LEWISTOWN, MT 59457	N/A	PC	CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER	3,690,035.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	95,277.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATTRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	103,796.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATTRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	153,102.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD	244,860.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA	438,659.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE	221,420.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD	244,860.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA	279,999.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE	93,443.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	1,072,041.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)	666,216.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES	1,249,403.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	1,255,105.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES	1,226,580.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)	665,654.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	679,025.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	684,686.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	1,009,535.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE	1,421,241.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE	1,093,319.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ROLE OF PPAR-ALPHA IN PROMOTING BRUSH BORDER MATURITY OF INTESTINAL ENTEROCYTES	439,601.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	725,157.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D	228,375.
CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY, MO 64108	N/A	PC	TYPE 1 DIABETES RAPID LEARNING LAB	1,399,624.
CIVICA FOUNDATION 2912 WEST EXECUTIVE PARKWAY LEHI, UT 84043	N/A	PC	AFFORDABLE INSULIN	2,500,000.
CIVICA FOUNDATION 2912 WEST EXECUTIVE PARKWAY LEHI, UT 84043	N/A	PC	AFFORDABLE INSULIN	2,500,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION	243,216.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	1,445,914.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT	138,626.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES	452,465.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	5,200,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT	145,605.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES	463,512.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	700,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE	1,243,053.
CONSORCI INSTITUT D'INVESTIGACIONES BIOMDICAS AUGUST PI I SUNYER ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE- PATHOPHYSIOLOGY AND IMAGING	261,570.
CRITICAL PATH INSTITUTE 1730 E. RIVER RD. TUCSON, AZ 85718	N/A	PC	T1D CONSORTIUM 2.0	266,741.
CRITICAL PATH INSTITUTE 1730 E. RIVER RD. TUCSON, AZ 85718	N/A	PC	T1D CONSORTIUM 2.0	266,741.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE	588,266.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	IBD VENTURES ACADEMIC INCUBATOR	1,180,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	TRAINING AWARDS PROGRAM - CLASS OF 2021	1,067,400.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE	588,266.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	IBD VENTURES ACADEMIC INCUBATOR	1,180,400.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CROHNS PATIENTS IN CANADA	275,588.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE	284,646.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CROHNS PATIENTS IN CANADA	286,838.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE	297,612.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	374,912.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 & 2022 OPERATING SUPPORT FOR CROHN'S AND COLITIS UK: KNOWLEDGE AND EVIDENCE PERSONNEL	75,900.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF A PEDIATRIC-SPECIFIC CROHNS DISEASE ELECTRONIC MEDICAL RECORD TO DRIVE CARE CONSISTENCY AND ENHANCE TRANSITIONS IN CARE	115,418.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	509,790.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	525,177.
DE LA SALLE SOLIDARIET INTERNAZIONALE ONLUS VIA AUREALIA, 476 ROME, ITALY	N/A	PC	ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY	94,780.
DIABETES NSW 26 ARUNDEL ST SYDNEY, AUSTRALIA	N/A	PC	IMPROVE OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, VIA GEOGRAPHIC EXPANSION AND COUNTRY-DRIVEN INITIATIVES	3,000,000.
DIABETES NSW 26 ARUNDEL ST SYDNEY, AUSTRALIA	N/A	PC	IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES	3,000,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DREAMED DIABETES LTD. 14 KAPLAN ST PETAH TIKVA, ISRAEL	N/A	NC	INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES	1,350,000.
DUKE UNIVERSITY C/O OFFICE OF RESEARCH SUPPORT DURHAM, NC 27705-4677	N/A	PC	AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AS A SAFEGUARD AGAINST INSULIN-INDUCED HYPOGLYCEMIA IN T1D	71,503.
DUKE UNIVERSITY C/O OFFICE OF RESEARCH SUPPORT DURHAM, NC 27705-4677	N/A	PC	AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AS A SAFEGUARD AGAINST INSULIN-INDUCED HYPOGLYCEMIA IN T1D	203,497.
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	29,310.
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	11,725.
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	283,099.
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	313,686.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	302,430.
FAIRVIEW HEALTH SERVICES 2450 RIVERSIDE AVE MINNEAPOLIS, MN 55454	N/A	PC	IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE	4,889,200.
FAIRVIEW HEALTH SERVICES 2450 RIVERSIDE AVE MINNEAPOLIS, MN 55454	N/A	PC	IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE	1,960,000.
FAIRVIEW HEALTH SERVICES 2450 RIVERSIDE AVE MINNEAPOLIS, MN 55454	N/A	PC	IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE	3,176,500.
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND CAMPUS BIOTECH GENEVA, SWITZERLAND	N/A	PC	ACCESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT	1,614,046.
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND CAMPUS BIOTECH GENEVA, SWITZERLAND	N/A	PC	ACCESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT	779,789.
FRANCISCAN CARE SERVICES INC 430 N MONITOR ST WEST POINT, NE 68788	N/A	PC	TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE	42,729.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FRANCISCAN CARE SERVICES INC 430 N MONITOR ST WEST POINT, NE 68788	N/A	PC	TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE	17,093.
FRIENDS OF THE ISRAEL DEFENSE FORCES 60 EAST 42 STREET NEW YORK, NY 10165	N/A	PC	IMPACT! SCHOLARSHIP PROGRAM	503,200.
FUND FOR PUBLIC HOUSING, INC. 90 CHURCH STREET NEW YORK, NY 10007	N/A	PC	DEVELOPING AND ACTIVATING GREENSPACE USING THE CONNECTED COMMUNITIES' PARTICIPATORY PROCESS AT FOUR NYCHA DEVELOPMENTS	1,630,000.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER	2,200,000.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER	2,200,000.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	251,522.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	397,123.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	402,672.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	187,672.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	143,892.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	480,848.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	485,617.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	485,616.
GLOBAL SOLIDARITY FUND 425 LEXINGTON AVE. NEW YORK, NY 10017	N/A	PC	JOB CREATION IN ETHIOPIA	1,508,200.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GUARDIAN ORG FOUNDATION 900 17TH STREET NW, SUITE 250 WASHINGTON, DC 20006	N/A	PC	A GROWING CRISIS: NON-COMMUNICABLE DISEASES, AN INDEPENDENT JOURNALISM SERIES BY THE GUARDIAN	625,000.
HADASSAH MEDICAL ORGANIZATION EIN KEREM ADDRESS: KALMAN YA'AKOV MAN STREET JERUSALEM, ISRAEL	N/A	PC	CREATING AND EQUIPPING A NEW COMPREHENSIVE DIAGNOSTIC AND INTERVENTIONAL IMAGING CENTER	681,600.
HADASSAH MEDICAL ORGANIZATION EIN KEREM ADDRESS: KALMAN YA'AKOV MAN STREET JERUSALEM, ISRAEL	N/A	PC	CREATING AND EQUIPPING A NEW COMPREHENSIVE DIAGNOSTIC AND INTERVENTIONAL IMAGING CENTER	454,400.
HEALTH ADVOCACY SUMMIT, INC. 1962 DOCKSIDE DRIVE GREENWOOD, IN 46143	N/A	PC	CROHNS AND COLITIS YOUNG ADULTS NETWORK LEARNING COMMUNITY, ROUNDTABLE ON ADOLESCENTS AND YOUNG ADULTS WITH IBD	60,060.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS DISEASE	362,703.
HELEN KELLER INTERNATIONAL ONE DAG HAMMARSKJOLD PLAZA NEW YORK, NY 10017	N/A	PC	A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT	1,441,293.
HELEN KELLER INTERNATIONAL ONE DAG HAMMARSKJOLD PLAZA NEW YORK, NY 10017	N/A	PC	A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT	1,652,490.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-02 STUDY: IDENTIFICATION OF INFANTS WITH HIGH RISK OF TYPE 1 DIABETES FOR PRIMARY PREVENTION	1,431,241.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	859,607.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,481,163.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,040,499.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED T1D RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	2,584,495.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	178,540.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,481,162.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	2,193,719.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	4,136,248.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	870,315.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH AND AUTOIMMUNITY OUTCOMES IN CHILDREN	82,445.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD BIOSAMPLE RFP	1,046,486.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	EUROPEAN PRE-T1D REGISTRY	196,089.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH AND AUTOIMMUNITY OUTCOMES IN CHILDREN	80,432.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	870,314.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,352,233.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	2,193,718.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	4,136,248.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	49,500.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	1,004,503.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,352,232.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD BIOSAMPLE RFP	95,294.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	1,004,503.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,486,275.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,486,274.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,412,946.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,412,946.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,479,330.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,479,329.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	526,471.
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KAISER HEALTH NEWS RURAL HEALTH DESK	1,458,159.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D	285,339.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS	217,256.
HILLEL YAFFE MEDICAL CENTER HA-SHALOM ST. HADERA, ISRAEL	N/A	GOV	EYE INSTITUTE AND AMBULATORY SURGERY CENTER	3,158,400.
HOLY ROSARY HEALTHCARE FOUNDATION 2600 WILSON STREET MILES CITY, MT 59301	N/A	PC	HOLY ROSARY HEALTHCARE COMPREHENSIVE CANCER CENTER	2,000,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	15,775.
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	117,600.
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	39,438.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	STUDY TO EVALUATE SAFETY AND TOLERABILITY OF ORAL BFAHF-2 IN PEDIATRIC SUBJECTS WITH MILD-TO-MODERATE CROHN'S DISEASE	214,842.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES	220,000.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE MELODY TRIAL: MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHN'S DISEASE	759,619.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	404,688.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE FOR NYCS MOST VULNERABLE MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.	672,617.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	305,349.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES	220,000.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE FOR NYCS MOST VULNERABLE MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.	779,716.
INNODIA HERESTRAAT 49 LEUVEN, BELGIUM	N/A	NC	INNODIA NONPROFIT LAUNCH FOR THE CARE AND PREVENTION OF T1D.	434,183.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	87,446.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	164,873.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	92,999.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	98,553.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	94,105.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	99,659.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	97,317.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	60,914.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET GAINESVILLE, FL 32608	N/A	PC	INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY	341,606.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.	375,221.
IOWA DEPARTMENT OF PUBLIC HEALTH 321 EAST 12TH DES MOINES, IA 50319	N/A	GOV	IOWA FIRST RESPONDER AED INITIATIVE	58,968.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: LARGE ADULT STUDY	159,838.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	283,542.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING	468,008.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	410,774.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	413,871.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	357,597.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	188,007.
JDRF AUSTRALIA 80-84 CHANDOS STREET, ST LEONARDS, 2065, NSW, AUSTRALIA SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA	1,196,912.
JDRF AUSTRALIA 80-84 CHANDOS STREET, ST LEONARDS, 2065, NSW, AUSTRALIA SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA	997,843.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	FOCUSING DEVELOPMENT EFFORTS TO ACCELERATE COMMERCIAL RELEASE OF CLOSED LOOP SENSOR SYSTEM	147,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	FOCUSING DEVELOPMENT EFFORTS TO ACCELERATE COMMERCIAL RELEASE OF CLOSED LOOP SENSOR SYSTEM	175,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE	133,332.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A 3-B-HYDROXYBUTYRATE BINDING PROTEIN BASED CONTINUOUS KETONE MONITORING MICROSENSOR	200,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	AUTOIMMUNITY SCREENING FOR KIDS PROGRAM TRANSITION TOWARDS A SUSTAINABLE SCREENING FOR T1D AND CELIAC DISEASE IN COLORADO	555,046.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	150,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	150,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE	133,334.
JDRF T1D FUND, LLC 50 MILK STREET, 16TH FLOOR BOSTON, MA 02109	N/A	PC	T1D FUND INITIATIVE TO DRIVE PHARMA INVESTMENT IN T1D	500,000.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING	1,300,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING	652,589.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS	568,782.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	ENGINEERED CYTOKINE/ANTIBODY FUSION PROTEIN TO TREAT CROHNS DISEASE	750,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING	657,403.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS	571,287.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	941,354.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	857,270.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JUVENILE DIABETES RESEARCH FOUNDATION CANADA 235 YORKLAND BLVD., SUITE 600 TORONTO, CANADA	N/A	PC	JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE	19,000.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY	297,898.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	246,662.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY	770,816.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	T CELL RECEPTOR SEQUENCING IN TYPE 1 DIABETES - BIOMARKER DISCOVERY AND TECHNOLOGY DEVELOPMENT	115,097.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL	195,494.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	HYPO - RESOLVE - EVALUATION OF BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA	307,779.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS	278,644.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,069,889.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,325,562.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,147,254.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	825,146.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,296,483.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	369,984.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS	208,787.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	778,535.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	781,151.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,079,926.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	649,424.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	600,891.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	606,581.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
LUCAS COUNTY HEALTH CENTER 1200 NORTH 7TH STREET CHARITON, IA 50049	N/A	PC	AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER	17,970.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	MOBILE MAMMOGRAPHY UNIT	31,500.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	MOBILE MAMMOGRAPHY UNIT	31,500.
MADISON COUNTY MEMORIAL HOSPITAL 300 W. HUTCHINGS STREET WINTERSET, IA 50273	N/A	GOV	IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM	15,187.
MAINEHEALTH 22 BRAMHALL STREET PORTLAND, ME 04102	N/A	PC	TRANSFORMING RURAL DIABETES CARE IN MAINE	848,894.
MAINEHEALTH 22 BRAMHALL STREET PORTLAND, ME 04102	N/A	PC	TRANSFORMING RURAL DIABETES CARE IN MAINE	596,795.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	WIRELESS INFRARED IMAGING CAPSULE FOR PINPOINTING INFLAMMATION IN CROHNS DISEASE	752,326.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	CROHN'S DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION AND BETTER TREATMENT	705,894.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS	300,000.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS	300,000.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	FEASIBILITY OF OFF-SITE REMOTE CONTROL ROBOTIC PERCUTANEOUS CORONARY INTERVENTIONS: A PILOT ANIMAL FEASIBILITY STUDY	385,906.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	334,407.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	MILITARY SCIENCES MEDICAL TRAINING 2022-2024	250,000.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	151,705.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SC 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	137,500.
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SC 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	412,500.
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SC 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	275,000.
MEDICINES FOR HUMANITY, INC. 800 HINGHAM STREET ROCKLAND, MA 02370	N/A	PC	MAI MBELEKI II EXPANSION	322,909.
MEDICINES FOR HUMANITY, INC. 800 HINGHAM STREET ROCKLAND, MA 02370	N/A	PC	MAI MBELEKI II EXPANSION	436,472.
MILLE LACS HEALTH SYSTEM 200 ELM STREET NORTH ONAMIA, MN 56359	N/A	PC	TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM	17,020.
MILLE LACS HEALTH SYSTEM 200 ELM STREET NORTH ONAMIA, MN 56359	N/A	PC	TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM	6,809.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MINNESOTA ACADEMY OF FAMILY PHYSICIANS FOUNDATION 1400 VANBUREN STE STE 215 MINNEAPOLIS, MN 55413	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	2,016,319.
MINNESOTA ACADEMY OF FAMILY PHYSICIANS FOUNDATION 1400 VANBUREN STE STE 215 MINNEAPOLIS, MN 55413	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	1,801,545.
MINNESOTA RURAL HEALTH ASSOCIATION 27011 460TH AVE HENNING, MN 56551	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA	318,700.
MINNESOTA RURAL HEALTH ASSOCIATION 27011 460TH AVE HENNING, MN 56551	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA	378,700.
MINNESOTA STATE COLLEGES AND UNIVERSITIES 30 E. 7TH STREET ST. PAUL, MN 55101	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA	217,428.
MINNESOTA STATE COLLEGES AND UNIVERSITIES 30 E. 7TH STREET ST. PAUL, MN 55101	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA	205,285.
MONROE COUNTY HOSPITAL 6580 165TH STREET ALBIA, IA 52531	N/A	GOV	EPHARMACY AT MONROE COUNTY HOSPITAL & CLINICS	7,031.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MONTANA PEDIATRICS 259 W. FRONT STREET MISSOULA, MT 59802	N/A	NC	CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D	417,700.
MONUMENT HEALTH STURGIS HOSPITAL 2140 JUNCTION AVE. STURGIS, SD 57785	N/A	PC	EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL	16,568.
NATIONAL ACADEMY OF SCIENCES 500 5TH STREET NW WASHINGTON, DC 20001	N/A	PC	STRENGTHENING MINORITY SERVING INSTITUTIONS	150,000.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	836,732.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	621,487.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	753,478.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BERING LAND BRIDGE VISITOR CENTER	1,163,270.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER	1,850,000.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	2023-2025 PARTNERSHIP	1,911,525.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	2023-2025 PARTNERSHIP	1,582,350.
NEBRASKA DEPT. OF HEALTH & HUMAN SERVICES, DIVISION OF PUBLIC HEALTH 301 CENTENNIAL MALL SOUTH LINCOLN, NE 68508	N/A	GOV	NEBRASKA FIRST RESPONDER AED PROJECT	309,887.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,230,038.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA FIRST RESPONDER AED PROJECT	153,920.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,239,092.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA FIRST RESPONDER AED PROJECT	130,670.
NEVADA HEALTH CENTERS, INC. 3325 RESEARCH WAY CARSON CITY, NV 89706	N/A	PC	QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM	48,108.
NEVADA HEALTH CENTERS, INC. 3325 RESEARCH WAY CARSON CITY, NV 89706	N/A	PC	QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM	48,108.
NEVADA RURAL HOSPITAL PARTNERS FOUNDATION, INC. 4600 KIETZKE LANE RENO, NV 89502	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS	27,500.
NEVADA RURAL HOSPITAL PARTNERS FOUNDATION, INC. 4600 KIETZKE LANE RENO, NV 89502	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS	27,500.
NEW DESTINY HOUSING CORPORATION 12 W. 37TH STREET, 7TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AFTERCARE INTERVENTION TO IMPROVE HOUSING AND HEALTH STABILITY FOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS	281,806.
NEW VENTURE FUND 1201 CONNECTICUT AVE NW, SUITE 300 WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)	1,468,813.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC	867,832.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC	614,668.
NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVENUE NEW YORK, NY 10016	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	2,756,847.
NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVENUE NEW YORK, NY 10016	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	3,692,303.
NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVENUE NEW YORK, NY 10016	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	1,360,453.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS	100,123.
NORTH DAKOTA DEPARTMENT OF HEALTH 600 E BOULEVARD AVENUE BISMARCK, ND 58505-0200	N/A	GOV	NORTH DAKOTA LAW ENFORCEMENT AED PROJECT	27,500.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	DISSEMINATION PILOT: THE IMPLEMENTATION OF NOVEL INTERVENTIONS IN CHILDREN'S HEALTHCARE (NICH) IN ANOTHER HEALTHCARE SYSTEM	322,462.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	DISSEMINATION PILOT: THE IMPLEMENTATION OF NOVEL INTERVENTIONS IN CHILDREN'S HEALTHCARE (NICH) IN ANOTHER HEALTHCARE SYSTEM	322,462.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT	1,783,316.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	NICH BAY AREA EXPANSION	654,234.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT	1,795,816.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	292,821.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	292,821.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	318,978.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	64,900.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	1,167,087.
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY 1 LETTERMAN DRIVE SAN FRANCISCO, CA 94129	N/A	PC	UNDERSTANDING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.	358,140.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE	1,838,580.
PAWNEE COUNTY MEMORIAL HOSPITAL 600 I STREET PAWNEE CITY, NE 68420	N/A	GOV	ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL	7,139.
PENNINGTON COUNTY HEALTH AND HUMAN SERVICES 321 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	GOV	PENNINGTON COUNTY CRISIS STABILIZATION UNIT	1,000,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PENNINGTON COUNTY HEALTH AND HUMAN SERVICES 321 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	GOV	PENNINGTON COUNTY CRISIS STABILIZATION UNIT	1,000,000.
PERKINS COUNTY HOSPITAL DISTRICT 900 LINCOLN AVE GRANT, NE 69140	N/A	GOV	TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES	36,761.
PERKINS COUNTY HOSPITAL DISTRICT 900 LINCOLN AVE GRANT, NE 69140	N/A	GOV	TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES	14,706.
PHILLIPS COUNTY HOSPITAL ASSOCIATION 311 S. 8TH AVENUE EAST MALTA, MT 59538	N/A	PC	TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY	64,193.
PHILLIPS COUNTY HOSPITAL ASSOCIATION 311 S. 8TH AVENUE EAST MALTA, MT 59538	N/A	PC	TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY	25,448.
PIONEER MEDICAL CENTER 301 WEST 7TH AVE BIG TIMBER, MT 59011	N/A	PC	TELE-PHARMACY AT PIONEER MEDICAL CENTER	24,968.
PIONEER MEDICAL CENTER 301 WEST 7TH AVE BIG TIMBER, MT 59011	N/A	PC	TELE-PHARMACY AT PIONEER MEDICAL CENTER	9,988.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02138- 5366	N/A	PC	PRE-SYMPTOMATIC AUTOANTIBODY AND VIRAL PROFILE OF US MILITARY PERSONNEL WITH ADULT-ONSET TYPE 1 DIABETES	126,636.
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION	310,123.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S	1,186,800.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S	746,990.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	454,441.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	USING NATURAL LANGUAGE PROCESSING OF CLINICAL DOCUMENTATION TO IMPROVE PERSONALIZATION OF CARE IN CROHN'S DISEASE	369,880.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	187,370.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	92,033.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	408,267.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	92,033.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13	308,267.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	4,885,390.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	DEVELOPING OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES	190,677.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	1,296,918.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGION HOVEDSTADEN KONGENS VNGE 2 HILLEROD, DENMARK	N/A	GOV	CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?	375,228.
REGION HOVEDSTADEN KONGENS VNGE 2 HILLEROD, DENMARK	N/A	GOV	CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?	113,358.
RESEARCH TRIANGLE INSTITUTE 3040 EAST CORNWALLIS ROAD RESEARCH TRIANGLE PARK, NC 27709-2194	N/A	PC	USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY	826,376.
RESEARCH TRIANGLE INSTITUTE 3040 EAST CORNWALLIS ROAD RESEARCH TRIANGLE PARK, NC 27709-2194	N/A	PC	USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY	1,110,288.
RIVER'S EDGE HOSPITAL AND CLINIC 1900 N. SUNRISE DRIVE ST. PETER, MN 56082	N/A	GOV	TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL	43,913.
RIVER'S EDGE HOSPITAL AND CLINIC 1900 N. SUNRISE DRIVE ST. PETER, MN 56082	N/A	GOV	TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL	17,567.
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY	1,552,050.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES	73,424.
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES	75,165.
SAINT LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD SAINT LOUIS, MO 63103	N/A	PC	IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES	608,000.
SAINT LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD SAINT LOUIS, MO 63103	N/A	PC	IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES	608,523.
SANFORD RESEARCH 2301 E 60TH STREET N SIOUX FALL, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	1,086,430.
SANFORD RESEARCH 2301 E 60TH STREET N SIOUX FALL, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	1,118,635.
SAPIR ACADEMIC COLLEGE D.N. HOF ASHKELON REGIONAL COUNCIL SHAAR HANEDEV, ISRAEL	N/A	PC	PLANNING FOR SAPIR ACADEMIC COLLEGE LAW SCHOOL BUILDING	303,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SCHWARTZ/REISMAN SCIENCE EDUCATION CENTER, REHOVOT, (R.A.) HERZL ST. 234 REHOVOT, ISRAEL	N/A	PC	THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT	1,982,305.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT	934,083.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT	989,083.
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK, 1ST FLOOR NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	200,000.
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK, 1ST FLOOR NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	170,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	400,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	HEALTHY FUTURE FOR ALL (HF4A) IMPROVING WATER, SANITATION, HYGIENE AND NUTRITION	962,857.
SOCIAL SCIENCE RESEARCH COUNCIL ONE PIERREPONT PLAZA, 15TH FLOOR BROOKLYN, NY 11201	N/A	PC	DATA2GO.NYC REVAMP AND DATA CLINIC	597,446.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER	26,976.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER	10,791.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AK 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	903,411.
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AK 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	818,043.
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH 9 PRINCES ST MELBOURNE, AUSTRALIA	N/A	PC	WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?	298,224.
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH 9 PRINCES ST MELBOURNE, AUSTRALIA	N/A	PC	WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?	255,857.
STATE OF NV, DEPT OF CONSERVATION AND NATURAL RES., DIV OF STATE PARKS 901 S. STEWART ST., SUITE 5005 CARSON CITY, NV 89701	N/A	PC	ICE AGE FOSSIL STATE PARK TRAILS AND OUTDOOR AMENITIES	2,800,000.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227 AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO T1D CARE	875,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE III	1,245,075.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STIFTELSEN FOR UTBILDNING (IOIBD) DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD	132,000.
STIFTELSEN FOR UTBILDNING (IOIBD) DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD	132,000.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	1,917,417.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	1,520,614.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	2,567,417.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	650,000.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	1,283,708.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	633,709.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	2,567,417.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	650,000.
TECHNISCHE UNIVERSITAT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	GENOMIC INFLUENCE OF MATERNAL TYPE 1 DIABETES - UNDERSTANDING PROTECTION AGAINST TYPE 1 DIABETES	210,829.
TECHNISCHE UNIVERSITAT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	FR1DA IN SACHSEN	60,079.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	GENETICS INSTITUTE AND GENOMICS CENTER	1,118,516.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS	346,330.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	GENETICS INSTITUTE AND GENOMICS CENTER	1,420,270.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS	268,340.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH	2,078,769.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH	2,664,333.
THE ASPEN INSTITUTE INC. 2300 N STREET WASHINGTON, DC 20037	N/A	PC	BUILDING VISIONARY AND EFFECTIVE TEAMS TO ACCELERATE PROGRESS AGAINST TYPE 1 DIABETES (T1D) AND OTHER NON-COMMUNICABLE DISEASES (NCDS)	998,081.
THE BANQUET 900 E 8TH ST SIOUX FALLS, SD 57103	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
THE BARUCH PADEH MEDICAL CENTER, PORIYA THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	THE HELMSLEY REHABILITATION CENTER OF THE NORTH	5,431,730.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS	971,014.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS	1,129,976.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY	249,337.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	GENETIC PROTECTION BY HLA-DQ6 IN T1D	352,126.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	1,355,310.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA	331,133.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND INDEX AND A HISTOPATHOLOGY INDEX FOR STRICTURING SMALL BOWEL CROHNS DISEASE	111,750.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	1,321,210.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA	236,313.
THE DIATRIBE FOUNDATION 804 HAIGHT STREET SAN FRANCISCO, CA 94117	N/A	PC	DIATRIBE LEARN MENTAL HEALTH SERIES	100,285.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	126,154.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE	121,036.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CROHNS DISEASE: A KNOWLEDGE TRANSLATION STRATEGY	89,047.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	137,153.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	QUANTITATIVE PROTEOMIC PROFILING OF FIBROSTENOTIC CROHNS DISEASE PATIENTS	247,654.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	127,077.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	137,417.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE	191,883.
THE HOPE CENTER 615 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES	548,276.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES	555,480.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE	1,032,574.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE	1,081,289.
THE JEWISH AGENCY FOR ISRAEL 48 KING GEORGE STREET JERUSALEM, ISRAEL	N/A	PC	THE JEWISH AGENCY SECURITY FUND (THE FUND)	161,477.
THE LEGATUM INSTITUTE FOUNDATION 11 CHARLES STREET LONDON, UNITED KINGDOM	N/A	NC	PHASE TWO OF US PROSPERITY INDEX: EXPANDING COUNTY-LEVEL INDEX TO INCLUDE WYOMING AND DEEPENING IMPACT	50,000.
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD. (CC) YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN-ISRAELIS PURSUING NURSING DEGREES	220,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	FASTERCURES LEADERSLINK PROGRAM EXPANSION	250,000.
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	FASTERCURES LEADERSLINK PROGRAM EXPANSION	250,000.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS	321,984.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D	594,335.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D	1,597,074.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA OFFICE OF CONTRACTS AND GRANTS LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	568,851.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA OFFICE OF CONTRACTS AND GRANTS LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	568,027.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	THE DRUGGABLE GPCROME IN CROHNS DISEASE	1,092,733.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN	1,016,890.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	THE DRUGGABLE GPCROME IN CROHNS DISEASE	1,091,471.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	269,368.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	241,173.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	241,173.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	269,368.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL	300,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	835,489.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	202,073.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	ASK THE EXPERTS	575,810.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	COMPLEMENT SYSTEM IN THE INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY	124,200.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02	266,200.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	1,008,526.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	DIABETIC KETOACIDOSIS TRENDS AND RESOURCE UTILIZATION AT DIAGNOSIS OF TYPE 1 DIABETES IN THE UNITED STATES	157,700.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL	300,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	178,454.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY	612,073.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	994,996.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT MEDICAL CENTER	993,626.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT	2,284,718.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	COMPREHENSIVE INDIVIDUALIZED PROACTIVE THERAPY OF CROHN'S DISEASE: THE CURE STUDY	228,294.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	THE HELMSLEY CENTER FOR INNOVATIVE SURGICAL TRAINING	4,395,700.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	704,764.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	756,699.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	188,118.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX (HAREDI) MEN PURSUING B.S. DEGREES IN NURSING	253,818.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	334,798.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	429,646.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SUPPORT FOR T1D TRANSITION PROGRAMS	200,000.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	413,263.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	351,258.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SUPPORT FOR T1D TRANSITION PROGRAMS	150,000.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA SCIENCE CONTINUATION	181,471.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA EXPANDED SUPPORT	163,010.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND	784,751.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND	333,042.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	444,246.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES.	159,623.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	212,881.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)	854,515.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	209,222.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES.	179,714.
THE UNIVERSITY OF MANCHESTER OXFORD RD MANCHESTER, UNITED KINGDOM	N/A	PC	A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION	1,113,915.
THE UNIVERSITY OF MANCHESTER OXFORD RD MANCHESTER, UNITED KINGDOM	N/A	PC	A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION	692,839.
THE UNIVERSITY OF QUEENSLAND CUMBRAE STEWART BUILDING #72 BRISBANE, AUSTRALIA	N/A	PC	LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES	435,713.
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BOULEVARD DALLAS, TX 75390-9020	N/A	GOV	IMMUNE CHECKPOINT ENGINEERED BETA CELL AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF TYPE I DIABETES	275,000.
THE UNIVERSITY OF WESTERN AUSTRALIA 35 STIRLING HIGHWAY CRAWLEY, AUSTRALIA	N/A	PC	CGM ASSESSMENTS OF ENDIA CHILDREN	94,107.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	THE QUANTUM MATERIALS DEVICES FABRICATION LAB	1,750,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	2,500,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	DECODING THE CLINICAL IMPACT OF HOST AND MICROBIAL INTESTINAL PROTEOMIC LANDSCAPE IN CROHNS DISEASE	961,620.
TOWNSEND HEALTH SYSTEMS, INC. 110 NORTH OAK TOWNSEND, MT 59644	N/A	PC	TELE-PHARMACY AT BILLINGS CLINIC BROADWATER	15,112.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, MI 47401-3654	N/A	GOV	COLLABORATIVE EFFORT TO VALIDATE MICRORNA AS BIOMARKERS OF T1D	426,380.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, MI 47401-3654	N/A	GOV	TARGETING METABOLIC DRIVERS OF B CELL DIFFERENTIATION IN TYPE 1 DIABETES	58,372.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE	285,079.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS	407,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE	293,370.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS	407,000.
UNITED JEWISH APPEAL FEDERATION OF JEWISH PHILANTHROPIES OF NY INC 130 EAST 59TH STREET NEW YORK, NY 10022	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
UNITED NATIONS DEVELOPMENT PROGRAMME 1 UNITED NATIONS PLAZA NEW YORK, NY 10017	N/A	PC	INCREASING ACCESS TO HEALTHCARE FOR PEOPLE LIVING WITH DIABETES AND OTHER NCDS	339,777.
UNITED STATES AFRICAN DEVELOPMENT FOUNDATION 1400 I STREET NW WASHINGTON, DC 20005	N/A	GOV	LIVELIHOOD IMPROVEMENT PROGRAM	1,283,255.
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	869,232.
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	784,421.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITAIR MEDISCH CENTRUM UTRECHT HEIDELBERGLAAN 100 UTRECHT, NETHERLANDS	N/A	GOV	EPITHELIAL-BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD	173,250.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT HEIDELBERGLAAN 100 UTRECHT, NETHERLANDS	N/A	GOV	EPITHELIAL-BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD	173,250.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	LONGITUDINAL STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN AND ADOLESCENTS WITH NEW-ONSET T1D	62,567.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING	213,582.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING	213,602.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	233,094.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	576,839.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY COLLEGE LONDON GOWER STREET LONDON, UNITED KINGDOM	N/A	PC	SPIT-C: USING SALIVA TO PREDICT CROHNS DISEASE	94,104.
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	866,199.
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	677,700.
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	707,339.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY AND IMMUNOTHERAPY BIRMINGHAM, UNITED KINGDOM	N/A	PC	DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES: AN EXPERIMENTAL MEDICINE STUDY	233,307.
UNIVERSITY OF BRISTOL SENATE HOUSE BRISTOL, UNITED KINGDOM	N/A	PC	TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY	431,779.
UNIVERSITY OF BRISTOL SENATE HOUSE BRISTOL, UNITED KINGDOM	N/A	PC	TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY	358,900.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - A NOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE	718,215.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)	500,000.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)	353,223.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - A NOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE	713,088.
UNIVERSITY OF DUNDEE NETHERGATE DUNDEE, UNITED KINGDOM	N/A	PC	HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA	133,804.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM	566,086.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	ADVANCING B-CELL SPECIFIC THERAPY BY IDENTIFYING B-CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS	126,104.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES	403,451.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM	451,469.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	665,910.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	569,086.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY	1,231,291.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY	176,239.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION	204,566.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	748,244.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION	199,968.
UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC. 2385 IRVING HILL ROAD LAWRENCE, KS 66045	N/A	PC	PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D	706,324.
UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC. 2385 IRVING HILL ROAD LAWRENCE, KS 66045	N/A	PC	PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D	579,370.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	881,959.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	473,409.
UNIVERSITY OF MELBOURNE LEVEL 4, ALAN GILBERT BUILDING VICTORIA, AUSTRALIA	N/A	PC	ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR	880,551.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	326,055.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	328,238.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES	286,197.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES	242,826.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES	581,625.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR	1,027,184.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR	1,116,830.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE & HEALTH SCIENCES GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	61,479.
UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE & HEALTH SCIENCES GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	54,978.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	503,082.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	848,637.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	542,672.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING	284,289.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING	263,104.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	243,196.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	280,115.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	ANALOGUE VS HUMAN INSULIN FOR YOUTH WITH TYPE 1 DIABETES IN LOW-RESOURCE SETTINGS: A RANDOMIZED CONTROLLED TRIAL (ANHUT1D TRIAL).	998,931.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	237,102.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	196,411.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	198,646.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	198,646.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	200,927.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	200,927.
UNIVERSITY OF TOLEDO 3000 ARLINGTON AVENUE TOLEDO, OH 43614-2595	N/A	GOV	TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH	110,480.
UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION 580 MASSIE ROAD CHARLOTTESVILLE, VA 22903	N/A	PC	GENERAL OPERATING SUPPORT FOR THE CATHERINE MURPHY KEATING '87 RESTRICTED FUND	50,000.
UPPSALA UNIVERSITET BOX 256 UPPSALA, SWEDEN	N/A	GOV	ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION	229,347.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	MRI OF THE PANCREAS IN T1D	373,041.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY	659,685.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEVELOPMENT OF AN ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GUT CELL ATLAS	248,256.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	68,349.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	SCREENING HUMAN ISLETS TO IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA	221,931.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	200,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	275,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEVELOPMENT OF AN ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GUT CELL ATLAS	248,256.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	121,999.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	163,405.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	275,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	232,525.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	182,168.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	36,595.
VANDERBILT UNIVERSITY SPONSORED PROGRAMS ADMINISTRATION NASHVILLE, TN 37203-2417	N/A	PC	NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING	275,000.
VANDERBILT UNIVERSITY SPONSORED PROGRAMS ADMINISTRATION NASHVILLE, TN 37203-2417	N/A	PC	NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING	275,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	233,495.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	318,000.
VETERANS MEMORIAL HOSPITAL 40 1ST STREET, SE WAUKON, IA 52172	N/A	GOV	ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL	30,504.
VIVLI, INC. 14 STORY STREET, SUITE 406 CAMBRIDGE, MA 02138	N/A	PC	DATA SHARING PLATFORM FOR T1-DEXI DATASETS	72,174.
VIVLI, INC. 14 STORY STREET, SUITE 406 CAMBRIDGE, MA 02138	N/A	PC	DATA SHARING PLATFORM FOR T1-DEXI DATASETS	72,174.
WARREN MEMORIAL HOSPITAL 905 2ND ST. FRIEND, NE 68359	N/A	GOV	TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM	25,335.
WARREN MEMORIAL HOSPITAL 905 2ND ST. FRIEND, NE 68359	N/A	GOV	TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM	11,027.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130	N/A	PC	CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE	338,970.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130	N/A	PC	RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING	330,000.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130	N/A	PC	CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE	488,300.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130	N/A	PC	RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING	330,000.
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER	1,673,164.
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE	863,618.
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE	202,620.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WEIZMANN INSTITUTE OF SCIENCE POB 26 REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	500,000.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA 27, SWITZERLAND	N/A	PC	STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT	3,521,461.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA 27, SWITZERLAND	N/A	PC	STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT	2,738,915.
WYOMING DEPARTMENT OF HEALTH 6101 YELLOWSTONE RD. SUITE 400 CHEYENNE, WY 82009	N/A	GOV	WYOMING FIRST RESPONDER AED PROJECT	16,000.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	298,606.
YEHUDA ABARBANEL GOVERNMENT HOSPITAL 15 KEREN KAYEMET ST. BAT YAM, ISRAEL	N/A	GOV	MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS	454,960.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	EXPANSION AND RENOVATION OF THE CANCER INSTITUTE AT SHAMIR MEDICAL CENTER	1,978,286.

Total from continuation sheets

Underpayment of Estimated Tax by Corporations

Attach to the corporation's tax return. FORM 990-PF

2022

Go to www.irs.gov/Form2220 for instructions and the latest information.

Name **THE LEONA M. AND HARRY B. HELMSLEY
CHARITABLE TRUST**

Employer identification number
13-7184401

Note: Generally, the corporation is not required to file Form 2220 (see Part II below for exceptions) because the IRS will figure any penalty owed and bill the corporation. However, the corporation may still use Form 2220 to figure the penalty. If so, enter the amount from page 2, line 38, on the estimated tax penalty line of the corporation's income tax return, but **do not** attach Form 2220.

Part I Required Annual Payment

1	Total tax (see instructions)		1	1,659,683.
2a	Personal holding company tax (Schedule PH (Form 1120), line 26) included on line 1			
2b	Look-back interest included on line 1 under section 460(b)(2) for completed long-term contracts or section 167(g) for depreciation under the income forecast method			
2c	Credit for federal tax paid on fuels (see instructions)			
2d	Total. Add lines 2a through 2c			
3	Subtract line 2d from line 1. If the result is less than \$500, do not complete or file this form. The corporation does not owe the penalty		3	1,659,683.
4	Enter the tax shown on the corporation's 2021 income tax return. See instructions. Caution: If the tax is zero or the tax year was for less than 12 months, skip this line and enter the amount from line 3 on line 5		4	14,577,769.
5	Required annual payment. Enter the smaller of line 3 or line 4. If the corporation is required to skip line 4, enter the amount from line 3		5	1,659,683.

Part II Reasons for Filing - Check the boxes below that apply. If any boxes are checked, the corporation **must** file Form 2220 even if it does not owe a penalty. See instructions.

- 6 The corporation is using the adjusted seasonal installment method.
- 7 The corporation is using the annualized income installment method.
- 8 The corporation is a "large corporation" figuring its first required installment based on the prior year's tax.

Part III Figuring the Underpayment

	(a)	(b)	(c)	(d)	
9 Installment due dates. Enter in columns (a) through (d) the 15th day of the 4th (Form 990-PF filers: Use 5th month), 6th, 9th, and 12th months of the corporation's tax year	9	08/15/22	09/15/22	12/15/22	03/15/23
10 Required installments. If the box on line 6 and/or line 7 above is checked, enter the amounts from Sch A, line 38. If the box on line 8 (but not 6 or 7) is checked, see instructions for the amounts to enter. If none of these boxes are checked, enter 25% (0.25) of line 5 above in each column	10	414,921.	414,921.	414,920.	414,921.
11 Estimated tax paid or credited for each period. For column (a) only, enter the amount from line 11 on line 15. See instructions	11	4,983,219.	4,000,000.	4,700,000.	2,500,000.
Complete lines 12 through 18 of one column before going to the next column.					
12 Enter amount, if any, from line 18 of the preceding column	12		4,568,298.	8,153,377.	12,438,457.
13 Add lines 11 and 12	13		8,568,298.	12,853,377.	14,938,457.
14 Add amounts on lines 16 and 17 of the preceding column	14				
15 Subtract line 14 from line 13. If zero or less, enter -0-	15	4,983,219.	8,568,298.	12,853,377.	14,938,457.
16 If the amount on line 15 is zero, subtract line 13 from line 14. Otherwise, enter -0-	16		0.	0.	
17 Underpayment. If line 15 is less than or equal to line 10, subtract line 15 from line 10. Then go to line 12 of the next column. Otherwise, go to line 18	17				
18 Overpayment. If line 10 is less than line 15, subtract line 10 from line 15. Then go to line 12 of the next column	18	4,568,298.	8,153,377.	12,438,457.	

Go to Part IV on page 2 to figure the penalty. Do not go to Part IV if there are no entries on line 17 - no penalty is owed.

Part IV Figuring the Penalty

	(a)	(b)	(c)	(d)
19 Enter the date of payment or the 15th day of the 4th month after the close of the tax year, whichever is earlier. (C corporations with tax years ending June 30 and S corporations: Use 3rd month instead of 4th month. Form 990-PF and Form 990-T filers: Use 5th month instead of 4th month.) See instructions	19			
20 Number of days from due date of installment on line 9 to the date shown on line 19	20			
21 Number of days on line 20 after 4/15/2022 and before 7/1/2022	21			
22 Underpayment on line 17 x $\frac{\text{Number of days on line 21} \times 4\% (0.04)}{365}$...	22 \$	\$	\$	\$
23 Number of days on line 20 after 6/30/2022 and before 10/1/2022	23			
24 Underpayment on line 17 x $\frac{\text{Number of days on line 23} \times 5\% (0.05)}{365}$...	24 \$	\$	\$	\$
25 Number of days on line 20 after 9/30/2022 and before 1/1/2023	25			
26 Underpayment on line 17 x $\frac{\text{Number of days on line 25} \times 6\% (0.06)}{365}$...	26 \$	\$	\$	\$
27 Number of days on line 20 after 12/31/2022 and before 4/1/2023	27			
28 Underpayment on line 17 x $\frac{\text{Number of days on line 27} \times 7\% (0.07)}{365}$...	28 \$	\$	\$	\$
29 Number of days on line 20 after 3/31/2023 and before 7/1/2023	29			
30 Underpayment on line 17 x $\frac{\text{Number of days on line 29} \times \%}{365}$	30 \$	\$	\$	\$
31 Number of days on line 20 after 6/30/2023 and before 10/1/2023	31			
32 Underpayment on line 17 x $\frac{\text{Number of days on line 31} \times \%}{365}$	32 \$	\$	\$	\$
33 Number of days on line 20 after 9/30/2023 and before 1/1/2024	33			
34 Underpayment on line 17 x $\frac{\text{Number of days on line 33} \times \%}{365}$	34 \$	\$	\$	\$
35 Number of days on line 20 after 12/31/2023 and before 3/16/2024	35			
36 Underpayment on line 17 x $\frac{\text{Number of days on line 35} \times \%}{366}$	36 \$	\$	\$	\$
37 Add lines 22, 24, 26, 28, 30, 32, 34, and 36	37 \$	\$	\$	\$
38 Penalty. Add columns (a) through (d) of line 37. Enter the total here and on Form 1120, line 34; or the comparable line for other income tax returns	38 \$			0.

* Use the penalty interest rate for each calendar quarter, which the IRS will determine during the first month in the preceding quarter. These rates are published quarterly in an IRS News Release and in a revenue ruling in the Internal Revenue Bulletin. To obtain this information on the Internet, access the IRS website at www.irs.gov. You can also call 1-800-829-4933 to get interest rate information.

Schedule A Adjusted Seasonal Installment Method and Annualized Income Installment Method

See instructions.

Form 1120-S filers: For lines 1, 2, 3, and 21, "taxable income" refers to excess net passive income or the amount on which tax is imposed under section 1374(a), whichever applies.

Part I Adjusted Seasonal Installment Method

Caution: Use this method only if the base period percentage for any 6 consecutive months is at least 70%. See instructions.

Table with 5 columns: (a) First 3 months, (b) First 5 months, (c) First 8 months, (d) First 11 months. Rows include taxable income for various periods (1a-1c, 3a-3c), calculations (4-6), and tax amounts (7-19).

Part II Annualized Income Installment Method

		(a)	(b)	(c)	(d)
		First <u>2</u> months	First <u>3</u> months	First <u>6</u> months	First <u>9</u> months
20	Annualization periods (see instructions)				
21	Enter taxable income for each annualization period. See instructions for the treatment of extraordinary items	198,716,739.	282,958,582.	643,198,946.	871,595,843.
22	Annualization amounts (see instructions)	6.000000	4.000000	2.000000	1.333330
23a	Annualized taxable income. Multiply line 21 by line 22	1,192,300,434.	1,131,834,328.	1,286,397,892.	1,162,124,885.
23b	Extraordinary items (see instructions)				
23c	Add lines 23a and 23b	1,192,300,434.	1,131,834,328.	1,286,397,892.	1,162,124,885.
24	Figure the tax on the amount on line 23c using the instructions for Form 1120, Schedule J, line 2, or comparable line of corporation's return	16,572,976.	15,732,497.	17,880,931.	16,153,536.
25	Enter any alternative minimum tax (trusts only) for each payment period (see instructions)				
26	Enter any other taxes for each payment period. See instr.				
27	Total tax. Add lines 24 through 26	16,572,976.	15,732,497.	17,880,931.	16,153,536.
28	For each period, enter the same type of credits as allowed on Form 2220, lines 1 and 2c. See instructions				
29	Total tax after credits. Subtract line 28 from line 27. If zero or less, enter -0-	16,572,976.	15,732,497.	17,880,931.	16,153,536.
30	Applicable percentage	25%	50%	75%	100%
31	Multiply line 29 by line 30	4,143,244.	7,866,249.	13,410,698.	16,153,536.

Part III Required Installments

		1st installment	2nd installment	3rd installment	4th installment
		Note: Complete lines 32 through 38 of one column before completing the next column.			
32	If only Part I or Part II is completed, enter the amount in each column from line 19 or line 31. If both parts are completed, enter the smaller of the amounts in each column from line 19 or line 31	4,143,244.	7,866,249.	13,410,698.	16,153,536.
33	Add the amounts in all preceding columns of line 38. See instructions		414,921.	829,842.	1,244,762.
34	Adjusted seasonal or annualized income installments. Subtract line 33 from line 32. If zero or less, enter -0-	4,143,244.	7,451,328.	12,580,856.	14,908,774.
35	Enter 25% (0.25) of line 5 on page 1 of Form 2220 in each column. Note: "Large corporations," see the instructions for line 10 for the amounts to enter	414,921.	414,921.	414,920.	414,921.
36	Subtract line 38 of the preceding column from line 37 of the preceding column				
37	Add lines 35 and 36	414,921.	414,921.	414,920.	414,921.
38	Required installments. Enter the smaller of line 34 or line 37 here and on page 1 of Form 2220, line 10. See instructions	414,921.	414,921.	414,920.	414,921.

Form 2220 (2022)

** ANNUALIZED INCOME INSTALLMENT METHOD USING STANDARD OPTION

FORM 990-PF INTEREST ON SAVINGS AND TEMPORARY CASH INVESTMENTS STATEMENT 1

SOURCE	(A) REVENUE PER BOOKS	(B) NET INVESTMENT INCOME	(C) ADJUSTED NET INCOME
INTEREST FROM SAVINGS	4,992,185.	4,992,185.	
TOTAL TO PART I, LINE 3	4,992,185.	4,992,185.	

FORM 990-PF DIVIDENDS AND INTEREST FROM SECURITIES STATEMENT 2

SOURCE	GROSS AMOUNT	CAPITAL GAINS DIVIDENDS	(A) REVENUE PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME
DIVIDENDS AND INTEREST FROM SECURITIES	53,271,499.	0.	53,271,499.	126,037,349.	
TO PART I, LINE 4	53,271,499.	0.	53,271,499.	126,037,349.	

FORM 990-PF OTHER INCOME STATEMENT 3

DESCRIPTION	(A) REVENUE PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME
FX TRANSACTION NET LOSS	-3,721,210.	-3,793,103.	
CLASS ACTION PROCEEDS, NET	17,056.	17,056.	
OTHER PARTNERSHIP INCOME	40,911,519.	37,759,358.	
SECTION 951(A) INCOME INCLUSION	0.	4,671,829.	
GRANT RECOVERIES	500.	0.	
OTHER NON-TAXABLE INCOME	14,795.	0.	
TOTAL TO FORM 990-PF, PART I, LINE 11	37,222,660.	38,655,140.	

FORM 990-PF

LEGAL FEES

STATEMENT 4

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
HAROLD A MERIAM III (INVESTMENT RELATED)	18,879.	18,879.		0.
LOEB & LOEB LLP (GENERAL AND ADMINISTRATIVE)	76,950.	0.		89,475.
ROPES & GRAY LLP (INVESTMENT RELATED)	130,533.	130,533.		0.
PATTERSON BELKNAP WEBB & TYLER LLP (GENERAL & ADMINISTRATIVE)	226,572.	0.		182,279.
OTHER LEGAL FEES	35,896.	0.		27,012.
TO FM 990-PF, PG 1, LN 16A	488,830.	149,412.		298,766.

FORM 990-PF

ACCOUNTING FEES

STATEMENT 5

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
DEMASCO, SENA & JAHELKA LLP (BOOKKEEPING)	34,989.	4,944.		20,343.
PKF O'CONNOR DAVIES, LLP (AUDIT & TAX)	754,225.	543,175.		162,390.
PRICEWATERHOUSECOOPERS ADVISORY LTD. (GRANTS ADMINISTRATION)	115,449.	0.		117,738.
OTHER ACCOUNTING CONSULTANTS	14,616.	0.		19,794.
TO FORM 990-PF, PG 1, LN 16B	919,279.	548,119.		320,265.

FORM 990-PF

OTHER PROFESSIONAL FEES

STATEMENT 6

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
CETERA SERVICES LLC (PROGRAM CONSULTING)	98,098.	0.		87,359.
COLLER VI (INVESTMENT MANAGEMENT)	369,475.	369,475.		0.
COLLER VII (INVESTMENT MANAGEMENT)	463,217.	463,217.		0.
DF DENT & COMPANY, INC. (INVESTMENT MANAGEMENT)	630,200.	630,200.		0.

FIDUCIARY MANAGEMENT, INC. (INVESTMENT MANAGEMENT)	645,119.	645,119.	0.
GAVEA INVESTMENT FUND V B L.P. (INVESTMENT MANAGEMENT)	1,069,010.	1,069,010.	0.
GAVEA V PLUS (INVESTMENT MANAGEMENT)	51,077.	51,077.	0.
GENESIS ANALYTICS (PROGRAM CONSULTING)	101,960.	0.	151,960.
GLOBAL HEALTH STRATEGIES (PROGRAM CONSULTING)	601,417.	0.	558,754.
GLOBAL STRATEGY GROUP LLC (PUBLIC RELATIONS)	300,000.	0.	325,000.
IFP GLOBAL EQUITY LP (INVESTMENT MANAGEMENT)	1,080,516.	1,080,516.	0.
IMM PRODUCTIONS INC. (PUBLIC RELATIONS)	51,401.	0.	29,701.
LEAH WEST (PROGRAM CONSULTING)	67,200.	0.	68,800.
NGOSOURCE (GRANTS MANAGEMENT CONSULTING)	98,390.	0.	94,915.
OTHER CONSULTING FEES - GENERAL MANAGEMENT	143,654.	3,960.	138,660.
OTHER CONSULTING FEES - GRANTS MANAGEMENT	78,340.	0.	78,454.
OTHER CONSULTING FEES - HUMAN RESOURCES	81,321.	4,250.	60,271.
OTHER CONSULTING FEES - INFORMATION TECHNOLOGY	11,009.	0.	16,569.
OTHER INVESTMENT MANAGEMENT & CONSULTING FEES	2,215.	2,215.	0.
OTHER PROGRAM RELATED CONSULTING FEES	230,211.	0.	230,433.
OTHER PUBLIC RELATIONS CONSULTING FEES	21,718.	0.	18,312.
OTHER RECRUITMENT FEES	85,778.	0.	81,835.
PRECISION ADVISORS, LLC DBA PRECISION FOR VALUE, LLC (PROGRAM CONSULTING)	79,656.	0.	68,040.
SCISTORIES LLC (PUBLIC RELATIONS)	175,000.	0.	173,275.
SOLUTION SIMPLE (INFORMATION TECHNOLOGY)	342,684.	38,705.	271,914.
STARWOOD X (INVESTMENT MANAGEMENT)	4,022,881.	4,022,881.	0.
THE FORWARD GROUP (PROGRAM CONSULTING)	87,040.	0.	87,040.
T. ROWE PRICE ASSOCIATES INC. (INVESTMENT MANAGEMENT)	902,581.	902,581.	0.
WILSHIRE ASSOCIATES INCORPORATED (INVESTMENT ADVISORY)	465,953.	465,953.	0.
TO FORM 990-PF, PG 1, LN 16C	12,357,121.	9,749,159.	2,541,292.

FORM 990-PF

TAXES

STATEMENT 7

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
STATE UBI AND OTHER TAXES	2,144,102.	0.		0.
FOREIGN TAXES WITHHELD	539,426.	2,824,376.		0.
FEDERAL EXCISE TAX	11,955,389.	0.		0.
FEDERAL UNRELATED BUSINESS INCOME TAX	2,540,000.	0.		0.
TO FORM 990-PF, PG 1, LN 18	17,178,917.	2,824,376.		0.

FORM 990-PF

OTHER EXPENSES

STATEMENT 8

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
AMERICAN DEPOSITARY RECEIPT FEE	14,759.	14,759.		0.
CONSULTING REIMBURSEMENTS CUSTODY, BANK, & PERFORMANCE REPORTING FEES	126,833.	0.		106,618.
FILING FEES AND PENALTIES INFORMATION	828,583.	828,528.		55.
TECHNOLOGY/COMPUTERS	2,926.	0.		4,539.
INSURANCE	1,608,732.	259,091.		1,489,125.
OFFICE EXPENSES	393,802.	46,136.		348,004.
PORTFOLIO DEDUCTIONS	1,009,161.	345,552.		684,777.
TO FORM 990-PF, PG 1, LN 23	13,280,837.	51,667,723.		0.
	17,265,633.	53,161,789.		2,633,118.

FORM 990-PF

CORPORATE STOCK

STATEMENT 9

DESCRIPTION	BOOK VALUE	FAIR MARKET VALUE
ALPHABET INC, 32,514 SHRS	3,381,456.	3,381,456.
AMAZON.COM INC, 62,440 SHRS	6,449,428.	6,449,428.
AMERICAN TOWER CORP, 9,313 SHRS	1,903,018.	1,903,018.
ANSYS INC, 16,010 SHRS	5,328,128.	5,328,128.
ATLASSIAN CORP, 3,724 SHRS	637,437.	637,437.
BIO-TECHNE CORP, 60,654 SHRS	4,499,920.	4,499,920.
BLACKLINE INC, 27,781 SHRS	1,865,494.	1,865,494.
CBRE GROUP INC, 65,438 SHRS	4,764,541.	4,764,541.
CABLE ONE INC, 1,885 SHRS	1,323,270.	1,323,270.
CARMAX INC, 42,075 SHRS	2,704,581.	2,704,581.
COSTAR GROUP INC, 37,037 SHRS	2,549,997.	2,549,997.
CROWDSTRIKE HOLDINGS INC, 12,929 SHRS	1,774,635.	1,774,635.
DANAHER CORP, 22,680 SHRS	5,716,267.	5,716,267.
DOLLAR GENERAL CORP, 17,420 SHRS	3,666,213.	3,666,213.
ECOLAB INC, 25,314 SHRS	4,190,226.	4,190,226.
ENDA VA PLC, 19,526 SHRS	1,311,757.	1,311,757.
FASTENAL CO, 59,691 SHRS	3,219,733.	3,219,733.
GUIDEWIRE SOFTWARE INC, 54,117 SHRS	4,440,300.	4,440,300.
HEICO CORP, 31,842 SHRS	4,327,328.	4,327,328.
IDEXX LABORATORIES INC, 2,985 SHRS	1,492,739.	1,492,739.
ILLUMINA INC, 16,733 SHRS	3,891,259.	3,891,259.
INTUITIVE SURGICAL INC, 17,554 SHRS	4,484,520.	4,484,520.
MARKEL CORP, 1,279 SHRS	1,633,807.	1,633,807.
MASTERCARD INC, 17,212 SHRS	6,255,013.	6,255,013.
MICROSOFT CORP, 16,736 SHRS	4,824,989.	4,824,989.
MOODY'S CORP, 13,298 SHRS	4,069,454.	4,069,454.
OLD DOMINION FREIGHT LINE INC, 6,551 SHRS	2,232,843.	2,232,843.
QUALCOMM INC, 32,515 SHRS	4,148,264.	4,148,264.
S&P GLOBAL INC, 16,804 SHRS	5,793,515.	5,793,515.
SBA COMMUNICATIONS CORP, 6,996 SHRS	1,826,446.	1,826,446.
SITEONE LANDSCAPE SUPPLY INC, 20,904 SHRS	2,861,130.	2,861,130.
SPROUT SOCIAL INC, 8,650 SHRS	526,612.	526,612.
THERMO FISHER SCIENTIFIC INC, 9,077 SHRS	5,231,710.	5,231,710.
TRANSDIGM GROUP INC, 8,842 SHRS	6,516,996.	6,516,996.
VEEVA SYSTEMS INC, 16,876 SHRS	3,101,640.	3,101,640.
VERISK ANALYTICS INC, 11,005 SHRS	2,111,419.	2,111,419.
VISA INC, 29,616 SHRS	6,677,223.	6,677,223.
VULCAN MATERIALS CO, 33,046 SHRS	5,669,372.	5,669,372.
WNS HOLDINGS LTD, 8,376 SHRS	780,392.	780,392.
WASTE CONNECTIONS INC, 28,069 SHRS	3,903,556.	3,903,556.
WEST PHARMACEUTICAL SERVICES I, 5,916 SHRS	2,049,717.	2,049,717.
WILLSCOT MOBILE MINI HOLDINGS, 43,251 SHRS	2,027,607.	2,027,607.
WORKIVA INC, 11,503 SHRS	1,178,022.	1,178,022.
ALPHABET INC, 72,435 SHRS	7,513,683.	7,513,683.
AVERY DENNISON CORP, 33,942 SHRS	6,073,242.	6,073,242.
BERKSHIRE HATHAWAY INC, 25,167 SHRS	7,770,815.	7,770,815.
BLACKROCK INC, 5,136 SHRS	3,436,600.	3,436,600.
BOOKING HOLDINGS INC, 3,637 SHRS	9,646,815.	9,646,815.
CDW CORP/DE, 34,555 SHRS	6,734,424.	6,734,424.
CARLISLE COS INC, 22,167 SHRS	5,011,294.	5,011,294.
CARMAX INC, 77,051 SHRS	4,952,838.	4,952,838.
DOLLAR GENERAL CORP, 32,069 SHRS	6,749,242.	6,749,242.

DOLLAR TREE INC, 39,975 SHRS	5,738,411.	5,738,411.
FRESENIUS MEDICAL CARE AG & CO, 129,576 SHRS	2,754,786.	2,754,786.
KONINKLIJKE PHILIPS NV, 209,149 SHRS	3,837,884.	3,837,884.
MASCO CORP, 121,524 SHRS	6,042,173.	6,042,173.
MICRON TECHNOLOGY INC, 106,364 SHRS	6,418,004.	6,418,004.
NORTHERN TRUST CORP, 64,709 SHRS	5,702,804.	5,702,804.
OMNICOM GROUP INC, 62,210 SHRS	5,868,891.	5,868,891.
PACCAR INC, 72,048 SHRS	5,273,914.	5,273,914.
PROGRESSIVE CORP/THE, 25,222 SHRS	3,608,259.	3,608,259.
SAP SE, 49,464 SHRS	6,259,669.	6,259,669.
SCHLUMBERGER LTD, 63,706 SHRS	3,127,965.	3,127,965.
CHARLES SCHWAB CORP/THE, 135,357 SHRS	7,090,000.	7,090,000.
SMITH & NEPHEW PLC, 149,359 SHRS	4,168,610.	4,168,610.
SONY GROUP CORP, 94,227 SHRS	8,541,678.	8,541,678.
TJX COS INC/THE, 35,452 SHRS	2,778,019.	2,778,019.
UNILEVER PLC, 101,750 SHRS	5,283,878.	5,283,878.
UNITEDHEALTH GROUP INC, 16,258 SHRS	7,683,368.	7,683,368.
ARCH CAPITAL GROUP LTD, 52,935 SHRS	3,592,698.	3,592,698.
EATON CORP PLC, 25,890 SHRS	4,435,993.	4,435,993.
FERGUSON PLC, 55,421 SHRS	7,412,559.	7,412,559.
UNILEVER PLC, 95,831 SHRS	4,965,272.	4,965,272.
NINTENDO CO LTD, 175,300 SHRS	6,758,317.	6,758,317.
RECKITT BENCKISER GROUP PLC, 67,581 SHRS	5,145,657.	5,145,657.
INFORMA PLC, 692,646 SHRS	5,931,580.	5,931,580.
GSK PLC, 342,443 SHRS	6,050,581.	6,050,581.
NOVARTIS AG, 87,389 SHRS	8,012,372.	8,012,372.
NESTLE SA, 40,044 SHRS	4,885,670.	4,885,670.
CIE FINANCIERE RICHEMONT SA, 55,725 SHRS	8,899,652.	8,899,652.
BOOKING HOLDINGS INC, 2,661 SHRS	7,058,063.	7,058,063.
BRISTOL-MYERS SQUIBB CO, 127,359 SHRS	8,827,252.	8,827,252.
CORTEVA INC, 86,257 SHRS	5,202,160.	5,202,160.
EBAY INC, 116,222 SHRS	5,156,770.	5,156,770.
ELECTRONIC ARTS INC, 49,720 SHRS	5,988,774.	5,988,774.
FOX CORP, 207,253 SHRS	7,056,965.	7,056,965.
INTERCONTINENTAL EXCHANGE INC, 53,873 SHRS	5,618,415.	5,618,415.
JOHNSON & JOHNSON, 25,557 SHRS	3,961,335.	3,961,335.
MICROSOFT CORP, 17,519 SHRS	5,050,728.	5,050,728.
NEWS CORP, 338,693 SHRS	5,849,228.	5,849,228.
NEWS CORP, 135,863 SHRS	2,368,092.	2,368,092.
ORACLE CORP, 91,710 SHRS	8,521,693.	8,521,693.
RITCHIE BROS AUCTIONEERS INC, 156,348 SHRS	8,800,824.	8,800,824.
S&P GLOBAL INC, 12,457 SHRS	4,294,800.	4,294,800.
SALESFORCE INC, 42,550 SHRS	8,500,639.	8,500,639.
TRANSUNION, 72,687 SHRS	4,516,770.	4,516,770.
ZILLOW GROUP INC, 24,908 SHRS	1,088,480.	1,088,480.
ZILLOW GROUP INC, 138,528 SHRS	6,160,340.	6,160,340.
AON PLC, 23,026 SHRS	7,259,868.	7,259,868.
CHINA RENAISSANCE HOLDINGS LTD, 127,556 SHRS	118,132.	118,132.
MEITUAN, 183,364 SHRS	3,351,962.	3,351,962.
AFFIRM HOLDINGS INC, 85,000 SHRS	957,950.	957,950.
AIRBNB INC, 28,899 SHRS	3,595,036.	3,595,036.
BILL HOLDINGS INC, 6,110 SHRS	495,765.	495,765.
CROWDSTRIKE HOLDINGS INC, 8,124 SHRS	1,115,100.	1,115,100.
DIGITALOCEAN HOLDINGS INC, 19,878 SHRS	778,621.	778,621.
DOORDASH INC, 22,663 SHRS	1,440,460.	1,440,460.
META PLATFORMS INC, 10,000 SHRS	2,119,400.	2,119,400.
GUARDANT HEALTH INC, 4,000 SHRS	93,760.	93,760.
LYFT INC, 17,155 SHRS	159,027.	159,027.

PDD HOLDINGS INC, 191,556 SHRS	14,539,100.	14,539,100.
ROBLOX CORP, 72,000 SHRS	3,238,560.	3,238,560.
SENTINELONE INC, 23,937 SHRS	391,609.	391,609.
SNOWFLAKE INC, 11,358 SHRS	1,752,426.	1,752,426.
UBER TECHNOLOGIES INC, 22,578 SHRS	715,723.	715,723.
UIPATH INC, 155,893 SHRS	2,737,481.	2,737,481.
ZOOM VIDEO COMMUNICATIONS INC, 11,000 SHRS	812,240.	812,240.
NU HOLDINGS LTD/CAYMAN ISLANDS, 338,840 SHRS	1,612,878.	1,612,878.
TOTAL TO FORM 990-PF, PART II, LINE 10B	512,806,017.	512,806,017.

FORM 990-PF

OTHER INVESTMENTS

STATEMENT 10

DESCRIPTION	VALUATION METHOD	BOOK VALUE	FAIR MARKET VALUE
JPM US LARGE CAP	FMV	89,887,853.	89,887,853.
SPDR TRUST SERIES I	FMV	112,725,127.	112,725,127.
JPM CORE BOND	FMV	1,275,527,805.	1,275,527,805.
JPM SHORT DURATION BOND	FMV	358,827,222.	358,827,222.
CHATHAM	FMV	110,403,032.	110,403,032.
CHATHAM OFFSHORE	FMV	108,855,967.	108,855,967.
CAMBER	FMV	125,446,113.	125,446,113.
ORBIMED GENESIS FUND	FMV	36,492,369.	36,492,369.
JERICHO	FMV	162,925,513.	162,925,513.
SEQUOIA CAP GLOBAL	FMV	159,113,105.	159,113,105.
BLACKROCK US DEBT	FMV	220,413,634.	220,413,634.
ACADIAN FRONTIER	FMV	8,586,357.	8,586,357.
HIGHCLERE INTL SC	FMV	122,902,800.	122,902,800.
HIGHCLERE INTL SMID	FMV	63,832,240.	63,832,240.
LA CAPITAL GLOBAL	FMV	79,280,835.	79,280,835.
LACM WORLD SMALL CAP	FMV	79,786,302.	79,786,302.
MARATHON GLOBAL	FMV	104,282,397.	104,282,397.
SILCHESTER INTL	FMV	132,194,805.	132,194,805.
BAYVIEW	FMV	995,218.	995,218.
EIG ENERGY FUND XVI	FMV	43,841,076.	43,841,076.
EIG ENERGY XV	FMV	6,046,353.	6,046,353.
FDAF DISLOCATED II	FMV	31,319,465.	31,319,465.
FDAF DISLOCATED III	FMV	40,161,460.	40,161,460.
FDAF DISLOCATED IV	FMV	29,173,276.	29,173,276.
GSO CAP SOLUTION III	FMV	5,494,379.	5,494,379.
GSO CAPITAL SOLS II	FMV	2,731,586.	2,731,586.
HIG BAYSIDE III	FMV	3,888,027.	3,888,027.
MHR INST PARTNERS IV	FMV	65,625,654.	65,625,654.
MHR AXIOM	FMV	180,117,878.	180,117,878.
NEWMARKET IIFC	FMV	19,881,377.	19,881,377.
ORBIMED ROYALTY II	FMV	1,818,353.	1,818,353.
ACCEL GROWTH FUND IV	FMV	23,306,105.	23,306,105.
ACCEL GROWTH II	FMV	11,525,805.	11,525,805.
ACCEL GROWTH III	FMV	14,062,197.	14,062,197.
ACCEL GROWTH V	FMV	30,856,064.	30,856,064.
ACCEL GROWTH VI	FMV	11,116,513.	11,116,513.
ACCEL INDIA V	FMV	13,627,732.	13,627,732.
ACCEL INDIA VI	FMV	9,007,512.	9,007,512.
ACCEL INDIA VII	FMV	1,445,976.	1,445,976.

ACCEL LEADERS FUND	FMV	8,403,924.	8,403,924.
ACCEL LEADERS II	FMV	8,298,931.	8,298,931.
ACCEL LEADERS III	FMV	24,969,812.	24,969,812.
ACCEL XI	FMV	6,436,480.	6,436,480.
ACCEL XII	FMV	20,600,164.	20,600,164.
ACCEL XIII	FMV	15,293,694.	15,293,694.
ACCEL XIV	FMV	9,478,212.	9,478,212.
ACCEL XV	FMV	4,127,349.	4,127,349.
AH BIO FUND I	FMV	8,001,820.	8,001,820.
AH BIO FUND II	FMV	16,525,099.	16,525,099.
AH BIO III	FMV	16,135,427.	16,135,427.
AH BIO IV	FMV	1,633,128.	1,633,128.
AH CNK IV	FMV	3,542,478.	3,542,478.
AH CNK SEED I	FMV	1,381,507.	1,381,507.
AH FUND VII	FMV	11,579,104.	11,579,104.
AH FUND VIII	FMV	2,054,633.	2,054,633.
AH III	FMV	34,421,513.	34,421,513.
AH III PARALLEL	FMV	6,537,207.	6,537,207.
AH IV	FMV	36,119,833.	36,119,833.
AH IV PARALLEL	FMV	15,175,771.	15,175,771.
AH LSV FUND II	FMV	18,761,485.	18,761,485.
AH LSV FUND III	FMV	8,558,632.	8,558,632.
AH LSV I	FMV	18,115,427.	18,115,427.
AH V	FMV	43,552,481.	43,552,481.
AH V PARALLEL	FMV	22,036,088.	22,036,088.
AH VI	FMV	27,983,122.	27,983,122.
ANGELENO INV III	FMV	18,452,053.	18,452,053.
ARBORETUM III	FMV	4,460,534.	4,460,534.
ARBORETUM IV	FMV	20,124,269.	20,124,269.
ARBORETUM V	FMV	16,318,215.	16,318,215.
ARBORETUM VI	FMV	405,367.	405,367.
COLLER VI	FMV	5,196,586.	5,196,586.
COLLER VII	FMV	29,003,442.	29,003,442.
COLLER VIII	FMV	25,169,457.	25,169,457.
CONGRUENT CONTINUITY	FMV	6,433,756.	6,433,756.
CRESTVIEW ELO	FMV	11,498,951.	11,498,951.
CRESTVIEW III	FMV	42,364,783.	42,364,783.
CRESTVIEW IV	FMV	26,969,399.	26,969,399.
EIG ENERGY XVII	FMV	12,533,917.	12,533,917.
EMERGENCE III	FMV	59,036,371.	59,036,371.
EMERGENCE IV	FMV	32,038,902.	32,038,902.
EMERGENCE OPP I	FMV	6,419,545.	6,419,545.
EMERGENCE V	FMV	26,452,742.	26,452,742.
EMERGENCE VI	FMV	3,844,612.	3,844,612.
EPIRIS ELEC CO INV	FMV	11,433,291.	11,433,291.
EPIRIS II	FMV	23,727,202.	23,727,202.
EPIRIS III	FMV	14,650,108.	14,650,108.
FORTISSIMO IV	FMV	28,048,549.	28,048,549.
FORTISSIMO V	FMV	20,602,148.	20,602,148.
FRAZIER GTH BUYOUT X	FMV	8,367,762.	8,367,762.
FRAZIER IX	FMV	7,560,219.	7,560,219.
FRAZIER OVERAGE	FMV	3,944,391.	3,944,391.
FRAZIER PUBLIC FUND	FMV	14,574,138.	14,574,138.
FRAZIER SUNMD CO INV	FMV	6,000,000.	6,000,000.
FRAZIER X	FMV	12,212,810.	12,212,810.
FRAZIER XI	FMV	2,049,716.	2,049,716.
GAVEA IV	FMV	1,534,310.	1,534,310.
GAVEA V	FMV	2,971,242.	2,971,242.

GAVEA V PLUS	FMV	961,041.	961,041.
GENERL ATLANTIC 2013	FMV	71,292,650.	71,292,650.
GENERL ATLANTIC 2018	FMV	91,410,994.	91,410,994.
HIG BIOVENTURE II	FMV	14,753,715.	14,753,715.
HIG BRAZIL	FMV	3,241,268.	3,241,268.
HIG BRAZIL LATAM B	FMV	19,618,616.	19,618,616.
HIG BRAZIL LATAM C	FMV	19,618,616.	19,618,616.
HIG CAPITAL V	FMV	13,303,155.	13,303,155.
HIG GROWTH B&E F II	FMV	17,091,289.	17,091,289.
HIG GROWTH III	FMV	4,250,306.	4,250,306.
HIG MID MARKET II	FMV	19,315,641.	19,315,641.
HIG MID MARKET III	FMV	16,819,112.	16,819,112.
IDG BREYER	FMV	6,289,258.	6,289,258.
IDG CHINA CAP III	FMV	31,294,212.	31,294,212.
IDG CHINA VTR IV	FMV	37,847,043.	37,847,043.
IDG CHINA VTR V	FMV	43,351,289.	43,351,289.
IDG-ACCEL CHINA CAP	FMV	16,259,701.	16,259,701.
IDG-ACCEL CHINA GWTH	FMV	17,903,730.	17,903,730.
IRON POINT IV	FMV	20,712,705.	20,712,705.
JPM PEG SECONDRY III	FMV	6,280,144.	6,280,144.
ORBIMED ASIA III	FMV	54,142,529.	54,142,529.
ORBIMED ASIA IV	FMV	17,375,333.	17,375,333.
ORBIMED ISRAEL	FMV	6,273,845.	6,273,845.
ORBIMED ISRAEL II	FMV	20,517,862.	20,517,862.
ORBIMED PI IX	FMV	960,558.	960,558.
ORBIMED PI VI	FMV	10,180,145.	10,180,145.
ORBIMED PI VII	FMV	25,368,476.	25,368,476.
ORBIMED PI VIII	FMV	16,357,264.	16,357,264.
ORBMIED ASIA V	FMV	901,247.	901,247.
PEP IV CORE	FMV	20,908.	20,908.
PEP IV SUPPL	FMV	5,093.	5,093.
PEP VI	FMV	12,898,545.	12,898,545.
PITANGO GROWTH	FMV	59,461,225.	59,461,225.
PITANGO GROWTH II	FMV	19,989,681.	19,989,681.
PITANGO HEALTHTECH I	FMV	11,088,645.	11,088,645.
PITANGO SPV	FMV	21,871,504.	21,871,504.
PITANGO VI, LP	FMV	28,795,364.	28,795,364.
PITANGO VTR VII	FMV	35,656,703.	35,656,703.
PITANGO VTR VIII	FMV	14,198,006.	14,198,006.
RIDGEWOOD III	FMV	44,869,309.	44,869,309.
RIDGEWOOD IV	FMV	28,696,697.	28,696,697.
S CAPITAL	FMV	28,544,455.	28,544,455.
S CAPITAL II	FMV	12,164,961.	12,164,961.
S CAPITAL III	FMV	388,428.	388,428.
SCF LIQUID PORTFOLIO	FMV	27,524,885.	27,524,885.
SEQUOIA CH GWTH VI	FMV	20,303,939.	20,303,939.
SEQUOIA CH VTR IX	FMV	577,864.	577,864.
SEQUOIA CH VTR VIII	FMV	4,178,822.	4,178,822.
SEQUOIA CHINA GR III	FMV	97,694,383.	97,694,383.
SEQUOIA CHINA GR IV	FMV	25,069,894.	25,069,894.
SEQUOIA CHINA GRTH V	FMV	31,408,680.	31,408,680.
SEQUOIA CHINA VE VII	FMV	6,175,889.	6,175,889.
SEQUOIA CHINA VTR IV	FMV	7,986,024.	7,986,024.
SEQUOIA CHINA VTR V	FMV	9,003,849.	9,003,849.
SEQUOIA CHINA VTR VI	FMV	7,209,166.	7,209,166.
SEQUOIA GBL GRTH III	FMV	105,050,777.	105,050,777.
SEQUOIA GG 3 CH ANX	FMV	11,510,178.	11,510,178.
SEQUOIA GLB GROWTH	FMV	28,821,426.	28,821,426.

SEQUOIA GLB GRWTH II	FMV	43,970,010.	43,970,010.
SEQUOIA IND GWT IV	FMV	551,014.	551,014.
SEQUOIA IND GWTH III	FMV	10,109,448.	10,109,448.
SEQUOIA IND VTR VII	FMV	2,697,610.	2,697,610.
SEQUOIA INDIA V	FMV	12,012,935.	12,012,935.
SEQUOIA INDIA VI	FMV	10,886,516.	10,886,516.
SEQUOIA INDIA VIII	FMV	548,857.	548,857.
SEQUOIA ISRAEL V	FMV	5,870,937.	5,870,937.
SEQUOIA SCOUT III	FMV	2,216,538.	2,216,538.
SEQUOIA SCOUT IV	FMV	1,008,155.	1,008,155.
SEQUOIA SEA I	FMV	1,223,188.	1,223,188.
SEQUOIA US ECO I	FMV	195,389.	195,389.
SEQUOIA US EXP I	FMV	1,952,416.	1,952,416.
SEQUOIA US GROWTH V	FMV	1,157,680.	1,157,680.
SEQUOIA US GRTH VIII	FMV	12,172,711.	12,172,711.
SEQUOIA US GRWTH VII	FMV	8,803,688.	8,803,688.
SEQUOIA US GWTH IX	FMV	7,332,439.	7,332,439.
SEQUOIA US GWTH VI	FMV	5,642,511.	5,642,511.
SEQUOIA US GWTH X	FMV	120,686.	120,686.
SEQUOIA US VENT XVI	FMV	7,404,060.	7,404,060.
SEQUOIA US VTR XIV	FMV	13,842,026.	13,842,026.
SEQUOIA US VTR XV	FMV	4,674,483.	4,674,483.
SEQUOIA US VTR XVII	FMV	2,757,453.	2,757,453.
SQUOIA GG 3 US IN AX	FMV	12,369,891.	12,369,891.
STARWOOD X	FMV	20,971,322.	20,971,322.
STARWOOD XI	FMV	39,460,847.	39,460,847.
STARWOOD XII	FMV	10,877,498.	10,877,498.
TAURUS RESOURCES II	FMV	44,794,352.	44,794,352.
WTI VLL IX	FMV	17,073,600.	17,073,600.
WTI VLL VII	FMV	8,812,400.	8,812,400.
WTI VLL VIII	FMV	16,243,990.	16,243,990.
WTI VLL X	FMV	4,206,969.	4,206,969.
YORK CO INVEST 1	FMV	1,314,740.	1,314,740.
TOTAL TO FORM 990-PF, PART II, LINE 13		6,449,780,993.	6,449,780,993.

FORM 990-PF DEPRECIATION OF ASSETS NOT HELD FOR INVESTMENT STATEMENT 11

DESCRIPTION	COST OR OTHER BASIS	ACCUMULATED DEPRECIATION	BOOK VALUE
FURNITURE, FIXTURES AND EQUIPMENT	2,745,200.	1,679,582.	1,065,618.
LEASEHOLD IMPROVEMENTS	7,160,401.	1,365,827.	5,794,574.
WORK IN PROGRESS	30,127.	0.	30,127.
TOTAL TO FM 990-PF, PART II, LN 14	9,935,728.	3,045,409.	6,890,319.

FORM 990-PF

OTHER ASSETS

STATEMENT 12

DESCRIPTION	BEGINNING OF YR BOOK VALUE	END OF YEAR BOOK VALUE	FAIR MARKET VALUE
ACCRUED INCOME RECEIVABLE	1,399,923.	1,995,290.	1,995,290.
DUE FROM BROKER	107,058,082.	12,161,295.	12,161,295.
RETIREMENT PLAN ASSET	1,898,891.	1,969,036.	1,969,036.
ADVANCES AND OTHER RECEIVABLES	22,058.	64,252.	64,252.
PREPAID FEDERAL EXCISE TAX	2,228,391.	5,573,002.	5,573,002.
PROGRAM RELATED INVESTMENTS	20,909,674.	25,653,304.	25,653,304.
OPERATING LEASE RIGHT OF USE ASSET	0.	8,596,861.	8,596,861.
TOTAL TO FORM 990-PF, PART II, LINE 15	133,517,019.	56,013,040.	56,013,040.

FORM 990-PF

OTHER LIABILITIES

STATEMENT 13

DESCRIPTION	BOY AMOUNT	EOY AMOUNT
DEFERRED FEDERAL EXCISE TAX	37,437,887.	22,248,640.
RETIREMENT PLAN LIABILITY	2,509,260.	2,748,166.
ACCRUED VACATION	1,452,558.	890,327.
DEFERRED RENT EXPENSE	560,586.	0.
REFUNDABLE DEPOSITS	319.	0.
GRANT REFUNDS PENDING MODIFICATION	1,005,850.	6,355,762.
OPERATING LEASE LIABILITIES	0.	9,441,992.
TOTAL TO FORM 990-PF, PART II, LINE 22	42,966,460.	41,684,887.

FORM 990-PF

NAME OF FOREIGN COUNTRY IN WHICH
ORGANIZATION HAS FINANCIAL INTEREST

STATEMENT 14

NAME OF COUNTRY

AUSTRALIA
AUSTRIA
BELGIUM
CANADA
DENMARK
FINLAND
FRANCE
GERMANY
HONG KONG
INDONESIA
ITALY
JAPAN
NETHERLANDS
NEW ZEALAND
NORWAY
PORTUGAL
SINGAPORE
KOREA (SOUTH)
SPAIN
SWEDEN
SWITZERLAND
TAIWAN
UNITED KINGDOM

FORM 990-PF

TRANSFERS TO CONTROLLED ENTITIES
PART VI-A, LINE 11

STATEMENT 15

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT
OF TRANSFER

52,819,565.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY
FEEDER, L.P.

98-1142649

ADDRESS

2929 ARCH STREET 17TH FLOOR
PHILADELPHIA, PA 19104

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT
OF TRANSFER

489,903.

TOTAL AMOUNT OF TRANSFERS TO CONTROLLED ENTITIES

53,309,468.

FORM 990-PF

TRANSFERS FROM CONTROLLED ENTITIES
PART VI-A, LINE 11

STATEMENT 16

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

CHATHAM CO-INVEST

85-0651355

ADDRESS

26 MAIN STREET, SUITE 204
CHATHAM, NJ 07928

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

80,000,000.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

LACM WORLD SMALL CAP EQUITY FUND, L.P.

83-2888004

ADDRESS

11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

25,000,000.

THE LEONA M. AND HARRY B. HELMSLEY CHARI

13-7184401

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

12,800,624.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY
FEEDER, L.P.

98-1142649

ADDRESS

2929 ARCH STREET 17TH FLOOR
PHILADELPHIA, PA 19104

DESCRIPTION OF TRANSFER

DISTRIBUTION

AMOUNT
OF TRANSFER

3,288,065.

TOTAL AMOUNT OF TRANSFERS FROM CONTROLLED ENTITIES

121,088,689.

FORM 990-PF

SCHEDULE OF CONTROLLED ENTITIES
PART VI-A, LINE 11

STATEMENT 17

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

CHATHAM CO-INVEST

85-0651355

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

26 MAIN STREET, SUITE 204
CHATHAM, NJ 07928

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

ESTATE OF LEONA M. HELMSLEY

20-7535047

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

HELMSLEY ENTERPRISES, INC.

13-2665914

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

LACM WORLD SMALL CAP EQUITY FUND, L.P.

83-2888004

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST

61-1915057

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UNITED KINGDOM WC2H 9EA

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY
FEEDER, L.P.

98-1142649

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

2929 ARCH STREET 17TH FLOOR
PHILADELPHIA, PA 19104

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

PITANGO SPV

98-1492234

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.
HERZLIYA, ISRAEL

FORM 990-PF

PART VII - LIST OF OFFICERS, DIRECTORS
TRUSTEES AND FOUNDATION MANAGERS

STATEMENT 18

NAME AND ADDRESS	TITLE AND AVRG HRS/WK	COMPEN- SATION	EMPLOYEE BEN PLAN CONTRIB	EXPENSE ACCOUNT
SANDOR FRANKEL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 25.00	141,667.	0.	0.
DAVID PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 35.00	141,667.	0.	0.
WALTER PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 32.00	141,667.	0.	0.
SARAH E. PAUL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF EXECUTIVE OFFICER 40.00	747,100.	178,123.	0.
JACQUELINE F. BAUSCH C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	GENERAL COUNSEL 40.00	561,541.	82,702.	0.
ROSALIND M. HEWSENIAN C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF INVESTMENT OFFICER 40.00	1,739,805.	193,856.	0.
NICHOLAS J. SCHIAVO C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF FINANCIAL OFFICER 40.00	413,802.	124,112.	0.
TOTALS INCLUDED ON 990-PF, PAGE 6, PART VII		3,887,249.	578,793.	0.

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBARTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET
LONDON, ON, CANADA

GRANT AMOUNT

3,390,428.

DATE OF GRANT

11/20/18

AMOUNT EXPENDED

2,471,716.

PURPOSE OF GRANT

STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM

DATES OF REPORTS BY GRANTEE

PRIOR + 1/2020, 6/2020, 12/2020, 1/2021, 6/2021, 12/2021, 6/2022, 2/2023,
7/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASITY MADAGASCAR

GRANTEE'S ADDRESS

LOT IAB 39 TER C ANALAMHINTSY
ANTANANARIVO, MADAGASCAR, 101

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
284,790.	03/01/17	284,790.

PURPOSE OF GRANT

IMPLEMENT SUSTAINABLE MANAGEMENT STRATEGIES FOR WETLAND CONSERVATION

DATES OF REPORTS BY GRANTEE

2/2018, 2/2019, 5/2020, 9/2021, 10/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

GRANTEE'S ADDRESS

125 S WACKER DRIVE, SUITE 600
CHICAGO, IL 60606

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,500,000.	11/20/21	681,030.

PURPOSE OF GRANT

EXPANSION OF THE DANATECH PLATFORM TO MIMPROVE T1D CARE

DATES OF REPORTS BY GRANTEE

1/2022, 5/2022, 12/2022, 1/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

GRANTEE'S ADDRESS

125 S WACKER DRIVE, SUITE 600
CHICAGO, IL 60606

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,679,637.	07/11/18	2,679,637.

PURPOSE OF GRANT

AADE TECHNOLOGY INSTITUTE: DANA - DIABETES ADVANCED NETWORK ACCESS

DATES OF REPORTS BY GRANTEE

2/2019, 8/2019, 1/2020, 8/2020, 1/2021, 6/2021, 3/2022, 7/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD.

GRANTEE'S ADDRESS

55 VICTORIA PARADE, LEVEL 2
FITZROY, AUSTRALIA, 3065

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,560,371.	07/23/20	1,600,433.

PURPOSE OF GRANT

FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES

DATES OF REPORTS BY GRANTEE

2/2021, 8/2021, 2/2022, 7/2022, 8/2022, 2/2023, 8/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD.

GRANTEE'S ADDRESS

55 VICTORIA PARADE, LEVEL 2
FITZROY, AUSTRALIA, 3065

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,719,569.	02/15/17	3,719,569.

PURPOSE OF GRANT

THE ENIGMA STUDIES -TO IMPROVE CARE OF CROHN'S

DATES OF REPORTS BY GRANTEE

3/2019, 7/2019, 11/2019, 1/2020, 4/2020, 10/2020, 11/2020, 3/2021, 9/2021,
3/2022, 2/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

BIORASIS, INC.

GRANTEE'S ADDRESS

1392 STORRS RD U4213, ATL ROOM 106
STORRS, CT 06269

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,016,000.	02/06/18	1,988,500.

PURPOSE OF GRANT

EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 2/2020, 5/2020, 8/2020, 11/2020, 2/2021, 7/2021, 5/2022, 11/2022,
5/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

CAPILLARY BIOMEDICAL, INC.

GRANTEE'S ADDRESS

2 WRIGLEY
IRVINE, CA 92617

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,500,000.	09/02/20	1,428,325.

PURPOSE OF GRANT

ADVANCED EXTENDED INFUSION SET TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

10/2020, 3/2021, 4/2021, 10/2021, 1/2022, 5/2022, 6/2022, 3/2023, 8/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DIABETOMICS, INC.

GRANTEE'S ADDRESS

2345 NE OVERLOOK DRIVE, SUITE #140
HILLSBORO, OR 97006

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,031,900.	01/11/18	4,031,900.

PURPOSE OF GRANT

POINT-OF-CARE RAPID TESTS FOR T1D SCREENING AND INTERVENTION

DATES OF REPORTS BY GRANTEE

PRIOR +10/2020, 4/2021, 10/2021, 12/2021, 2/2022, 4/2022, 9/2022, 10/2022,
7/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DREAMED DIABETES LTD.

GRANTEE'S ADDRESS

14 KAPLAN ST
PETAH TIKVA, ISRAEL, 4952701

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,850,000.	02/23/23	0.

PURPOSE OF GRANT

INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES

DATES OF REPORTS BY GRANTEE

5/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DREAMED DIABETES LTD.

GRANTEE'S ADDRESS

14 KAPLAN ST
PETAH TIKVA, ISRAEL, 4952701

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,585,828.	02/01/16	3,585,828.

PURPOSE OF GRANT

MD-LOGIC PUMP GUIDE4U - ADVISORY SYSTEM TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

10/2016, 1/2017, 7/2017, 9/2017, 2/2018, 6/2018, 9/2018, 12/2019, 1/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

GRAND CANYON UNIVERSITY

GRANTEE'S ADDRESS

3300 WEST CAMELBACK ROAD
PHOENIX, AZ 85017

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,274,027.	06/26/19	2,208,383.

PURPOSE OF GRANT

DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR

DATES OF REPORTS BY GRANTEE

6/2020, 7/2020, 7/2021, 4/2022, 1/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

HEALTH FINANCE INSTITUTE

GRANTEE'S ADDRESS

1690 NORTH QUINN STREET
ARLINGTON, VA 22209

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,163,666.	12/16/19	3,163,666.

PURPOSE OF GRANT

HEALTH FINANCE INSTITUTE SEED GRANT: CATALYZING FINANCING AND PARTNERSHIPS TO ADDRESS THE GLOBAL BURDEN OF CHRONIC DISEASE

DATES OF REPORTS BY GRANTEE

4/2020, 7/2020, 12/2020, 3/2021, 1/2022, 1/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INNODIA

GRANTEE'S ADDRESS

HERESTRAAT 49
LEUVEN, VLAAMS-BRABANT, BELGIUM, 3000

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,189,643.	10/13/22	19,453.

PURPOSE OF GRANT

INNODIA NONPROFIT LAUNCH FOR THE CARE AND PREVENTION OF T1D.

DATES OF REPORTS BY GRANTEE

12/2022, 4/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, IRELAND, 48163

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,583,742.	10/22/20	1,798,379.

PURPOSE OF GRANT

DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.

DATES OF REPORTS BY GRANTEE

6/2021, 12/2021, 8/2022, 11/2022, 12/2022, 8/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, IRELAND, 48163

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
172,967.	03/23/22	172,967.

PURPOSE OF GRANT

POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES:
"INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY"

DATES OF REPORTS BY GRANTEE

3/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, IRELAND, 48163

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,556,119.	06/22/23	0.

PURPOSE OF GRANT

THE EXTENT STUDY TO IMPROVE THE CARE OF CROHN'S DISEASE.

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

NURU INTERNATIONAL

GRANTEE'S ADDRESS

2020 PENNSYLVANIA AVE NW
WASHINGTON, DC 20006

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,680,506.	11/25/13	4,680,506.

PURPOSE OF GRANT

CREATING A SELF-SUSTAINING, SCALING, AGRICULTURE-BASED DEVELOPMENT MODEL

DATES OF REPORTS BY GRANTEE

6/2014, 1/2015, 11/2015, 12/2015, 1/2017, 2/2018, 1/2019, 1/2020, 6/2020,
1/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

PERCUSENSE, INC,

GRANTEE'S ADDRESS

25134 RYE CANYON LOOP
VALENCIA, CA 91355

GRANT AMOUNT

2,500,000.

DATE OF GRANT

09/02/20

AMOUNT EXPENDED

1,350,000.

PURPOSE OF GRANT

DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

7/2021, 8/2021, 10/2021, 5/2022, 4/2023, 5/2023, 7/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

STARTUP HEALTH T1D PRI LP

GRANTEE'S ADDRESS

2000 BROADWAY, 18TH FLOOR
NEW YORK, NY 10023

GRANT AMOUNT

5,000,000.

DATE OF GRANT

01/30/23

AMOUNT EXPENDED

0.

PURPOSE OF GRANT

CATALYZING SEED AND EARLY-STAGE COMPANIES DEVELOPING INNOVATIVE T1D CARE SOLUTIONS

DATES OF REPORTS BY GRANTEE

3/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE LEGATUM INSTITUTE FOUNDATION

GRANTEE'S ADDRESS

11 CHARLES STREET
LONDON, UNITED KINGDOM, W1J 5DW

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
78,169.	09/21/21	78,169.

PURPOSE OF GRANT

PHASE TWO OF US PROSPERITY INDEX: EXPANDING COUNTY-LEVEL INDEX TO INCLUDE WYOMING AND DEEPENING IMPACT

DATES OF REPORTS BY GRANTEE

1/2022, 10/2022, 1/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE UNIVERSITY OF QUEENSLAND

GRANTEE'S ADDRESS

CUMBRAE STEWART BUILDING #72, THE UNIVERSITY OF QUEENSLAND
BRISBANE, QUEENSLAND, AUSTRALIA, 4072

GRANT AMOUNT

1,667,706.

DATE OF GRANT

09/08/21

AMOUNT EXPENDED

829,416.

PURPOSE OF GRANT

LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES

DATES OF REPORTS BY GRANTEE

1/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE UNIVERSITY OF QUEENSLAND

GRANTEE'S ADDRESS

CUMBRAE STEWART BUILDING #72, THE UNIVERSITY OF QUEENSLAND
BRISBANE, QUEENSLAND, AUSTRALIA, 4072

GRANT AMOUNT

226,017.

DATE OF GRANT

05/22/23

AMOUNT EXPENDED

0.

PURPOSE OF GRANT

GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF
ISLET AUTOIMMUNITY

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THETIS PHARMACEUTICALS, LLC

GRANTEE'S ADDRESS

54 DANBURY ROAD, SUITE 285
RIDGEFIELD, NJ 06877

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
5,069,660.	02/24/22	1,570,712.

PURPOSE OF GRANT

DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHN'S DISEASE

DATES OF REPORTS BY GRANTEE

5/2022, 8/2022, 11/2022, 3/2023, 5/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ZUCARA THERAPEUTICS

GRANTEE'S ADDRESS

1300-661 UNIVERSITY AVENUE
TORONTO, ON, CANADA, M5G 0B7

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,900,000.	02/06/18	3,900,000.

PURPOSE OF GRANT

PRECLINICAL DEVELOPMENT OF ZT-01 TO PREVENT HYPOGLYCEMIA IN T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 7/2021, 10/2021, 2/2022, 4/2022, 7/2022, 11/2022, 2/2023, 4/2023, 7/2023

ANY DIVERSION BY GRANTEE

NONE

FORM 990-PF

OTHER PROGRAM-RELATED INVESTMENTS

STATEMENT 20

DESCRIPTION

AMOUNT

THETIS PHARMACEUTICALS, LLC - DEVELOPMENT OF NOVEL RESOLVIN
E1 THERAPY FOR CROHN'S TREATMENT

903,630.

DESCRIPTION

AMOUNT

BIORASIS, INC. - EARLY FEASIBILITY STUDIES OF THE
GLUCOWIZZARD

340,000.

TOTAL TO FORM 990-PF, PART VIII-B, LINE 3

1,243,630.

990-PF

INVOLVEMENT WITH NONCHARITABLE ORGANIZATIONS
PART XVI, LINE 1, COLUMN (D)

STATEMENT 21

NAME OF NONCHARITABLE EXEMPT ORGANIZATION

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

DESCRIPTION OF TRANSFERS, TRANSACTIONS, AND SHARING ARRANGEMENTS

GRANT IN SUPPORT OF EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE

GENERAL EXPLANATION

STATEMENT 22

FORM/LINE IDENTIFIER AND DESCRIPTION/RETURN REFERENCE

FORM 990-PF, PART VI-A, LINE 11: - CONTROLLED ENTITIES

EXPLANATION:

THE FOLLOWING CONTROLLED ENTITIES ARE NOT EXCESS BUSINESS HOLDINGS:

CHATHAM CO-INVEST
26 MAIN STREET, SUITE 204
CHATHAM, NJ 07928
EIN# 85-0651355

ESTATE OF LEONA M. HELMSLEY
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169
EIN# 20-7535047

HELMSLEY ENTERPRISES, INC.
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169
EIN# 13-2665914

LACM WORLD SMALL CAP EQUITY FUND, L.P.
11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025
EIN# 83-2888004

MARATHON-LONDON GLOBAL SELECT
ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UK WC2H 9EA
EIN# 61-1915057

MHR LONGEVITY PARTNERS
1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105
EIN# 98-1471155

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.
2929 ARCH STREET 17TH FLOOR
PHILADELPHIA, PA 19104
EIN# 98-1142649

PITANGO SPV
BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.
HERZLIYA, ISRAEL
EIN# 98-1492234

GENERAL EXPLANATION

STATEMENT 23

FORM/LINE IDENTIFIER

FORM 990-PF, PART VII, LINE 1 AND 2, COLUMN (C), COMPENSATION:

EXPLANATION:

ALL REPORTED COMPENSATION AMOUNTS INCLUDE "SALARY, FEES, BONUSES AND SEVERANCE PAYMENTS RECEIVED BY EACH PERSON LISTED," AS WELL AS CURRENT YEAR PAYMENTS OF AMOUNTS REPORTED OR REPORTABLE AS DEFERRED COMPENSATION IN CURRENT OR PRIOR YEARS.